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Summary
Cervical malignancy is the fourth most common cause of cancer-related mortality
in women worldwide; infection with high-risk human papillomavirus (HRHPV) is
responsible for over 500,000 cases of cervical carcinoma each year, approximately 90%
of which are squamous cell carcinomas (SCCs). Over half of all HPV-positive cervical
SCCs are caused by the deregulated expression of HPV16 oncogenes E6 and E7 in
proliferating basal cells of the cervical squamous epithelium. The major risk factor
associated with cervical neoplastic progression is integration of HRHPV into the host
genome, which is detected in ∼85% of HPV16-positive cervical carcinomas. The work
presented in this doctoral thesis sought to provide insights into our understanding of
the process of HPV16 integration as well as to elucidate mechanisms that deregulate
both virus and host gene expression following integration.
The W12 cell model system used in this project is a polyclonal cervical ker-
atinocyte line generated by explant culture of a low-grade cervical squamous intraep-
ithelial lesion (LSIL) that arose following natural infection with HPV16. Through
single cell cloning of a long-term culture W12 series, twenty-four isogenic clones,
each containing a different site of HPV16 integration, were developed. The W12
clones were isolated in the absence of selective pressure, and as such represent the
range of integration events that occur in a pre-malignant lesion at the early stages
of carcinogenesis, prior to integrant selection. Despite identical genetic backgrounds,
expression levels of oncogenes E6 and E7 varied up to 16-fold between the W12
clones. Expression of HPV oncogenes is ultimately determined by transcription fac-
tor binding to the non-coding long control region (LCR) of the viral genome. The
initial result of this study found that genomic mutations affecting transcription factor
binding at the LCR of the W12 clones was not a cause of differential viral expression,
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concluding that epigenetic control may be at play.
In order to provide a tractable system, cells without full-length HPV16 concate-
merisation and with four or less copies of integrated virus DNA per cell were used
for further analysis. Higher levels of virus expression per template were associated
with increased levels of histone post-translational modification (PTM) hallmarks of
transcriptionally active chromatin and reduced levels of repressive hallmarks. There
was greater abundance of the active/elongating form of the RNA polymerase-II en-
zyme (RNAPII-Ser2P), together with CDK9, the component of positive transcrip-
tion elongation factor-b (P-TEFb) responsible for the Ser2 phosphorylation. The
changes observed were functionally significant, as cells with higher HPV16 expres-
sion per template showed greater sensitivity to depletion and/or inhibition of histone
acetyl transferases and CDK9, as well as reduced sensitivity to histone deacetylase
inhibition.
Employing next generation sequencing data available for five representative W12
clones, the sites of HPV16 host integration were identified. This confirmed that the
virus preferentially inserts into areas of active and open regions of host chromatin, as
indicated by the abundance of active PTMs and DNaseI sites and absence of repres-
sive PTMs. HPV16 integration occurs both within genes and at intergenic regions.
Features of the integration sites confirm integration occurs either via direct insertion
or by a looping mechanism whereby adjacent regions of the host are amplified result-
ing in local rearrangements. The genomic sequence of the host at the specific site of
virus integration showed increased levels of microhomology with the virus genome,
hence a mechanism of microhomology-mediated end-joining-dependent integration
is likely. HPV16 integration is also associated with changes in host gene expression
at least 2.5 megabases away from the integration locus; in the cases where HPV16
integrated directly into a host gene the introduction of the HPV16 promoter resulted
a dramatic increase in the expression of downstream exons.
The three-dimensional (3D) structure of the nucleus and physical interactions
between stretches of the genome over long distances (i.e. enhancer and promoters) are
known to exert an additional level of gene regulation. Identification of 3D virus-host
interactions in the W12 clones employing the newly developed and unique ‘Sequence
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Capture of Regions Interacting with Bait Loci Hi-C’ (SCRiBL-Hi-C) protocol showed
that both short- (∼50 kb), and long-range (∼1 Mb) interactions occur during the
early stages of carcinogenesis. Direct HPV16-host 3D interactions were shown to be
associated with host gene expression changes, and, in addition, insertion of the virus
can disrupt normal host architecture.
Together, the data in this thesis indicate that transcription and subsequent ex-
pression of the HPV16 genome is controlled by multiple layers of epigenetic reg-
ulation. As such, therapeutics targeting the viral epigenome could be beneficial in
modulating HPV16 expression in cases of cervical carcinoma. Virus-host interactions
should be further investigated to determine whether changes to the host genome as
a result of virus integration make a significant contribution to early cell selection
events during carcinogenesis.
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Chapter 1
Introduction
1
Introduction
1.1 Cervical cancer
Cervical cancer is the fourth most common cause of cancer-related mortality in
women worldwide, with an estimated 266,000 women expected to die from the disease
each year1. The global burden of cervical cancer is largely dependent on geographical
location. The mortality rate varies 18-fold between different regions of the world;
86% of all cases arise in less developed regions, including Melanesia, Eastern and
Middle Africa, where mortality rates are in excess of 20 per 100,0001(Figure 1.1).
The discrepancy can be explained by the introduction of effective, population-wide
screening programs in developed countries, which have served to dramatically reduce
the incidence of cervical carcinoma and associated mortality.
Figure 1.1: Estimated age-standardised rates (per 100,000) of cervical
cancer mortality worldwide in 2012. Reproduced from GLOBOCAN, 20121.
The classification of cervical cancers is dependent on the type of epithelium it
develops from; whilst the vast majority (∼85%) of cervical cancers represent squa-
mous cell carcinomas (SCCs), adenocarcinomas and adenosquamous carcinomas are
also seen2. SCCs arise from squamous cells that cover the outer surface of the cervix
(ectocervix); in comparison, adenocarcinomas derive from glandular epithelial cells
scattered along the endocervical canal3.
Cervical SCC is the most prevalent cervical cancer type and develops from a pre-
malignant lesion through a spectrum of well-defined transformations. Progression is
associated with the expansion of the proliferative compartment within the squamous
epithelium and increasing cell atypia. Cervical carcinogenesis is a model for early
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detection due to the long and well-known natural history of the disease. Prior to
invasive disease, cervical abnormalities can be assessed by cervical cytology employ-
ing a test known as the Papanicolaou (Pap) smear, first described by Dr. George
Papanicolaou in 19414. The test requires obtaining a sample of cervical epithelial
cells, which are then graded on the level of dysplasia and resultant disease severity
is inferred. Over the years a number of grading systems have been developed to in
an effort to improve and standardise cervical cytology reporting5. The first grading
system employed was introduced in 1973 and was structured upon a three-tiered clas-
sification of cervical intraepithelial neoplasia (CIN), based purely on the histology
of the cervical lesion. HPV-induced squamous intraepithelial lesions are regarded as
precursor lesions and are graded into three different risk categories depending on pro-
portion of the cervical epithelium occupied by dysplastic cells: CIN1, CIN2 or CIN3
corresponding to one-third, two-thirds or full thickness, respectively6. Importantly
lesions graded CIN1–3 do not show invasion of the basement membrane, which is
characteristic of malignant disease7. However, the CIN grading system was not fully
clinically relevant; discrepancies between the classification of cervical lesions and
biological behaviour led to difficulties in determining effective treatment strategies.
As such, a two-tiered Bethesda grading system was devised in 19888. Cervical pre-
malignant lesions are graded into low-grade or high-grade squamous intraepithelial
lesions (LSIL or HSIL, respectively), both corresponding to the risk of progression
to invasive cancer9. To correlate both grading systems, LSILs usually correspond to
CIN1, whilst HSILs encompass CIN2 and CIN3 lesions (Figure 1.2).
However, only a subset of cervical precursor lesions progress to cervical cancer;
currently because of the lack of predictive markers, clinicians and pathologists are
not able to distinguish the lesions that will progress from those that will not10. In
women who are immunocompetent the rates of spontaneous regression (i.e. without
intervention) for a CIN1 or CIN2 lesion range from 40–60% and only a very small
percentage progress to develop a higher-grade lesion11, 10. Moreover, of those that
do develop CIN3, less than half will progress to invasive cancer6. Despite this, when
a CIN3 lesion is identified healthcare professionals are duty bound to offer surgical
intervention as the lesion holds the risk of developing into invasive cancer; as such
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there are fewer data available on the spontaneous regression of CIN3 lesions6.
Following the diagnosis of invasive disease, a patient is staged based on the size
and spread of the tumour according to the International Federation of Gynecology
and Obstetrics (FIGO) guidelines. Carcinoma of the uterine cervix grows locally,
and primarily extends to the uterus and paracervical tissues and the pelvis. As
such, tumours that are strictly confined to the cervix are classified as stage I whereas
stage II-IV tumours extend beyond the cervix with increasing distance from the
initial cervical lesion12.
Figure 1.2: Diagram of cervical neoplastic progression. This diagram repre-
sents increasing cell atypia and progressive loss of differentiation of cells at the surface
of the epithelium, indicative of cervical neoplastic progression. Approximate corre-
spondence between the two-tier Bethesda and the three-tier CIN grading systems
are demonstrated (Adapted from Groves & Coleman, 20152).
1.2 Human Papillomavirus (HPV) and Cervical
Cancer
Virus infections are responsible for approximately 15% of cancer cases worldwide13.
Malignancies include Burkitts lymphoma, Kaposi sarcoma and hepatocellular carci-
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nomas to name but a few, each caused by infection with Epstein-Barr virus (EBV),
human herpes virus 8 (HHV-8/KSHV) and Hepatitis B and C viruses (HBV &
HCV), respectively14. Cervical cancer is another example of virus-driven disease,
with almost all cases (99.7%) caused as a result of persistent infection and ineffec-
tive clearance of human papillomaviruses (HPV); as such, infection with HPV is
accepted to be a necessary cause of cervical cancer15, 16. HPV infection has also
been attributable to the pathogenesis of other cancers including those of the vagina
(78%), penis (51%), anus (88%), vulva (<48%) and oropharynx (<51%)17. These
carcinomas are typically caused by infection with the high-risk group of HPVs, which
have a higher oncogenic potential than the low-risk types.
Over 200 HPVs have been recognised and are classified by genotype into five
evolutionary groups based upon whether they infect cutaneous or mucosal epithelia
and their disease associations18, 19. The most well studied HPV type is the mucosal
alpha papillomaviruses, over forty of which have been shown to infect the anogenital
mucosa20. As previously mentioned, this group is further subdivided into high-risk
(HRHPV) and low-risk groups (LRHPV) based on their oncogenic potential. Whilst
LRHPVs, typically HPV6 and 11, can cause benign epithelial hyperplasias (genital
warts), they are not associated with intraepithelial neoplasia. In contrast, HRHPVs
including HPV16, 18, 31 and 45 are associated with over 90% of cervical malignancies,
with HPV16 alone accounting for over half of all cases worldwide21, 22.
Despite this, infection with HRHPV does not inevitably mean that cervical abnor-
malities will develop; only 0.3% to 1.2% of initial infections will eventually progress to
invasive cervical cancer23. Although HPV infection is a common sexually transmit-
ted disease — the overall prevalence of HRHPV infection is 23%24 — approximately
90% of infections are spontaneously cleared by the host immune system within two
years25, 26. Persistent infection is seen in only 10-15% of women who are unable to
clear the infection2; HPV persistence is the main risk factor associated with progres-
sion and, as a result, these women are at greater risk of developing cervical cancer27.
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1.3 Clinical management of cervical cancer
As with all cancer types, prevention and early detection are far better than cure.
The recognition and understanding that infection with HPV is a necessary factor
of cervical cancer facilitated two major developments for cervical cancer prevention:
HPV vaccination and HPV DNA testing.
As previously mentioned, the first population-wide cervical screening program
the Pap smear test involves taking a sample of epithelial cells from the surface of
the cervix, which are then smeared onto a glass slide, stained, and the morphology
of the cells assessed. The identification of pre-cancerous or cancerous cells within
the sample informs the pathologist of the degree of cervical dysplasia4, 18. In parts
of the world where routine screening has been implemented, there has been a signifi-
cant decrease in the incidence and mortality as a result of cervical cancer28. Despite
this, there are a number of concerns with the Pap smear test due to its subjective
nature and lack of sensitivity. The test has a high false negative rate that varies
from 30% and 86% and it is inadequately sensitive (as low as 86%)29. Furthermore,
approximately 8% of Pap smears are inadequate for interpretation due to problems
with sample collection and the crude nature of slide preparation. As such, alternative
technologies have been investigated. Liquid-based cytology (LBC) was introduced to
address the aforementioned issues by making changes to sample processing methodol-
ogy. Instead of smearing the collected cervical epithelial cells onto a glass slide which
is subsequently fixed, the head of the collecting brush is broken off and placed into
a preservative fluid, this ensures that most, or all, of the cervical cells are retained.
The resulting fluid is then centrifuged to remove cellular debris, such as blood or
mucus, before the slide is prepared. Comparisons between Pap and LBC screening
methods showed that not only was there a significant decrease in the number of inad-
equate samples (from 9.1% to 1.5%), test sensitivity was increased by 12% with the
introduction of LBC technologies. As such, in 2003 the National Institute of Clinical
Excellence (NICE) recommended LBC as the main method for cervical screening30.
More recently molecular HPV-testing has been suggested as a new approach
for screening. Several randomised trials have indicated that molecular techniques
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lead to greater diagnostic sensitivity and reproducibility, particularly when detecting
CIN2 or CIN3 lesions, when compared with cervical cytology31. In addition, HPV
testing gives women the choice to self-sample. Low attendance of screening programs
remains a major obstacle in the prevention of cervical cancer in both developed
and developing countries. As such, self-sampling offers an alternative to attending
healthcare clinics and it is likely that more women would engage and be effectively
screened. Cervical cancer mainly occurs in unscreened or under-screened women; it
is estimated that approximately 50% of women diagnosed with cervical cancer have
never had a cervical cytology test and 10% have not had one in the last five years
prior to diagnosis32. To ensure the most robust screening, there is an argument for
co-testing, i.e. cytology and HPV-testing. In this way, the small subset of women
with cervical cancer that test negative with common HPV assays but positive for
cytology would also be identified33.
Screening programs facilitate early disease detection, however, only a primary
prevention strategy, such as vaccination against HPV infection, can address the fun-
damental cause of the disease. As previously stated, most HPV infections resolve
with time and the virus is cleared as a result of a successfully mediated immune re-
sponse. Upon natural infection, neutralizing antibodies against the major coat pro-
tein L1, which self assemble into virus-like-particles (VLPs), are produced26. Based
upon the natural clearance of an HPV infection, numerous prophylactic HPV vac-
cines have been developed and are widely used across the world. In 2006 the Food
and Drug Administration (FDA) approved Gardasil (Merck), a quadrivalent vaccine
developed for the prevention of disease associated with infection with different HPV
types: cervical cancer (HPV 16 & 18), genital intraepithelial neoplasia (HPV 6, 11,
16 & 18), and genital warts (HPV 6 & 11). Subsequently two additional vaccines
were approved in 2009 and 2014: Ceravix (GlaxoSmithKline), a bivalent vaccine
against HRHPV types 16 and 18, and Gardasil 9 (Merck), the most advanced pro-
phylactic vaccine to date, which protects against nine HPV types: 6, 11, 16, 18, 31,
33, 45, 52 and 5834, 35.
The immune response to HPV infection and/or vaccination is type-specific. Ide-
ally vaccines would protect against all HRHPV types or should, at least, be tailored
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to specific regions of the world as the prevalence and distribution of HRHPV types
differ between geographical locations. HPV16 and HPV18 are predominant in Eu-
rope, North America and Asia; however, in other continents different strains are
more prevalent such as HPV31 in South America and HPV52 in Africa36. As such,
the current prophylactic vaccines are tailored towards the population of developed
countries and are unable to prevent all cases of cervical cancer worldwide, particu-
larly in developing regions where the need is greatest. Furthermore, at present, both
vaccines are prohibitively expensive for wide scale use in developing countries with
a cost of ∼$325–$403 for the recommended three doses36.
While prophylactic HPV vaccines are able to block an initial infection and ef-
fectively prime the immune response against future infections, they are unable to
eradicate prior infection. Another area of active investigation is the development of
therapeutic vaccines, used to treat established infections. Unlike prophylactic HPV
vaccines, which are used to generate neutralizing antibodies against virus particles,
therapeutic HPV vaccines are used to stimulate cell-mediated immune responses to
specifically target and kill infected cells37. The HPV-encoded early proteins, specif-
ically E6 and E7, are the main targets for therapeutic vaccines since they are con-
sistently expressed in HPV-associated malignancies and pre-cancerous lesions and
play a crucial role in the generation and maintenance of HPV-associated disease38.
A number of therapeutic vaccine approaches have been developed and include: live
vector-, protein-, nucleic acid-, and cell-based immunisation strategies. These are
currently being tested in clinical trials and present as a viable therapeutic option in
cervical disease38, 39.
The development of cervical cancer treatments is much less advanced than pri-
mary (HPV vaccination) and secondary (screening via cytology and HPV testing)
prevention strategies. Current treatment options are based upon the pre-cancerous
or cancer stage and tumour size. A range of surgical options including conisation of
cervix, hysterectomy and pelvic trachelectomy are offered to women with early stage
disease (CIN3 and stage I cancer) depending on their desire to remain fertile; the 5-
year survival of patients presenting with localised disease exceeds 90%. As has been
previously mentioned however, the majority of women with CIN3 lesions will not
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develop cancer, raising the concern that over 50% of all patients are currently over-
treated at this stage of disease progression6. However, as the disease progresses the
estimated 5-year survival dramatically decreases; for women with cancers that have
spread within the region it is 57% and for cancers which have metastasised to distant
organs survival is estimated at only 17%40. For more advanced stages of the disease,
obtaining negative surgical margins becomes increasingly difficult and surgical resec-
tion becomes technically more challenging; in these instances if surgery remains a
viable option, chemotherapy and/or radiation is given in combination in an attempt
to improve treatment results. However, for patients with stage IV disease and distant
metastases, systemic chemotherapy with cisplatin remains the best option41. Novel
treatment options for patients with metastatic cancers and recurrent disease after
chemo-radiation therapy are being developed and include anti-angiogenic drugs and
antibody-based therapies, the first of which was approved by the FDA in 201442.
1.4 The HPV genome
1.4.1 Virus structure
HPVs are relatively small, non-enveloped viruses approximately 55 nm in diameter.
They consist of an icosahedral capsid composed of 72 capsomeres containing the
viral genome. Capsomeres are composed of two structural late proteins: L1, which
accounts for 80% of the virus particle, and the minor capsid protein L2. The HPV16
genome is a double-stranded, circular (episomal) DNA molecule, 7904 base pairs
(bp) in length, which is transcribed unidirectionally and all resultant transcripts are
polycistronic.
1.4.2 Genome organisation
The HPV16 genome is functionally divided into three regions: early, late and a long
control region (LCR), the domains of which are separated by two polyadenylation
(pA) sites. The early (E) region of the genome encodes seven common open reading
frames (ORFs): E6, E7, E1, E2, E4, E5 and E8 which are required for the regulation
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of viral DNA replication and viral gene expression43. Only E6 and E7, and possibly
E1 and E2 proteins are true early proteins in so much as they can be detected in
basal epithelial cells44. E1, E2, E4 and E5 are expressed in the supra-basal layers and
are considered intermediate proteins — actually the expression of E1 and E2 viral
replication proteins and transcription factors is greatest in the mid- to upper layers
of the epithelium (Figure 1.3 A)45, 43; currently, there is insufficient data to be sure of
the sites of E8 expression. During the replicative stage if HPV infection, E4 protein is
the first, and most abundant, late protein to be expressed in the mid to upper layers
of the epithelium which is also the location of maximum E5 expression43. The late
(L) region encodes the structural proteins L1 and L2 that form a virus capsid; these
genes are expressed only in the final stages of cellular differentiation in the upper
most, granular layer of the epithelium where viral DNA is packaged in the capsid to
be released to infection other cells (Figure 1.3 A)46. The LCR region is an 850 bp non-
coding, regulatory region that contains promoter sequences that direct transcription
of both the early and the late genes47, the origin of replication (Ori), as well as
multiple cis-acting sequences that regulate polyadenylation and viral late mRNA
stability48. The HPV16 genome contains two major promoters; the p97 promoter
lies upstream of the E6 ORF and is controlled primarily by upstream cis-elements in
the LCR, which are responsible for early gene expression. The second ‘late’ promoter,
p670, lies within the E7 ORF and is responsible for late gene expression, only being
induced in differentiated keratinocytes (Figure 1.3 B).
1.4.3 HPV16 oncogenes
When viruses function as carcinogenic agents, they are able to employ a variety of
mechanisms that result in cellular immortalisation and the transformation of human
cells. Immortalisation and direct transformation of infected cells occurs through the
expression of viral oncogenes, which are able to inactivate regulators of genome stabil-
ity, cell viability and cell cycle; the tumour suppressor proteins p53 and retinoblas-
toma protein (pRB), two key cell regulators, have been shown to be targeted for
degradation by a number of different virus oncogenes49. HPV16 encodes two onco-
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Figure 1.3: Genome organisation and the physical states of the HPV
genome. A) Schematic diagram of the HPV16 life cycle in a differentiating epithe-
lium. Viruses are show as light blue circles. Keratinocytes are in light orange color.
Nuclei are colored pink. The basement membrane is drawn with a grey line. The
key events in the virus replication cycle are indicated to the right hand side of the
diagram of the epithelium together with a schematic diagram of the gene expression
program of the virus within the infected epithelium. Shading on the arrows repre-
sents the quantity of expression of each protein subset during the virus replication
cycle. (Adapted from Graham & Faizo, 2017)43. B) The genomic organisation of
HPV16, highlighting the early (E) region, the late (L) region and the long control
region (LCR). The early (p97) and late (p670) promoters and early (AE) and late
(AL) polyadenylation sites are also indicated. (Adapted from Groves & Coleman,
20152).
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genic proteins E6 and E7, which function synergistically to infer limitless replicative
potential, evasion of apoptosis and genome instability, all of which are hallmarks of
cancer50. The many functions of the HPV16 oncogenes are summarised in Figure
1.4.
The HPV16 E6 gene encodes a basic protein of approximately 150 amino acids
(19 kDa) that contains two-zinc-binding regions. These binding domains are able to
associate with and degrade numerous cellular proteins including the major cell-cycle
checkpoint tumour suppressor protein p5351. The primary method of E6-directed
degradation of p53 is facilitated by the formation of a complex comprised of E6
and the E3-ubiquitin ligase called E6-associated protein (E6-AP), which is able to
bind the p53 protein. When the E6/E6-AP complex binds p53, p53 becomes rapidly
ubiquitinated resulting in subsequent proteasome-mediated degradation52. E6 is
also able to inhibit the expression of p53-regulated genes in an E6-AP-independent
manner by preventing the co-activating capacity of the histone acetyl transferase
p30053, 54. Under normal conditions, activated p53 functions include the initiation of
DNA repair pathways, cell cycle arrest, cell metabolism and/or apoptosis; however
in the presence of E6, p53 cannot accumulate, and the ability of the cell to arrest
mitosis in response to DNA damage is removed.
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Figure 1.4: Important functions of high-risk HPV E6 and E7 proteins.
The figure gives an overview of important direct and indirect effects of the α-genus
HPV E6 and E7 proteins on cellular pathways and processes. Important roles of E6
and E7 include degradation of cellular p53 and pRb, respectively. Red oval, general
down-regulation of cellular process or pathway; green oval, general up-regulation of
cellular process or pathway; brown oval, modulation of cellular process or pathway
(Adapted from Groves & Coleman, 20152).
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In addition to p53 degradation, HRHPV E6 oncoproteins have developed addi-
tional mechanisms to inhibit the apoptosis response by enhancing the degradation
or the induction of proteolytic inactivation of the pro-apoptotic proteins BAK and
FADD, respectively55. Preventing natural cellular apoptosis facilitates carcinogen-
esis by allowing mutations to accumulate as cells with damaged DNA continue to
replicate.
HRHPV E6 is also able to stimulate telomerase expression and activity, thereby
enabling replicative immortality55. In normal cells telomeres serve to protect the ends
of chromosomes from DNA damage including illegitimate fusions, and shorten at a
constant rate with progressive cell divisions as a result of tightly repressed telomerase.
However, in most immortalised cells — including 85–90% of cell derived from human
cancers — the expression of telomerase is increased resulting in the maintenance
of telomere length and the absence of cellular senescence56. In HRHPV infected
cells telomerase activity is stimulated via E6/E6-AP mediated ubiquitination and
the subsequent degradation of the transcriptional repressor NFX1-91. Degradation
of NFX1-91 results in transcriptional activation of the hTERT (human telomerase
reverse transcriptase) gene and additionally has a role in HPV16 E6 activation of
the oncogenic transcription factor NF-κβ 57, 55. Furthermore, E6 is able to manipu-
late normal cell properties including changes to cell-cell adhesion and cell polarity
properties by targeting PDZ domain-containing proteins for degradation, resulting
in cell transformation58.
E7 is a phosphoprotein of approximately 100 amino acids (13 kDa) that contains
a short motif (CR2) that mediates the interaction with the retinoblastoma tumour
suppressor protein (pRB) and its related proteins p130 and p10759; these proteins
are linked to cell cycle control and are degraded by the HRHPV E7 oncoprotein.
Normally, pRB binds and inactivates the transcription factors E2F 1-3, which main-
tain cells in a quiescent state in the G0/G1 phase of the cell cycle. However, E7
proteins target the active, hypo-phosphorylated form of pRb for proteasomal degra-
dation resulting in E2F-regulated transcription. Resultant transcription of cyclin
A and cyclin E positive regulators of cyclin dependent kinases (CDKs) induces
cell cycle progression into S-phase and sustained proliferative signaling55. E7 also
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interacts with the 600 kDa pRb-associated factor p600; p600 is known to play a role
in integrin-mediated signaling, and knockdown of p600 sensitises cells to apoptosis.
The E7-p600 interaction has been suggested to be an essential mechanism, indepen-
dent of pRB inactivation, for oncogene-induced cellular transformation58. Finally,
expression of HRHPV E7 can also cause genomic instability by inducing centrosome
amplification; this can lead to aneuploidy and structural chromosomal instability60.
The overall result of E7 activity is to allow cell growth without differentiation, which
can lead to immortalization.
The loss of function of both the p53 and pRb pathways through degradation and
inhibition plays a significant role in the development of most human cancers, and
confers a growth advantage to affected cells. Loss of pRb results in hyperproliferation
triggering apoptosis, which is blocked by the desensitisation of cells to checkpoint
signals as a result of the loss of p53. The cooperative action of E6 and E7 leads
to the emergence of a clonal population of cells with a growth advantage with a
predisposition for transformation and malignant progression61, 62. This dogma has
been illustrated using the W12 cell system (see section 1.5), and this thesis aims to
determine epigenetic mechanisms that regulate the expression of HPV16 E6 and E7
prior to malignancy.
1.4.4 HPV16 long control region (LCR)
The HPV16 LCR consists of non-coding DNA that contains a large number of cis-
responsive elements that control the replication and transcription of the virus. They
are extremely important for the viral biology, as they couple the expression of the
early and late genes to the differentiation of the squamous epithelia and affect the
amount of viral gene expression by feedback control. The regulatory elements are
short DNA sequence motifs that are recognised and bound by regulatory proteins
such as: transcriptional activators, repressor, terminators and initiators of replica-
tion. Once bound to the HPV16 genome, regulatory proteins affect the association of
the pre-initiation complex of the basal transcription machinery and thereby modulate
the rate of transcription initiation and elongation as well as DNA replication63.
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The HPV16 LCR can be divided into three sections, each with different func-
tions; the 5’ segment contains transcription termination signals and a nuclear matrix
attachment region, which mediates structural organisation of chromatin; the cen-
tral segment that contains epithelial cell-specific enhancers; and the 3’ segment that
contains the replication origin and the E6 promoter (p97)64 (Figure 1.5).
The 3’ segment containing the early promoter (p97) has a characteristic arrange-
ment of four cis-responsive elements including a TATA box which serves to bind the
transcription pre-initiation complex, a G-rich hexamer (GGGCGT) binding site for
the activating transcription factor Sp1, and two E2 binding sites; E2BS1 and E2BS2
positioned between the Sp1 binding site and the TATA box. The central LCR con-
tains a large transcriptional enhancer region composed of numerous cis-responsive
elements that are affected individually, but which modulate synergistically or antago-
nistically p97 promoter activity over a range of 2–3 orders of magnitude63. The most
noted transcriptional activators known to bind to the HPV16 enhancer region of the
LCR are NF1, AP1 (the principal activator of the epithelial enchancer), Oct1 and
TEF1. However, transcriptional activation can be antagonised through the binding
of repressive transcription factors, for example, YY1 and CDP, which act as negative
regulatory elements or silencers63, 64. The 5’ LCR contains the termination site for
the translation of the late genes L2 and L1 (Poly(A)L - AATAA) and also contains
a 79 nt RNA element termed the negative regulatory element (NRE) or late regu-
latory element (LRE); the LRE is located at the end of the L1 open reading frame
and spans the start of the late 3’ untranslated region; the element is a conserved
feature of papillomaviruses and inhibits late gene expression in undifferentiated ep-
ithelial cells43. The chromatin structure of the HPV16 LCR region also contributes
to the level of viral transcription. The HPV16 LCR is organised in the form of two
specifically position nucleosomes, one overlapping with the viral enhancer and one
with origin of replication and early promoter. Nucleosome positional transcription
experiments have revealed that the function of the early promoter is diminished due
to the reduced accessibility of the promoter sequences to transcriptional activators,
i.e. AP1 and the basic transcriptional machinery. However, post-translational modi-
fication of the nucleosomes (histone tails) and an excess of transcription factors AP1
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and Sp1 can overcome this repression to enhance transcriptional activity65.
Figure 1.5: The long control region (LCR) of the HPV16 genome. The
HPV16 LCR is positioned between the late and early virus gene regions. The virus
replication protein E1 binds as a dimer of hexamers at the origin of replication (Ori),
while the virus transcription factor E2 associates as a dimer at four E2 binding sites
(E2BSs). Transcription of early genes occurs from the early promoter (p97) and
is dictated by the binding of numerous host transcription factors and the virus E2
dimer across the enhancer, silencer and promoter regions. Activation of transcription
from the late promoter (p670) is dependent upon cell differentiation and binding of
differentiation-associated transcription factors. Poly(A)L, late polyadenylation site;
ORF, open reading frame associations (Adapted from Groves & Coleman, 20152).
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The role of E2 in transcriptional activation
Notably, papillomavirus genomes themselves encode a transcription factor, protein
E2, which regulates viral gene expression through binding to the four E2 binding
sites in the LCR (Figure 1.5). The E2 protein consists of a DNA-binding domain
and a transactivation domain that are linked by a serine-arginine-rich hinge region
and forms a highly stable dimer that binds to the E2 bindings sites located across
the LCR; two E2BSs are proximal to the viral early promoter, the third is located at
the origin of DNA replication and the fourth is located upstream of the keratinocyte
enhancer66. The E2 proteins function primarily by recruiting cellular factors to the
viral genome, which activate or repress transcriptional processes depending on the
context of the binding sites and nature of the associated cellular factors. Binding
of E2 to the E2BS1 induces transcriptional activation of the early promoter (p97),
resulting in enhanced productions of the E6, E7 and E2 proteins. When E2 concen-
tration rises to a high level, it also binds to the low affinity E2-binding sites E2BS2,
3, 4, respectively and represses transcription from the early promoter by compete-
ing with cellular transcription factors for binding sites67. Association of HPV16 E2
to E2BS1 and E2BS2 in close proximity to the HPV promoter sterically hinders the
binding of cellular factors such as Sp1 and TBP to proximal promoter elements in the
viral genome. Additionally, the binding of E2 protein to the E2BSs proximal to p97
promoter represses transcription through steric hindrance of the interaction with the
transcriptional initiation factor TFIID at the proximal TATA box and subsequent
Poll II pre-initiation complex assemble68, 69.
Activation of E2 proteins requires the cooperation of at least two E2 dimers bound
to their cognate sequences; these two E2 dimers could be adjacent (e.g. E2BS1 and
E2BS2) or distant from one another (e.g. E2BS1 and E2BS3). Dimerisation of
the HPV16 E2 amino-terminal transactivation domain over large distances has been
shown to induce looping of the intervening sequences, bring the proximal enhancer
and the proximal promoter together in 3D space, and is another potential mechanism
for E2 transcriptional regulation70, 71. Experimental evidence shows that enhancer-
binding proteins — such as Sp1 — can be targeted to promoter regions via direct
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interaction with E2 proteins that bind proximal to transcription start site through
the formation of stable DNA loops72; in this context, the activity of the p97 promoter
is increased as a result of E2-dependent enhancer looping.
One of the best-characterised interactors of E2 is the bromodomain-containing
protein (Brd4), which a member of the bromodomain and extra-terinal domain
(BET) protein family and is another cellular chromatin-binding factor that has a role
in the regulatory function of E269. In association with the major viral regulatory
protein E2, Brd4 is involved with multiple processes of the papillomavirus life cycle,
including the initiation of viral replication as well as viral genome segregation and
maintenance73, 69; Brd4 serves to tether E2 and the viral genomes to mitotic chromo-
somes in dividing cells, thus ensuring viral genome maintenance74. Moreover, Brd4
also plays a role in gene transcription from the viral early promoter73, 74; notably
Brd4 is required for transcriptional activation function of E275, 73, 74. Brd4 recruits
a variety of transcription factors and chromatin regulatory to control transcription;
these include the positive transcription elongation factor b (P-TEFb) and general
cofactor Mediator. It has been shown that the recruitment of P-TEFb is impor-
tant for E2s transcription activation activity73 and additionally the intrinsic histone
acetyltransferase (HAT) activity of Brd4 results in strong transcriptional activation
of target genes69. However, Brd4 has been shown to have a dual role in relation
to the regulation of viral transcription and has been identified in a transcriptional
silencing complex assembled by HPV E2. In this context, Brd4 acts as a cellular
co-repressor that reduces the activity of the early promoter resulting in decreased
expression of the HPV16 genome; recombinant Brd4 and E2 are both necessary and
sufficient to replace the purified E2 repressor complex in inhibiting AP-1-dependent
HPV transcription in an E2-binding site-specific manner76.
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1.4.5 HPV16 life cycle
HPVs are intracellular parasites and must deliver their genome into host cells, and
subsequently use host cellular machinery for viral replication. The viral capsid —
composed of structural viral proteins L1 and L2 — plays a key role in the establish-
ment of a viral infection providing the initial site of interaction between the virus
particle and the host cell77. Throughout the initiation of an HPV16 infection the L1
protein plays an essential role in maintaining the structural integrity of the capsid
as well as binding to host cell surface receptors, whereas the L2 protein ensures that
the viral genome is trafficked correctly to the host cell nucleus, where viral gene
expression can initiate78. Infection of the target keratinocyte by HPV16 is a highly
complex process; the initial virus-host interaction and virus entry mechanisms as
well as the molecules involved are still a subject of scientific debate77, 78. Initially,
infectious HPV16 particles bind to the basement membrane of the disrupted mucosal
epithelium and virus entry occurs in the basal keratinocytes (Figure 1.2). Attach-
ment is believed to occur through association between L1 components of virus capsid
and herparan sulphate proteoglycans (HSPG), which are frequently found in the ex-
tracellular matrix and on the surface of most cells. This initial attachment results in
a conformational change of the viral capsid, which facilitates L2 proteolytic cleavage
— the minor capsid protein L2 is cleaved by furin on the cell surface — and the
virus binds to an as yet unidentified receptor on the target cell77, 78. HPV16 is then
internalised into the cell and following endocytic transport and acidification, progres-
sive capsid disassembly occurs78, 79. Host cell cyclophilins release the majority of L1
protein from L2 protein, which remains in complex with the viral genome. The L2
protein then translocates across the endocytic membrane to engage factors that me-
diate transport to the trans-Golgi network (TGN)79. After the initiation of mitosis,
the HPV16 genome egresses from the TGN and associates with microtubules. Dur-
ing mitosis there is membrane dissolution and nuclear envelope breakdown, which
allows the L2:HPV16 DNA complex to migrate along microtubules into the nucleus
and to the condensed chromosomes of the host78, 80.
Once entered into the host cell nucleus, HPVs are reliant on the full complement of
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host replication proteins to mediate viral synthesis as the viral replication proteins
E1 and E2 are insufficient to complete replication of the virus genome81. Once
the virus enters the cells of the basal membrane it hijacks the cellular resources in
order to replicate its own genetic material and express HPV proteins in a temporal
and spatial pattern. Following entry into the cell, HPV genomes are established
as extrachromosomal elements (episomes) in the cell nucleus; after initial infection
basal keratinocytes undergo proliferation, increasing the number of cells harbouring
viral episomes. At this point viral genomes are maintained at low copy number
(∼10–200) through co-ordinated replication with the host DNA, and early viral gene
expression, particularly E1 and E2, is dominant44. As infected HPV-containing
daughter cells migrate from the basal layer and differentiate, the cell enters the
proliferating compartment of the epithelium, inducing the productive phase of the
viral life cycle. The resultant up-regulation of the early promoter leads to increased
levels of E6 and E7 proteins, which deregulate cell cycle control. The cell is now
permissive to viral replication and episomal copy number is dramatically increased
to thousands of copies within a single cell62, 82. An increase in activity of the late
viral promoter (p670) in the mid and upper layers of the epithelium results in the
expression of the structural L1 and L2 capsid proteins. Once associated, the late
proteins encapsidate newly synthesised viral genomes and produce infectious particles
(virions), which are shed from most superficial layers of the epithelium, and the virus
spreads44. The papillomavirus lifecycle takes 2–3 weeks, the time necessary for a
cervical keratinocyte to undergo complete differentiation, migrate from the basal to
the upper most layers of the epithelium, and desquamate83, 82
1.5 Integration of HRHPV and cervical carcino-
genesis
Mechanisms of HPV invasion and replication result in a very poor host humoral and
cell-mediated immune response. The replication of virus DNA and virus assembly
occurs in cells already destined to die at the skin surface as part of the normal process
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of skin shedding; as such, the productive cycle of HPV does not cause virus-induced
cytolysis or necrosis, and thus does not cause inflammation or the production of pro-
inflammatory cytokines, which would normally lead to a cascade of immunological
responses84, 83. In addition, by only infecting cells of the basal epithelium, the virus
evades immunologically competent cells in the upper layers of the skin. As a result,
in some cases, the virus is able to establish a persistent chronic infection, the single
most important risk factor for the development of cervical SCC and its precursors85.
Throughout the normal HPV life cycle the viral genome is maintained in an epi-
somal state. Although in pre-invasive SILs the HPV genome is predominantly found
in its episomal form, integration of the virus genome has been shown to correlate
with the progression of precancerous lesions (CIN2/3) to invasive cancer86, 27; indeed,
integration of HPV DNA into the host genome has been identified in 86.5% of all cer-
vical SCCs87. During HPV DNA integration, the virus genome usually breaks in the
E1 and/or E2 ORFs, resulting in a loss of these genes88. In contrast, the integrated
HPV genomes of selected cells faithfully retain the LCR and full length E6 and E7
ORFs meaning that all genomic elements required for the transcription of the viral
oncogenes are maintained. Truncation of E2, which regulates transcription from the
viral early promoter, results in the loss of E2-dependent negative feedback and, as
a consequence, the expression of the viral oncogenes E6 and E7 is dramatically in-
creased27. Additionally, fusion of HPV E6 and E7 encoding oncogene transcripts to
transcribed cellular sequences increases the stability of E6 and E7 transcripts pro-
duced from the integrated virus. This results in higher steady-state levels of the viral
oncoproteins and thus enhanced oncogenic activity89. As previously mentioned, not
only does increased expression of E6 and E7 result in deregulated cellular prolif-
eration and cell immortalisation, it also induces genomic instability facilitating the
malignant transformation of host cells and tumour formation90. Additionally, HPV
genome integration is associated with progression from polyclonal to monoclonal sta-
tus in CIN; this indicates that certain integration events confer a selective advantage
in a mixed population of cells91. Interestingly, where multiple HPV copies arranged
as concatemers have integrated, it is often only the most downstream genome that
remains transcriptionally active. The additional copies are silenced by DNA methyla-
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tion, which again may reflect clonal selection due to an optimal level of viral oncogene
expression92. Moreover, HPV integration sites are usually found only at a single or
few chromosomal loci in clonal cell populations of cervical cancers93.
The identification of HPV integration sites in various associated malignancies
is an active area of investigation. It has been shown that HPV integration fre-
quently occurs at, or in close proximity to, common fragile sites (CFSs) of the human
genome86, 94, 95; these are specific chromosomal loci particularly prone to breakage
and include the genomic loci 8q24.21. The proto-oncogene C-MYC is encoded for
within this region, the expression of which has been shown to dramatically increase
as a result of HPV16 integration96, 97, 87. The expression of host genes at or near
the integration site is changed as a result of HPV integration, which has been shown
to cause a wide-range of somatic mutations, copy number variations and structural
rearrangements of the host genome98. As well as increased expression of the viral
oncogenes, it is likely that alterations to host gene expression may also promote
malignant progression.
Determining the mechanism of HPV integration is also a current research area.
Integration is not part of the normal life cycle of HPV, and HPVs encode no inte-
grases or polymerases. HPV integration presumably occurs following double strand
breaks (DSBs) in host and viral DNA, hence the frequency of integrations occurring
in CFSs99. In addition to the body of evidence that suggests that HPV integra-
tion is non-random there is increasing evidence that HPV drives integration through
microhomology-mediated DNA repair pathways. Identical nucleotide sequences be-
tween the host and virus is commonly found across 1–10bp either site of the break-
point100, 87, 88, 101. The enrichment of microhomology at HPV integration sites has
led researchers to indicate that fork stalling and template switching (FoSTeS) and/or
microhomology-mediated break-induced replication (MMBIR) are likely mechanisms
for HPV integration87.
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1.6 W12: in vitro model of cervical neoplastic
progression
Given the nature of the disease, longitudinal investigations of cervical neoplastic
progression in vivo are difficult to perform as, once detected, the disease is treated
immediately. However, in vitro models are not subject to the same constraints and
allow unique insight into the development of the invasive phenotype — the W12
model is a unique example of such a system. The ‘parental’ W12 cell line is a poly-
clonal population of cervical squamous cells that were generated by explant culture of
a naturally occurring HPV16-positive cervical LSIL102. Growth in monolayer culture
restricts W12 cell differentiation and maintains the phenotype of the basal epithe-
lium, the key site of HRHPV transcriptional deregulation in cervical carcinogenesis
(Figure 1.2). At early passages, the HPV16 genome is maintained at ∼100–200 epi-
somal copies per cell and when grown in organotypic culture recapitulates an LSIL
phenotype90 (Figure 1.6 A). Individual culture series have been established by in-
dependent long-term in vitro cultivation (Figure 1.6 C); upon continuous passage
over 9–12 months, W12 mirrors the virus and host events seen in neoplastic progres-
sion in vivo. The most frequent outcome is the breakdown of episomal persistence,
with emergence of cells containing ∼1–10 copies of integrated HPV16. Integration
of HPV16 causes transcriptional deregulation of the virus resulting in an increased
level of oncoproteins E6 and E7 as well as genomic instability. In addition, when
grown in organotypic culture, the cells progress to HSIL and, eventually, SCC103, 90
(Figure 1.6 B). Hence, the W12 cell system remains the best available model for
HPV16 driven cervical carcinogenesis.
In a previous study, limiting dilution cloning from an early pass of polyclonal
parental W12 cells within series 2 was performed under non-competitive conditions.
This generated a panel of twenty-four clones that all arose from a common genetic
background and differ only by the site of HPV16 genome integration into the host
chromosomes. As such, the range of integration events that exist prior to episome
clearance and integrant emergence were identified, regardless of whether they had a
selective advantage in mixed cell populations104. As such, the W12 clones represent
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a unique system to examine the host and virus factors that determine selection of
a particular HPV16 integrant from the range that exists in a typical polyclonal
population of pre-malignant cervical keratinocytes.
Figure 1.6: The W12 cell system accurately models early cervical carcinogenesis.
(A) At early passages, polyclonal W12 cells recapitulate the LSIL from which they were derived.
(B) Following long-term passage, they progress through HSIL to SCC. (C) Independent long-term
culture series of W12 are characterised by spontaneous emergence of integrant-containing cells,
although episome-driven progression may also occur (e.g. Series 4EPI). The 24 W12 clones were
generated from W12 Series 2 cells (third row).
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1.7 Epigenetic regulation of the eukaryotic genome
For many years cancer research has focussed on the identification of genetic defects
leading to carcinogenesis. Following the initial discovery in 1983 of a point mutation
in the c-Ha-ras oncogene resulting in a human transforming gene, altered p21,105 a
large number of studies have focussed on the identification of novel DNA mutations
associated with tumour cell growth. It is, however, recognised that tumorigenesis
is a multistep process characterised by the accumulation of multiple interconnected
alterations including genetic, cytogenetic and epigenetic changes106. Epigenetics was
first described as ‘changes in phenotype without changes in genotype’107, whereby
epigenetic mechanisms transduce the inheritance of gene expression patterns without
altering the underlying DNA sequence; these mechanisms explain how two identical
genotypes can give rise to different phenotypes in response to the same environ-
mental stimulus. Epigenetic regulation of gene expression is a well-established phe-
nomenon that plays a role in a diverse range of biological processes, and its dereg-
ulation has been increasingly recognised as a hallmark of cancer108, 109, 110. Four
distinct mechanisms contribute to the field of epigenetics; DNA methylation, post-
translational modification (PTM) of histone proteins, chromatin remodelling and
noncoding RNAs110. Technological advances such as next-generation sequencing in
combination with the development of modification or site-specific antibodies have
enabled ChIP-seq analysis of the epigenome at, or near base-pair resolution. Com-
parisons between control and abnormal cells and tissues have revealed aberrant pat-
terns of epigenetic marks associated with cancer cells111, 112, as such, they represent
new biological targets in the development of cancer therapies113, 114.
1.7.1 DNA Methylation
DNA methylation is an epigenetic mark involving the covalent addition of a methyl
group (-CH3) to the C-5 position of the cytosine ring of DNA115. Methylation of
cytosine occurs almost exclusively in the context of CpG dinucleotides and it catal-
ysed by DNA methyltransferases (DNMTs). The maintenance of appropriate DNA
methylation plays a significant role in the regulation of a variety of molecular pro-
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cesses including the stability of chromosomal structure and the control of gene ex-
pression116. Due to changes in gene regulation caused by aberrant DNA methylation,
this was the first epigenetic mark to be associated with cancer111. There are two main
classifications of alterations to DNA methylation: hypermethylation, which refers to
the gain of methylation at specific sites that are undermethylated under normal con-
ditions and is associated with the stabilisation of transcriptional repression and loss
of gene function; and hypomethylation, which is associated with the loss of DNA
methylation in genome-wide regions and leads to genomic instability110. Interest-
ingly, the two contrasting phenomena coexist in the cancer cell117; hypermethylation
of CpG islands located in the promoters of tumour suppressor genes results in gene
silencing118, 119, and increased hypomethylation of gene-poor genomic areas such as
repeat sequences lead to a higher rate of chromosomal rearrangements120. During
tumour progression, the degree of hypomethylation of genomic DNA increases as the
lesion progresses from benign to an invasive cancer121; indeed, the HPV16 genome
— predominantly within the L1 and L2 genes — is highly methylated in cancer
cells and the methylation status increased with progression from low grade disease
to cancer67. The methylation state of the LCR is of particular interest as this region
regulates the expression levels of the E6 and E7 oncogenes. Each E2-binding site
contains two CpGs that can be mehtylated and in vitro experimnts have shown that
methylation of E2BS CpGs localised withint the promoter prevents E2 binding. This
results in the abrogation of E2-mediated inhibition of transcription at p97 promoter
contributing to enhanced E6 and E7 expression67.
1.7.2 MicroRNAs
The expression and activities of cellular proteins are regulated (among other factors)
by cellular noncoding microRNAs (miRNAs). MicroRNAs are noncoding regulatory
RNA molecules (18—25 nucleotides in length) that are derived from RNA polymerase
II transcripts of coding or non-coding genes. MicroRNA expression is often tissue- or
differentiation-specific; their temporal expression modulates gene expression at the
post-transcriptional level by base-pairing with complementary nucleotide sequences
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(seed matching) of target mRNAs122. Depending on the degree of sequence com-
plementarity, the binding of miRNAs to a target mRNA inhibits protein translation
and/or degrades the target mRNA. MicroRNAs are very often implicated in differ-
ent stages of cell transformation during carcinogenesis and their altered expression
in different cancer types has been considered a marker for diagnosis and therapy123.
1.7.3 Chromatin structure
The structure of genomic DNA within the nucleus of a cell is intrinsically linked to
the level of transcription and resultant gene expression124. Within the cell eukary-
otic DNA is packaged into a DNA/protein complex called chromatin; it is a highly
dynamic and organised structure composed of DNA, histones, and non-histone pro-
teins. The nucleosome is the fundamental unit of chromatin and is composed of
147 base pairs of DNA wrapped around a core of two copies of each H2A, H2B, H3
and H4 histone proteins125. Nucleosomes are linked together by 20–80 base pairs of
linker DNA. While the core histones are predominantly globular, highly basic his-
tone amino (N)-terminal tails protrude from the nucleosome unit providing a site for
enzymatic modification (Figure 1.7)126.
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Figure 1.7: Hierarchy of chromatin organisation in the mammalian cell
nucleus. From the top, genomic DNA is methylated (Me) on cytosine bases in
specific contexts, e.g. promoters, and is packaged into nucleosomes. Nucleosomes
vary in histone composition and post-translational modifications (e.g. histone H3
lysine 9 trimethylation (H3K9me3)). DNA in chromatin may remain accessible to
DNA-binding proteins such as transcription factors (TFs) and RNA polymerase II
(RNAPII) or may be further compacted dependent on the types of post-translational
modification present on the histones (Taken from Zhou et al., 2011124).
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Histone modifications regulate numerous DNA-dependent processes including
transcription, DNA replication and DNA repair127, while the effects of histone mod-
ifications operate via two main mechanisms. The first, involving the direct modifica-
tion(s) of amino acid residues on histone tails, directly influences the overall structure
of chromatin. This, in turn, determines the accessibility of genomic DNA to the tran-
scription machinery; there are at least eight distinct types of covalent modifications
that can occur at different amino acid residues and at different levels of complexity
(mono-, di-, or tri-) resulting in a vast array of modifications41, 128. Secondly, spe-
cific histone modifications can positively or negatively regulate the binding of effector
molecules such as transcription factors126.
1.7.4 Post-translational histone modifications
Histone modifications have crucial roles in the control of gene activity, DNA re-
pair, DNA replication, chromosome condensation and alternative splicing67. Post-
translational modifications (PTMs) are highly diverse and reversible, with distinct
protein groups responsible for attaching (writers), recognising and binding (read-
ers), and removing (erasers) each histone mark. The writers, readers and erasers of
epigenetic marks contribute towards and drive disease via aberrant activity through
the mediation of upstream signals as a result of mutation and/or altered expression
of epigenetic factors129. The acetylation of lysine residues was the first PTM to
be discovered130 and has been shown to be intrinsic to the control of transcription.
Acetylation occurs via histone acetyl transferase (HAT) enzymes; acetyl-CoA is used
as a cofactor to transfer an acetyl group to the -amino group of lysine side chains
in the histone protein. The covalent attachment of the acetyl group neutralises the
positive charge on a lysine residue disrupting the electrostatic interactions between
histone proteins and DNA, thus reducing the affinity between them. This results in
a less compact chromatin structure allowing for increased access by transcriptional
and replication machineries bringing about increased gene expression. Acetylation
marks are found at the highest density surrounding transcription start sites (TSSs)
of genes131 as well as within actively transcribed regions of the genome132, 133. In ad-
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dition, histone acetylation regulates gene expression indirectly through the action of
so-called bromodomain and extra-terminal (BET) proteins that recognise and bind
to acetylated residues at promoter regions134. These additional protein factors are
able to activate transcription factors, destabilise nucleosome structure by recruiting
additional chromatin remodellers and facilitate the binding of RNA polymerase II
immediately upstream of the TSSs135, 126, 129.
HATs fall into two major categories; type A, are mostly nuclear and have a diverse
range of targets when compared with the type B enzymes that are found mostly in
the cytoplasm of cells and only acetylate free histones. Type A HATs are classified
into three families depending on amino acid sequence homology and conformational
structure: GCN5 N-acetyltransferase (GNAT), MYST (MOZ/YBF2/SAS2/TIP60)
and CBP/p300 families136. The overall levels of histone protein acetylation are
controlled by the balance between the activities of HATs and histone deacetylases
(HDACs). HDACs are enzymes that catalyse the removal of acetyl groups from
histone lysine residues, thereby restoring the positive charge on the side chain of
lysine residues and stabilising the local chromatin architecture137.
In addition to acetylation, methylation — the addition of methyl moieties to
the side chains of lysine or arginine residues — is the second most common histone
modification that has been clinically associated with pathological epigenetic disrup-
tions in cancer cells138, 139. Histone methylation does not alter the charge of the
histone protein but rather serves as recognition marks that facilitate or prevent the
binding of proteins and protein complexes140. Proteins containing PHD-finger do-
mains141 or the so-called Tudor ‘royal’ family of domains (Tudor, PWWP, MBT and
chromodomains)142 bind to specific methylation signatures and are able to remodel
the structure of chromatin and/or facilitate the recruitment of additional chromatin
modifiers that affect the rate of transcription128, 126. As with acetylation, the methy-
lation of lysine or arginine residues at specific positions is carried out by enzymatic
writers termed histone methyltransferases (HMTs), and are removed by demethylase
enzymes; there is an additional level of complexity as these enzymes also modify the
appropriate residue to a specific degree, i.e. mono-, di- and/or tri-methyl state.
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1.8 Role of HPV16 viral oncogenes in modulating
epigenetic mechanisms
The regulation of host gene transcription via epigenetic mechanisms complement
those of non-epigenetic nature used by E6 and E7 HPV16 oncogenes in cellular
transformation to promote cell proliferation, evade immune response and avoid cell
death (see section 1.4.3). E6 and E7 oncoproteins interact with, and/or modulate
the expression, of many proteins involved in epigenetic regulation. These include:
DNA methyltransferases, histone-modifying enzymes and subunits of chromatin re-
modelling complexes and the expression of cellular microRNAs (Table 1.1)67.
Table 1.1: Interactions of HPV oncoproteins with cellular epigenetic mod-
ifiers. Reproduced from Durzynska et al.67.
1.8.1 HPV16 and DNA methylation
Aberrant DNA methylation of the cellular genome has been observed in various types
of HPV-associated cancers67; of particular interest to HPV-driven carcinogenesis if
the aberrant DNA methylation in a number of tumour suppressor genes. Exam-
ples include: hypermethylation of the gene CCNA1 which increases from 0% in the
disease free control group to 93% in cervical carcinoma patients143; increases in a
number of methylated sites in the promoter of the hTERT gene, where repressive
sequences were blocked by methylation increasing the hTERT production in HPV-
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dependent cells and cervical cancer cells144. In addition, following virus integration
into the host genome, the virus is able to modulate host methylation machinery to
regulate the expression of viral oncogenes genes in favour of the establishment of
persistent infection by evading the host immune defence145.
1.8.2 HPV16 and microRNAs
In HPV-dependent cancer cells, both E6 and E7 oncoproteins can influence cellular
miRNAs, which are regulated in most cases by transcription factors eg. c-Myc,
p53 and E2F. Examples of HPV16 oncogene-induced down-regulation of microRNAs
include: E6 expression results in the down-regulation of miR-34a expression via the
p53 protein, this leads to increased cell proliferation137; E7 expression down-regulates
miR-203 expression — high levels of miR-203 are inhibitory to HPV amplification
— facilitating productive viral replication in differentiating cells146. However, as
a result of HPV16 infection the expression of microRNAs can also be increased.
MicroRNA 21 — which targets the CCL20 gene — is significantly overexpressed to
regulate cellular processes including proliferation, apoptosis and migration of HPV16-
positive cervical squamous cells147. Not only does HPV16 alter the expression of
cellular microRNAs, but the miRNAs may also target HPV transcripts and change
the expression of papillomavirus genes in a differentiation-dependent manner122.
1.8.3 HPV16 and histone-modifying enzymes and chromatin
remodelling complexes
HPV16 E6 and E7 oncoproteins have been shown in interact with cellular epigenetic
modifiers — a full list is reported in Table 1. Specifically the interaction of HPV16
oncoproteins with HATs has been shown to affect the activity of these enzymes
toward non-histone substrates and to modulate their transcriptional coactivator ac-
tivity; one example includes the HAT p300/CBP. HPV16 E6 oncoprotein inhibits the
p300/CBP-mediated acetylation of p53 and through this mechanism represses p53-
dependent gene activation53, whereas HPV16 E7 forms a tertiary complex with both
p300/CBP and pRb which promotes acetylation of pRb resulting in the decrease of
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pRb expression148. E7 oncoprotein also interacts with p300/CBP-Associated Factor
(PCAF) HAT and reduces its ability to acetylate free histones in vitro 149. HPV16
E7 expression also causes epigenetic reprogramming of cells by modulating the activ-
ities of histone deacetylases (HDACs) and DNA methyltransferases (DNMTs). E7
expression has been shown to stimulate the activity of DNMT1 in vitro 150 as well
as the lysine demethylase KDM6B151; induction of these enzymes results in a reduc-
tion of global levels of the repressive H3K27me3 mark and consequently the loss of
polycomb repressive complex (PRC)-mediated repression. Additionally, E7 is able
to bind and sequester HDACs, resulting in the activation of several cellular promot-
ers. Examples include the enhanced expression of E2F by disruption of the repressive
pRb-HDAC complex responsible for regulation of E2F S-phase specific genes, leading
to increased cell proliferation152, as well as increased activity of hypoxia inducible
factor 1 (HIF-1), by inducing the dissociation of HDACs 1, 4, and 7 from the HIF-1a
protein subunit, resulting in increased levels of angiogenesis47.
1.9 Deregulated epigenetic regulation and cancer
Epigenetic modifications do not act in isolation but rather in combination with one
another to determine the correct chromatin conformation and levels of accessibil-
ity to ensure the required levels of gene expression is achieved. For example, the
repression of gene promoters by CpG hypermethylation is also associated with ad-
ditional repressive PTMs such as the deacetylation of histones H3 and H4, loss of
H3K4me3 and gain of H3K9me and H3K27me3153, 154 adding further complexity to
gene regulation.
Deviations and aberrant patterns of histone modifications are a hallmark of can-
cer. Alterations to the methylation and acetylation status of lysine residues on
histone 3 (H3) have been indicated in prostate cancer139 and have also been shown
to have prognostic relevance for patients with non-small cell lung cancer155. More-
over, global levels of specific PTMs have been used to identify patients with low-
grade bladder cancer156 and used as independent predictors of renal cell carcinoma
mortality112. In combination with the fact that epigenetic modifications are re-
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versible, allowing the malignant cell population to revert to a more normal state, the
epigenome has increasingly been targeted as a means of effective chemotherapy as
well as chemoprevention of cancer. There are numerous epigenetic modifiers, namely
DNA-methylation and HDAC inhibitors, in different stages of clinical trials157. Cur-
rent examples already used in the clinic are HDAC inhibitors Zolinza® (virinostat)
and Istodax® (romidepson) used for the treatment of T cell lymphoma158 whilst
Vidaza® (azacitidine) is used for the treatment of leukaemias159. For the treatment
of cervical cancer, enzymatic inhibitors of DNA methylation and histone deacetylases
have shown limited promise in phase I and II clinical trials, however their efficacy is
increased when combined in addition to radiation or chemo-radiation therapy41.
1.10 RNA polymerase II-dependent transcription
The transient modulation of chromatin structure by epigenetic mechanisms is re-
quired to facilitate the binding of the transcription machinery to DNA. In addition
to epigenetic regulation, gene expression is also controlled at the level of transcrip-
tion elongation by RNA polymerase II (RNAPII). Following binding of the gen-
eral transcription factors (GTFs) to the transcriptional start sites (TSSs) of genes,
RNAPII molecules are recruited and transcription is initiated upon phosphorylation
of Serine 5 (Ser5) on the carboxy-terminal domain (CTD) of RNAPII by cyclin-
dependent kinase 7 (CDK7)160. RNAPII molecules are able to transcribe a short
distance (20–50 bp) before entering a paused state, which is controlled by the pause
control elements: DRB-sensitivity-inducing factor (DSIF) and negative elongation
factors (NELFs), both of which are physically associated with the paused RNAPII
molecules161. Pause release and subsequent elongation requires the action of positive
elongation factor b (P-TEFb), composed of cyclin-dependent kinase 9 (CDK9) and
cyclin T1. The CDK9 subunit of P-TEFb mediates the release of paused RNAPII by
phosphorylating the pause control factors as well as the second serine residue (Ser2)
on the CTD of RNAPII; the latter mark is associated with active elongation of the
polymerase and results in processive mRNA production (Figure 1.8)162. Studies car-
ried out on other human viruses including HSV, CMV, EBV and HIV have shown
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that the recruitment and function of P-TEFb to paused RNAPII molecules is a nec-
essary step for active transcription163 and, therefore, the components of the P-TEFb
complex such as CDK9 are possible therapeutic targets. In recent years a number
of small molecule CDK9 inhibitors such as flavopiridol, dinaciclib and seliciclib have
been designed that demonstrate good antitumoral activity in vitro. However, thus
far, when tested in phase I clinical trials, their lack of specificity against other CDKs
and enzymes results in adverse events that make them unsuitable for clinical use164.
Despite this, pharmaceutical companies designing CDK9 inhibitors have the tools
required to improve the selectivity of CDK9 inhibitors and therefore they remain a
promising future therapeutic option.
Figure 1.8: Transcription regulation by the RNAPII CTD code. Step 1)
Recruitment of the core Pol II enzyme to the gene promoter with an unphospho-
rylated CTD through interaction with the Mediator complex. Pol II escapes the
promoter during the initiation phase upon phosphorylation of Ser5 of the CTD by
CDK7. Step 2) Pol II during promoter-proximal pausing; the arrival of P-TEFb
leads to the phosphorylation of NELF, DISF and Ser2, which leads to productive
transcription elongation shown in step 3. Step 4) Pol II transitions from transcription
elongation to termination (Taken from Harlen et al., 2017165).
In mammalian cells, more than half of all P-TEFb molecules are sequestered
within an inactive complex containing the 7SK small nuclear ribonucleoprotein par-
ticle (snRNP) and the HEXIM1 protein166. However, in conditions that require
rapid transcriptional induction, P-TEFb is released from the inactive complex167
and is recruited to paused RNAPII molecules for subsequent activation. The re-
cruitment of P-TEFb can occur via a number of different mechanisms; in the form
of a large complex called the super elongation complex (SEC)168, by specific DNA-
binding transcription factors such as c-Myc169 and/or through its interaction and
association with the bromodomain-containing protein 4 (BRD4)170. In the case of
c-Myc-mediated recruitment of P-TEFb, elevated levels of the transcription factor
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accumulate in the promoter regions of most active genes. P-TEFb is subsequently
recruited resulting in transcriptional amplification; thus, rather than binding and
regulating a new set of genes when overexpressed, c-Myc amplifies the output of the
existing gene expression program171. BRD4 is a member of the bromodomain and
extra terminal domain (BET) family, and is a reader of acetylated lysine residues on
histone tails. As previously discussed, H3K27ac is a mark of active chromatin and
is found at the TSS regions of genes. BRD4 mediates the recruitment of P-TEFb
to paused RNAPII molecules by binding the core CDK9/cyclin T1 complex through
its C-terminal extra terminal domain region172. BRD4 and resultant P-TEFb re-
cruitment is triggered by increased histone acetylation at, and near, the TSS. This
leads to the active transcription of genes and once again illustrates the intricacy
of epigenetic regulation. In addition to small molecule inhibitors of CDK9, phar-
macological inhibition of BET proteins, including BRD4, have also been shown to
have therapeutic activity in cancer models; inhibitors JQ1 and I-BET function by
competitively binding to the bromodomain pockets of the BET proteins resulting in
their displacement from the acetylated chromatin173. Adding to the complexity of
the regulation of gene transcription, elongating RNA polymerase II is also able to
trigger epigenetic cross talk between HMTs and DNA-methyltransferase enzymes to
ensure the fidelity of gene transcription initiation174.
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1.11 Rationale and aims of the investigation
The overall aim of this study was to determine epigenetic mechanisms of HPV16
and host gene transcriptional deregulation following virus integration during early
cervical carcinogenesis. The association between integration of the HPV16 genome
into the host and the severity of disease has been widely commented on, and is
known to be the major risk factor associated with disease progression. While a
number of studies have identified HPV integration sites present in cell lines derived
from advanced cancers, very little is known about how or why particular integration
events are selected for amongst a pre-malignant polyclonal population of cells.
The first part of this investigation aimed to ascertain epigenetic mechanisms that
directly control the level of transcription of the HPV16 genome, particularly the
oncogenes E6 and E7. The epigenome is controlled by a multitude of enzymatic
processes, the deregulation of which is a recognised hallmark of cancer109, 110. The
development of small molecule inhibitors of enzymes that play an integral part in the
regulation of the epigenome is currently an active area of pharmaceutical research.
An increasing number of novel therapeutic strategies are being designed to reverse
the abnormalities that are inherent to the cancer epigenome175. As such, findings
that suggest that the expression level of the HPV16 oncogenes is determined by
epigenetic mechanisms may indicate that cervical carcinomas could also be treated
in a similar manner.
To address this aim I have used a panel of W12 integrant clones that exhibit
different levels of HPV16 oncogene expression per template and have less than four
copies of the virus genome to compare the abundance of epigenetic modifications —
namely, post-translational modifications of histone tails and active RNA polymerase
II — at the virus genomes. Furthermore, the functional significance of enzymes
responsible for laying down the epigenetic marks has been evaluated and their impact
on the levels of oncogene expression determined.
The second aim of the investigation was to determine whether HPV16 integration
in pre-malignant, unselected cells results in the aberrant expression of host genes.
A number of studies have used advanced cervical cancer cell lines to demonstrate
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that HPV integration can cause a wide variety of somatic mutations, genomic am-
plifications and rearrangements resulting in the disruption of cellular genes (176, 97.
However, it remains unknown whether this phenomenon occurs as a result of all
integration events or whether it is seen only in cells that are ultimately selected for.
In order to address this aim, the virus-host breakpoints of each of the W12 five
clone integrant panel were accurately mapped using capture-sequencing technology
and, as a result, the mechanism of HPV16 integration hypothesised. Additionally,
interactions between the integrated virus and the host were analysed to further elu-
cidate regulation mechanisms of HPV16 transcription.
1.11.1 Hypothesis
With regard to the epigenetic landscape analysis conducted in this thesis, I hypoth-
esise that the epigenetic marks asscociated with the integrated HPV16 genome —
particularly at the 5’ LCR and at the site of the p97 promoter — will be reflective
of the levels of viral oncogene expression per template in the W12 clones tested in
this thesis. Specifically, I hypothesise that the abundance of active PTMs will be
more abundant at the LCR of highly expressing clones compared with low expression
clones, and that the opposite will be true regarding repressive PTMs. Additionally,
I hypothesis that the abundance of RNAPII and its various forms will also be pre-
dictive of viral oncogene expression in the W12 clones.
With regard to HPV16 integration, I hypothesise that in the W12 clones the
virus integrates into gene-rich regions of the host and most likely within a host gene
itself. In active regions of the genome the chromatin structure is relatively open when
compared to gene-poor regions to facilitate cellular machinery for transcription and
is therefore more susceptible to integration of the HPV16 genome. In addition, the
integration into an active host gene body means that host transcription machinery
will be in close proximity to the virus genome; dramatically increasing the likelihood
of HPV16 oncogenes being transcribed. I hypothesise that HPV16 integration with
have an effect on host gene expression, particularly of genes adjacent to the integrated
virus genome but that the host genes disrupted by HPV16 integration will not make
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a significant contribution to cell phenotype.
1.11.2 Published work
Results from Chapter 3 were published in Groves et al. Oncogene, 2016. Results
presented in this thesis are my own and have not been contributed to or supplemented
by any other authors on the published paper.
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2.1 Cell culture and cell treatments
2.1.1 Cell lines and cell culture maintenance
Three cells lines derived from cervical tissue were used in this study (Table 2.1), all
were grown in monolayer culture to mimic the basal layer of the epithelium. All cell
lines were grown in complete culture medium: Glasgow Minimum Essential Medium
(GMEM) supplemented with 10% (w/v) Fetal bovine serum (FBS) (Sigma-Aldrich,
St. Louis, U.S.), 2 mM L-glutamine (Thermo Fisher Scientific, Loughborough, UK)
and 100 U/ml of penicillin and 100 µg/ml of streptomycin (Thermo Fisher Scientific).
Cells derived from the W12 keratinocyte cell line were co-cultured with X-ray irra-
diated G3T3 feeder cells (Todaro and Green 1963) and grown in complete medium
as previously stated with the addition of 10−10 M cholera toxin (Sigma-Aldrich),
0.5 µg/ml hydrocortisone (Sigma-Aldrich), with 10 ng/ml epidermal growth factor
(EGF) (Sigma-Aldrich) added 24 hours after seeding. All cells were tested fortnightly
for mycoplasma contamination using Mycoplasma PlusTM PCR Primer Set (Agilent
Technologies, Santa Clara, U.S.).
Table 2.1: Details of cell lines used in this study.
A - M Stanley et al., 1989102; B Dall et al., 2008104; C - Friedl et al., 1970177; D - Baker
et al., 1987178; E - Todaro & Green, 1963179; *Authenticated by short tandem repeat
profiling by the American Type Culture Collection (Manassas, Va, USA)
42
Materials and Methods
2.1.2 Resuscitation of established cell lines from liquid ni-
trogen
Cells cryopreserved in freezing medium [90% (v/v) foetal calf serum (FCS), 10%
(v/v) dimethyl sulfoxide (DMSO)] were thawed rapidly in a 37 °C water bath. The
cryovial was decontaminated with 70% ethanol and transferred to a class II laminar
flow hood. The cell suspension was transferred into a 15 ml falcon tube containing 10
ml of cell type-dependent culture medium equilibrated to 37 °C, 5% carbon dioxide
(CO2) and spun at 600 RCF for 5 minutes. The supernatant was aspirated and
the cell pellet resuspended in 3 ml of the appropriate equilibrated medium. The
suspension was then used to seed a 10 cm2 dish (W12) or 75 cm2 tissue culture flask
(SiHa and G3T3) and cells were incubated at 37 °C, 5% CO2. For resuscitated W12
and NCx/6 cells, 3 x 106 irradiated G3T3 feeder cells were added before incubation.
2.1.3 Subculture of cell lines
For the subculture of cell lines, cells were grown at 37 °C in 5% CO2 and pas-
saged at approximately 80–90% confluency. Culture medium was aspirated and the
cells washed once with sterile phosphate-buffered saline (PBS) at room temperature
(RT); the subculture of W12 and NCx/6 cells required an additional PBS wash step
whereby the G3T3 feeder cells were removed by repeated spraying of the culture
dish surface with PBS using a 5 ml glass pipette and then aspirated. Following the
wash step, the PBS was aspirated before the addition of pre-warmed 0.5% Trypsin-
Ethylenediaminetetraacetic acid (Trypsin-EDTA Thermo Fisher Scientific) to the
cell monolayer; the volume of Trypsin-EDTA used was dependent on flask size (Ta-
ble 2.2). Cells were then incubated at 37 °C in 5% CO2 for approximately 5 minutes
until they had detached from the culture surface. The trypsin-cell suspension was
transferred to a 15 ml falcon tube and the culture surface rinsed with 5 ml of pre-
warmed complete growth medium, which was also added to the cell suspension. The
trypsin-cell suspension was fully neutralised by the addition of a further 5 ml culture
medium and mixed by inversion. The suspension was then spun at 600 RCF for 5
minutes, the supernatant aspirated and the pellet resuspended using a 5 ml glass
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pipette in 5 ml of culture medium to generate a single cell suspension. The number
of cells per ml was determined using a haemocytometer and cells were passaged at
the appropriate density into a fresh tissue culture vessel containing pre-warmed com-
plete growth medium (see Table 2.2) and placed at 37 °C, 5% CO2. If the culture
was G3T3 supported, X-ray irradiated G3T3 feeder cells were added at appropriate
concentrations (Table 2.2) before incubation. If W12 culture medium was used, 24
hours after initial plating, the medium was further supplemented with EGF at 10
ng/ml. Culture medium was subsequently changed every 2-3 days.
Table 2.2: Cell culture seeding densities and volumes
2.1.4 Subculture and X-ray irradiation of G3T3 cell line
The G3T3 cell line (mouse fibroblasts) was used to generate the feeder cells for mono-
layer culture of W12 and NCx/6 populations. G3T3 cells were grown in complete
GMEM culture medium at 37 °C, 5% CO2, and sub-cultured as described in section
2.1.3. Following sub-culture, the cells were lethally X-ray irradiated (18 minutes
X-ray irradiation at 420 rads/ minute) before being used as feeder cells in monolayer
culture.
2.1.5 Cryopreservation of cell cultures
Cells at 80–90% confluency were washed with PBS, trypsinised and centrifuged at
600 RCF for 5 minutes. The cell pellet was then resuspended in PBS and the
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concentration of the cell suspension determined using a haemocytometer. The cell
suspension was re-centrifuged at 600 RCF for 5 min and resuspended in freezing
medium [90% (v/v) FCS, 10% (v/v) DMSO] to achieve a concentration of 2 x 106
cells/ml. Cryovials containing 1 ml of the resuspended mix were placed at -80 °C
before being transferred to liquid nitrogen for long-term storage.
2.1.6 Cell treatment with small molecule inhibitors
Each drug (Sigma, unless specified) was dissolved in DMSO to generate a stock
solution of desired concentration and stored at -20 °C. Before use, the drug stock so-
lutions were diluted 1:500 in culture medium to give the required concentrations for
treatment (Table 2.3). When cells seeded 1-2 days prior reached 50-60 % confluency
the original cell medium was replaced with drug-supplemented medium. The plates
were then incubated for 16 hours at 37 °C, 5% CO2 before downstream process-
ing. Negative control cells were treated with equivalent volumes of DMSO vehicle
(vol/vol) to compensate for any DMSO-mediated effects on HPV16 transcript levels;
all qPCR results were normalised to this control.
Table 2.3: Drugs used for pharmacological inhibition of chromatin modifiers
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2.1.7 Cell transfection
Targeted gene knockdown was carried out using small interfering RNAs (siRNAs);
each target gene was depleted using human FlexiTube siRNAs (Qiagen, Crawley,
UK). All siRNAs were used at 10 nM with cells being transfected using Lipofectamine
RNAiMAX (Invitrogen, Paisley, UK) (Table 2.4).
Table 2.4: siRNA used for knockdown experiments
48 hours prior to transfection, cells were trypsinised and seeded into 6-well plates
(for protein extraction) or 12-well plates (for RNA extraction) using cell-type de-
pendent media (Table 2.5). 24 hours after seeding, medium was changed on all
wells and replaced with the appropriate medium without antibiotics. After a fur-
ther 24 hours, and with the cells at approximately 20–30% confluency, the cells were
washed with PBS (in the case of W12 feeder cells were washed off thoroughly) and
the appropriate volume of culture medium without antibiotics placed on the cells
and incubated at 37 °C, 5% CO2 before the cells were transfected with the gene
specific or control siRNA. Briefly, a mastermix was made containing Lipofectamine
RNAiMAX diluted in OptiMEM® (Thermo Fisher Scientific) and incubated at RT
for 5 minutes (Solution 1). During the incubation, siRNA (Qiagen) was added at the
desired concentration to OptiMEM® and incubated at RT for 5 minutes (Solution
2) (Table 2.5). The contents of both tubes were then gently mixed and incubated
for 20 minutes at RT. The siRNA:Lipofectamine complex was pipetted slowly into
each well and gently mixed with the culture medium covering the cells by rocking
the plate. The cells were then incubated at 37 °C, 5% CO2 for 12 hours.
Following the 12-hour transfection, the media:transfecting agent mix was aspi-
rated from each well and the cells washed once with PBS. This was replaced with
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fresh pre-warmed cell-type dependent culture medium without antibiotics, and for
W12 cells medium supplemented with irradiated feeder cells (Table 2.5). 24 hours
after transfection the media was changed again to cell-type dependent media supple-
mented with antibiotics and incubated at 37 °C, 5% CO2. Cells were harvested 48
hours after initial transfection.
Table 2.5: Details for 10 nM siRNA transfection
2.2 DNA analysis
2.2.1 DNA extraction
Genomic DNA (gDNA) was extracted from freshly pelleted cells from monolayer
culture. Cell pellets were resuspended in an appropriate amount of lysis buffer (10
mM Tris-Cl pH 8, 10 mM EDTA pH 8, 150 mM NaCl, 0.4% SDS) and 1 mg/ml
Proteinase K before being incubated for 10 minutes at 55 °C. The tubes were then
incubated for 16 hours at 37 °C in a water bath. If necessary, PBS was added to
viscous samples following Proteinase K digestion, before being transferred to phenol
resistant tubes. An equal volume of 1:1 Tris-saturated phenol:chloroform was added
and the samples and inverted to ensure thorough mixing. The tubes were then
centrifuged at 12,000 x g for 10 minutes. The upper aqueous phase was decanted
into fresh tubes and the phenol:chloroform extraction repeated. The upper phase
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was then removed to fresh tubes and 1/10th total volume of 3 M sodium acetate
(pH 5.2) was added. Two times the volume of ice-cold 100% ethanol was added
and the gDNAs were allowed to precipitate overnight at -20 °C. The gDNAs were
pelleted by centrifugation at 12,000 x g for 30 minutes before being washed in 1
ml of cold 70% ethanol and being transferred to 2 ml Eppendorf tubes. Following
a 10 minute centrifugation at 12,000 x g, the ethanol was removed and the gDNA
pellet air-dried, before resuspension in 50 µl double distilled water (ddH2O) and the
concentration determined using a spectrophotometer by measuring absorbance at
260nm (Nanodrop 2000, Thermo Fisher Scientific) and stored at 4 °C.
2.2.2 Polymerase chain reaction of HPV16 long control re-
gion (LCR)
PCR reactions were conducted to obtain a suitable concentration of DNA to enable
sequencing of the LCR DNA fragment of choice (20 ng/100bp in 10µl) and were
performed using a GeneAmp® PCR System 9700. A range of primers spanning the
HPV16 LCR were used in the following PCR reactions (Table 2.6). The reagents for
PCR were combined in 0.2 ml non-flex PCR tubes (Starlab); 43µl SuperMix, 1 µl
10µM primer mix, 4 µl 25ng/µl DNA and 2µl 2.5mM MgCl2. The reaction was then
carried out using the following cycling conditions: 2 min at 94 °C; 50 cycles of 94
°C for 30 seconds, 55 °C for 30 seconds, and 72 °C for 1 minute; 72 °C for 5 minutes
before cooling to 4 °C. The resultant PCR samples were kept at 4 °C until further
use. Both positive and negative controls for the PCR reaction were conducted; the
positive control mix contained E6/E7 primers, and a PCR mix without DNA and
another without primers were used as negative control reactions. The PCR products
were then mixed with 5 µl of Orange G (SigmaAldrich (O3756)) and run on a 1%
agarose gel alongside 100 bp and 1 kb ladders (New England Biolabs). The resultant
gel was visualised using a Quantity One UV machine (Bio-Rad).
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Table 2.6: Primers used for PCR analysis of LCR of HPV16 positive gDNA
samples
2.2.3 Polymerase chain reaction of virus-host breakpoints
The PCR reactions were conducted to obtain a suitable concentration of DNA to
enable sequencing of the hybrid virus-host fragment (20 ng/100 bp in 10µl) and were
performed using an MJ Research® PTC-255 Thermocycler. A range of primers were
used dependent on the W12 clone breakpoint as identified by the capture sequencing
reaction (Table 2.7). The reagents for PCR were combined in 0.2 ml non-flex PCR
tubes (Starlab); 2.5 µl Buffer 10X (Sigma), 2.5 µl 2 µM dNTP mix, 2.5 µl 2 µM
of both the forward and reverse primers, 2 µl 12.5 ng/µl DNA, 0.5 µl Taq DNA
polymerase with MgCl2 (Sigma, D9307) and 12.5 µl ddH2O. The reaction was then
carried out using the following cycling conditions: 2 minutes at 94 °C; 50 cycles
of 94 °C for 30 seconds, 50.2–60 °C for 30 seconds, and 72 °C for 2 minutes; 72
°C for 5 minutes before cooling to 4 °C. The resultant PCR samples were kept at
4 °C until further use. Both positive and negative controls for the PCR reaction
were conducted; the positive control mix contained E6/E7 primers, and a PCR
mix without DNA was used as a negative control. The PCR products were then
mixed with 2.5 µl of Orange G (SigmaAldrich (O3756)) and run on a 1% agarose gel
alongside a 100 bp ladder (New England Biolabs). The resultant gel was visualised
using a Quantity One UV machine (Bio-Rad).
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Table 2.7: Primers used for PCR analysis virus-host breakpoints
2.2.4 DNA gel extraction
Specific DNA bands identified by 2.2.2 and 2.2.3 were cut out and gel purified in
order to isolate the desired DNA fragment required for sequencing. Extraction of
the DNA from the agarose gel was completed using the QIAquick® Gel Extraction
Kit (Qiagen) according to the manufacturer’s instructions. Briefly, the excised band
was placed in a 1.5 ml Eppendorf tube and the mass of the gel fragment determined.
3x gel volumes of Buffer QG was added to each tube, where 100 mg = 100 µl, and the
sample incubated at 50 °C for 10 min. Once dissolved, 1x gel volume of isopropanol
was added and mixed. The sample mixture was then applied to a QIAquick column
in a 2 ml collection tube and placed in a centrifuge and spun at 17,900 x g for 1
minute. The flow through was discarded and the column washed with 500 µl Buffer
QG followed by 750 µl Buffer PE. The column was then placed into a clean microcen-
trifuge tube and DNA eluted in 30 µl ddH2O. The concentration of DNA was then
determined using a Thermo Scientific Nanodrop 2000 Spectrophotometer. The sam-
ples were then placed in a -20 °C freezer until further use. The DNA sequencing was
completed by the Department of Biochemistry, University of Cambridge according
to the specifications of the institute (DNA at 20 ng/100 bp in 10 µl).
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2.2.5 DNA sequencing analysis
The resultant sequencing files were viewed using DNA sequencing software Chro-
masPro (Technelysium). Chromatograms were used to assess the quality of the
sequence data and the alignment tool was used to compare samples as well as to
detect any changes to the expected sequence.
2.2.6 quantitative-PCR (qPCR) analysis of gDNA samples
To quantify the level of specific hybrid virus-host genomic sequences between sam-
ples, qPCR was used. qPCR was performed using 2 µl of 12.5 ng/µl gDNA (25 ng of
gDNA per qPCR reaction), 10 µl of qPCRBIO SyGreen Mix (PCRBiosystems) and
2 µl of 4 µM of forward and reverse primer pair mix (Table 2.8) in a final reaction
volume of 20 µl/well. Test reactions and no template controls were run in triplicate
on a realplex real-time PCR system (Mastercycler® Eppendorf). The cycling con-
ditions consisted of a 2 min initial denaturation at 95 °C, followed by 40 cycles at 95
°C for 15 sec, 58 °C for 20 sec, 72 °C for 15 sec and 76 °C for 5 seconds. Fluorescence
was measured at the last step of each cycle. Melting curve analyses were obtained
after each qPCR run at 65 °C to 90 °C and showed a single PCR product, confirming
specificity of amplification. Expression ratios of the genomic sequences were calcu-
lated using the comparative threshold cycle (Ct) method described by Pfaﬄ et al.,
2001180, with normalisation to the housekeeping gene GAPDH:
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Table 2.8: Primers used for qPCR analysis of gDNA samples
2.2.7 Calculating primer amplification efficiencies
Primer amplification efficiency (E) is the multiple by which the target is amplified
per PCR cycle, with a theoretical maximal value of 2. All primers used for qPCR
analysis were assessed for efficiency of amplification. These efficiencies were calcu-
lated by setting up reactions as described by 2.4.3 with neat, 1:2, 1:4, 1:10, 1:50 and
1:100 dilutions of gDNA from cells known to express the target. All reactions were
performed in triplicate in 96-well plates, using the SYBR® Green qPCR protocol de-
scribed in 2.4.3. The raw fluorescent data was exported to Microsoft Excel, and the
primer efficiency calculated using a program designed by Dr. Ian Roberts, Hutchin-
son/MRC Cancer Cell Unit, Cambridge. This program calculates primer efficiencies
by plotting the CT values (the intersection between an amplification curve and a
threshold line, i.e. the cycle threshold) for each reaction versus the log10 relative
amount of target amplicon. Linear regression was performed to determine a line of
best fit for the data points and the gradient of the line calculated. Primer efficiency
was calculated using the following equation: E = 10∧(-1/gradient). In addition to
the calculation of the primer efficiency, melting curves were run for new primer sets
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to confirm the presence of only one product; to produce melt curves, the final PCR
product was exposed to a temperature gradient from 60 °C to 95 °C with a heating
rate of 0.2 °C per second while fluorescence readouts are continually collected. The
melt curves are converted to distinct melting peaks by plotting the first negative
derivative of the fluorescence as a function of temperature (-dF/dT)181.
2.3 RNA analysis
2.3.1 RNA extraction from cell lines
Total RNA from cell lines was extracted using Tri Reagent (Sigma Aldrich). If
present in the tissue culture vessel, feeder cells were washed off using 1X PBS and
total RNA from the cells of interest extracted according to the manufacturer’s in-
structions; 1 ml/well of Tri Reagent was used to lyse cells from a 6-well plate and 500
µl/well for a 12-well plate. Briefly, The lysate was mixed by pipetting, transferred to
an RNase-free 1.5 ml Eppendorf tube and incubated for 5 minutes at RT to permit
the dissociation of nucleoprotein complexes. Saturated chloroform (200 µl per 1 ml
of Tri Reagent) was added to the lysate and extracts were inverted rapidly for 15
seconds and incubated at RT for 3 minutes before being centrifuged for 15 minutes
at 12,000 x g at 4 °C (Eppendorf centrifuge 5415R). The upper aqueous phase, con-
taining the RNA, was then transferred to a fresh 1.5 ml Eppendorf tube and 1 µl
GlycoBlueTM (Ambicon) and 500 µl isopropanol per 1 ml of Tri Reagent was added
to precipitate the RNA. Samples were vortexed to mix, incubated for 10 minutes at
RT, and then centrifuged at 12,000 x g for 10 minutes at 4 °C. The supernatant was
carefully removed and the RNA pellet washed in 1 ml of 75% ethanol per 1 ml of Tri
Reagent used. The supernatant was carefully removed and the pellet air-dried for ap-
proximately 10 minutes and re-suspended in 30 µl of nuclease-free water. The RNA
samples were placed at 58 °C for 10 minutes before the concentration and purity of
RNA was determined spectrophotometrically by measurements of absorbance at 260
and 280 nm using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific).
RNA was then either immediately used for complementary DNA (cDNA) synthesis
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or stored at -80 °C.
2.3.2 cDNA synthesis
Synthesis of complementary DNA (cDNA) from RNA was done using the Quanti-
Tect Reverse Transcription Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. In a first step, designed to ensure the removal of any con-
taminating genomic DNA, 1 µg of RNA template and 2 µl of Genomic DNA Wipe-
out buffer were added to an RNase-free 0.2 ml microcentrifuge tube together with
nuclease-free water up to a final volume of 14 µl. The reaction was incubated for 2
minutes at 42 °C and then samples placed immediately on ice. For the reverse tran-
scription reaction step, 1 µl Quantiscript reverse transcriptase, 4 µl Quantiscript RT
buffer and 1 µl RT primer mix (polyT plus random hexamer primers) were added to
0.2 ml microcentrifuge tubes containing RNA template. The mixture was then in-
cubated at 42 °C for 30 minutes to generate complementary DNA (cDNA), followed
by 3 minutes at 95 °C to inactivate the enzyme. Following the reverse transcription
reaction, the synthesised cDNA was diluted 1:10 using ddH2O, and was immediately
used for qPCR amplification or placed at -20 °C for long-term storage.
2.3.3 qPCR analysis of cDNA samples
qPCR was used to quantify the level of relative cDNA levels between samples. qPCR
was performed using 2 µl cDNA (5 ng cDNA per reaction), 12.5 µL SYBR® Green
JumpStartTM Taq ReadyMixTM Green Master Mix (Sigma), 2.5 µL 3 µM of forward
and reverse primer mix (0.3 µM per reaction, Sigma Aldrich, Table 2.9) in a final
reaction volume of 25 µL/well. The qPCR reaction was carried out in triplicate for
each primer pair in 96-well white PCR plates (Starlab) using an Eppendorf Master-
cycler ep gradient S realplex2. The cycling conditions consisted of a 2 minute initial
denaturation at 95 °C, followed by 40 cycles of 95 °C for 15 seconds, 58 °C for 20
seconds, 72 °C for 15 seconds and 76 °C for 5 seconds, and final extension 78 °C
for 8 minutes; fluorescence was measured at the last step of each cycle. The primer
efficiency of each qPCR primer was determined as 2.2.7.
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2.3.4 Quantification of transcript level changes
Based on Vandesompele and co-workers findings (Vandesomplele et al., 2002), a range
of housekeeping genes were tested for each different experimental condition in order
to obtain a baseline level of expression for comparative analysis of gene expression.
Gene expression ratios were calculated using the comparative threshold cycle (Ct)
method described by Pfaﬄ et al. 2004181 (see 2.2.6). The house keeping genes used
for normalisation were: GAPDH, YHWAZ, RPL13A and ACTB (Table 2.9).
Table 2.9: Primers used for qPCR analysis of cDNA samples
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2.4 Protein analysis
2.4.1 Total protein extraction
Cells were washed with cold PBS, lysed in cold radioimmunoprecipitation assay
(RIPA) lysis buffer (Thermo Fisher Scientific) (approximately 70 µl per well of a
6-well plate) supplemented with cOmpleteTM Protease Inhibitor Cocktail (Roche
Diagnostics Ltd., Burgess Hill, UK) (1:25 dilution). Cells were then scraped off
using a cell scraper and were transferred into a pre-cooled Eppendorf tube. After
15 minutes of continuous agitation on a vibrating shaking platform at 4 °C, cellular
debris was removed by centrifugation (15 minutes, 4 °C, 14,000 x g). The supernatant
was transferred to a fresh 1.5 ml Eppendorf tube and immediately quantified or
placed at -80 °C for long term storage.
2.4.2 Protein quantification
Total protein concentration was determined using Pierce bicinchoninic acid (BCA)
protein assay kit (Thermo Fisher Scientific) according to the manufacturer’s instruc-
tion with some modification. Briefly, protein samples were diluted with PBS (2 µl
of protein sample added to 12 µl of PBS, 1:7 dilution) and 3 µl of diluted sample
added to the well of 96-well plate in triplicate. The BSA stock standard at 1 mg/ml
concentration was used to generate a standard curve and was added to each well at
5 different volumes in triplicate: 0 µl (Blank), 1 µl, 3 µl, 5 µl, 7 µl and 10 µl. The
provided Reagent A and Reagent B were mixed together in a ratio of 1:50 and 200
µl of the mixture was added to each well and incubated for 30 minutes at RT in the
dark. Absorbance was measured at a wavelength of 570 nm using a Dynex Technolo-
gies plate reader and Revelation software. Protein concentrations were determined
using a standard curve (Figure 2.1).
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Figure 2.1: Example of a standard curve used for BCA assay to determine
protein concentration based on Absorbance values.
2.4.3 Protein sample preparation and SDS-PAGE separa-
tion
Quantified protein extract (25 µg) was added to 5 µl of NuPAGE LDS Sample Buffer
and 2 µl of NuPAGE Sample Reducing Agent (both from Novex, Thermo Fisher Sci-
entific) made up to a final volume of 20 µl with 1X PBS. Samples were denatured
for 10 min at 95 °C and run immediately or stored at -20 °C. The appropriate pre-
cast gel (all Thermo Fisher) (CDK9, TIP60, HDAC1 detection: 4–12% NuPAGETM
Bis-Tris Mini Gel; p300 detection: 3–8% NuPAGETM Tris-Acetate Protein Gel) was
placed in an XCell SureLock Mini-Cell and the inner tank filled with the appropriate
running buffer supplemented with 500 µl NuPAGE Antioxidant (NuPAGE MOPS
SDS Running Buffer or NuPAGE Tris-Acetate SDS Running buffer, respectively);
and the outer tank filled to the level of the well base Running Buffer without antiox-
idant. The samples were loaded, along with 5 µl of See Blue molecular weight ladder
(Novex, Thermo Fisher Scientific). Proteins were separated by electrophoresis at 150
V until the desired protein separation was achieved (approximately 1.5 hours).
2.4.4 Western blotting
A PVDF membrane (Thermo Fisher Scientific) and two pieces of 3MM Whatman®
filter paper were cut to 7 x 8 cm. The PDVF membrane was then activated by incu-
bation in 100% methanol for 15 seconds followed by a 2-minute rinse in ddH2O. The
activated membrane, along with the filter paper and four sponges were then placed
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in ice-cold Transfer Buffer (Thermo Scientific) supplemented with 10% ethanol and
0.1% NuPAGE Antioxidant. Protein samples separated by SDS-PAGE were trans-
ferred to the PVDF transfer membrane using the XCell SureLock Mini-Cell and
XCell IITM blot module. Firstly, XCell SureLock Mini-Cell was dismantled, gel sep-
arated from one of its plates and top lanes and very bottom part of the gel cut away.
A sheet of 3MM filter paper was then adhered to the gel and gel carefully peeled
away from the plastic plate. The equilibrated PVDF membrane was then carefully
placed on top of the gel ensuring that no air bubbles were present. Another sheet
of 3MM filter paper was placed on top of the PVDF membrane and the ‘sandwich’
placed on top of two pre-soaked two sponges that had been placed on top of the
cathode core of the XCell IITM blot module. Another 2 pre-soaked sponges were
then placed on top of the ‘sandwich’, the lid of the blot module placed on top and
the whole assembly inserted into the XCell SureLockTM Mini-Cell. The blot module
was topped up with Transfer Buffer, the outer reservoir filled with ice-cold ddH2O
and the whole device placed in a 4 °C room. The protein transfer was performed
for 2 hours at 30 V. After completion of the transfer, the blot module was disman-
tled and the membrane placed in Blocking Buffer (5% milk, 1% Tween in 1X PBS)
and incubated at 4 °C overnight with gentle rocking. After incubation in blocking
buffer, the membrane was transferred to an Antisera Buffer (5% milk, 0.1% Tween in
1X PBS) containing the primary antibody at the appropriate dilution (Table 2.10)
and incubated once more at 4 °C overnight with gentle rocking. The following day,
the membrane was washed 3 times for 5 minutes each with Antisera Buffer at RT
before incubation for 1 hour in species-specific HRP-conjugated secondary antibod-
ies diluted in Antisera buffer at RT. Following three further washes in 1X PBS +
0.05% Tween, the membrane was developed using enhanced standard chemilumi-
nesence (ECL) or ECL prime western blotting detection reagents (Amersham, GE
Healthcare, Little Chalfont, UK) according to the manufacturer’s instructions and
exposed to autoradiographic films at various time-points. If required, the blots were
stripped with Stripping Buffer (10 minute incubation at 37 °C in the dark; Thermo
Fisher Scientific) and blots incubated with blocking buffer and re-probed with differ-
ent primary antibodies. The images were scanned and densitometry analyses were
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performed using FluorChem-9900 imaging system software (Alpha Innotech, San Le-
andro, U.S), with normalisation to a loading control (β-tubulin) and referencing to
the chosen control samples set to 1.
Table 2.10: Antibodies used for Western Blotting
2.5 Chromatin immunoprecipitation (ChIP) assays
2.5.1 Cell fixation
W12 cells were grown to 70–80% confluency in a 15 cm tissue culture dish as in
2.1.3. Once ready to harvest, the cells were cross-linked using 20 ml Fixation Solu-
tion (540 µgl 37% formaldehyde, 20 ml cell culture medium; 1% final formaldehyde
concentration) on a shaking platform for 10 minutes at RT. The fixation reaction
was quenched by removal of the fixation solution followed by a wash with ice-cold 1X
PBS and the addition of 10 ml Glycine Stop-fix solution (1 ml 10X Glycine Buffer,
1 ml 10X PBS, 8 ml ddH2O) and rocking for 5 minutes at RT. The cells were then
washed for a second time with 1X PBS before being removed from the dish using a
cell scraper and 2 ml ice-cold cell scraping solution supplemented with 10 µgl 100
mM PMSF. The cell:solution mix was then transferred to a 15 ml Falcon tube and
placed on ice. The solution was spun at 720 RCF at 4 °C for 10 minutes and the cell
pellet frozen at -80 °C after the addition of 1 µl 100 mM PMSF and 1 µl protease
inhibitor cocktail (PIC) (both provided by Active Motif).
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2.5.2 Shearing of chromatin
The cell pellet was thawed and resuspended in 1 ml ice-cold Lysis Buffer supple-
mented with 5 µl PIC and 5 µl PMSF, and incubated on ice for 30 minutes. Fol-
lowing incubation, the nuclei were released from cells by performing 30 strokes in an
ice-cold dounce homogeniser. Samples were then centrifuged at 2,400 RCF for 10
minutes at 4 °C to pellet the nuclei, which were then resuspended in 400 µl Shearing
buffer before incubation at 37 °C for 5 minutes. Next, the DNA was sheared using
a sonicator (Active Motif, model no. Q120AM) at 25% power for 10 minutes of 30
seconds on 30 seconds off. The sheared chromatin samples were then centrifuged at
18,000 RCF at 4 °C for 10 minutes. The supernatant, containing the chromatin, was
collected and place in a fresh tube 1.5 ml Eppendorf tube and used immediately (see
2.5.3) or stored at -80 °C until later use. At this stage, a 50 µl aliquot of sheared
chromatin was removed for use as a control sample (input) for downstream process-
ing. The DNA shearing efficiency was then checked by running a small aliquot on a
1.5% agarose gel and the concentration of the chromatin sample was measured using
a Nanodrop 2000 Spectrophotometer.
2.5.3 Immunoprecipitation
Immunoprecipitation (IP) was performed by incubating 7 µg of chromatin per reac-
tion with protein G magnetic beads (25 µl), ChIP buffer1 (10 µl), PIC (1 µl) and
ChIP antibody (Table 2.11) to a final volume of 100 µl in siliconised microcentrifuge
tubes which were placed on an end-to-end rotator overnight at 4 °C. After overnight
incubation the beads were pelleted using a magnetic stand and the supernatant dis-
carded. The beads were then washed with ChIP buffer 1 followed by two washes with
ChIP buffer 2. After the wash steps, the beads were pelleted and the supernatant
discarded once more.
2.5.4 Elution of chromatin and cross-link reversal
The beads were then resuspended in 50 µl Elution Buffer AM2 and incubated at RT
on an end-to-end rotator. 50 µl Reverse Cross-linking Buffer was added to the eluted
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chromatin and samples placed quickly on a magnetic stand to pellet the beads. The
supernatant, containing the eluted chromatin, was transferred quickly to a fresh 1.5
ml Eppendorf tube. At this stage 10% of IP sample volume was taken from the
input DNA sample (from 2.5.2), 2 µl 5M NaCl added, and the total volume made
to 100 µl using ddH2O. All samples were incubated at 95 °C for 15 minutes, then
2 µl Proteinase K added to each before incubation at 37 °C for 1 hour, followed by
addition of 2 µl Proteinase K Stop Solution. The DNA samples were cleaned using
a QIAquick PCR Purification Kit (Qiagen) prior to qPCR, and the purified DNA
used for qPCR or stored at -20 °C.
2.5.5 ChIP-qPCR
qPCR of ChIP samples was performed as previously described (2 µl gDNA, see
section 2.2.6). Multiple primer pairs were used to test for enriched sequences at
different locations across the HPV16 genome (Table 2.12) and the primer efficiency
for each determined as in 2.2.7. To calculate the relative levels of enrichment of each
ChIP reaction for every primer set, the target Ct values were compared to input Ct
values before normalisation to a control region of the host as described in Table 2.11.
By incorporating the average Ct values of the input DNA in both the numerator
and the denominator of the equation, the number of viral copies in each clone is
accounted for.
2.6 Statistical analysis
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad
Software, La Jolla, U.S.). For comparisons between groups, an unpaired, two-tailed
Students t-test was used. P-values <0.05 were considered statistically significant.
Data are presented as mean ± SEM.
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Table 2.11: Antibodies used for ChIP experiments
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Table 2.12: Primers for ChIP-qPCR of HPV16 chromatin
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2.7 Fluorescent in situ hybridisation (FISH)
The method for performing 3D FISH with directly labelled DNA probes was based
upon the methods outlined in Bolland et al. 2013182, with a few alterations. See
Figure 2.2 for workflow.
2.7.1 Preparation of FISH slides
W12 G2p11 cells (same passage number as used in SCRiBL) were resuscitated and
grown in a 10 cm2 tissue culture dish as previously described. Once at 70–80%
confluency the cells were trypsinised, washed in ice-cold PBS and the concentration
determined. The cells were then diluted to 5 x 105 /ml in 1X PBS. 20 µl of the
cell suspension was then pipetted on to the centre of a polysineTM slide (VWR)
and incubated at RT for 30 minutes to allow the cells to settle and adhere to the
slide. Following incubation, the cells were fixed on the slide by submerging into 4%
paraformaldehyde (PFA) for 10 minutes. The fixation reaction was quenched by
placing the slides in a 155 mM glycine solution for 10 minutes at RT in a coplin
jar. The cells were then permeabilised in a 0.1% saponin/0.1% Triton-X/1X PBS
solution at RT for 10 minutes. The slides were then washed once in 1X PBS and
stored at -20 °C in 50% glycerol/1X PBS until further use (slide storage up to 1
month).
2.7.2 Growing BAC colonies
BAC clones were ordered from Thermo Scientific (Table 2.13). A pipette tip of each
BAC clone was used to streak bacteria onto an agar plate supplemented with 20
µg/ml (100 µg/ml for HPV16) and the agar plates incubated at 37 °C overnight.
Following incubation, a single colony was picked using a 200 µl pipette tip and used
to streak on a fresh agar plate with the appropriate concentration of chloramphenicol,
which was again incubated at 37 °C overnight and the original agar plate labelled,
wrapped in parafilm and stored at 4 °C. Following the second overnight incubation,
a pipette tip was used to pick a colony from the agar plate containing growth from
a single colony and placed in 5 ml LB broth supplemented with chloramphenicol (4
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µl), which was incubated at 37 °C with gentle shaking for 6-8 hours. Again, the
agar plate was wrapped in parafilm and stored at 4 °C for future use. This was then
transferred into 200 ml LB broth supplemented with chloramphenicol (160 µl) in a
1 L conical flask and incubated at 37 °C shaking at 2,500 rpm overnight (incubated
shaker, New Brunswick Scientific Incorporated). The reaction was stopped when the
solution appeared cloudy and was put on ice to cool. 700 µl of the overnight culture
in LB broth was mixed with 300 µl sterile 50% glycerol, mixed, and stored at -80
°C for future use. The remaining bacteria were harvested from the LB culture by
centrifugation at 6,000 RCF in an ultra centrifuge (Beckman AvantiTM J-20 series)
for 15 minutes at 4 °C, the pellet was then frozen at -20 °C until further use.
Table 2.13: details of BAC clones used in 3D FISH experiment
2.7.3 Extraction of BAC DNA
The extraction of BAC DNA was done using the NucleoBond® BAC 100 plasmid
DNA purification kit (Macherey-Nagel) according to the manufacturer’s instructions.
Briefly, the bacterial pellet (from 2.7.2) was defrosted on ice and the cells lysed
by resuspending the pellet in 24 ml Buffer S1 supplemented with RNase A (100
µg/ml). 24 ml Buffer S2 (pre-warmed to 30 °C) was added to the suspension mixed
by inversion, and incubated at RT for 3 minutes. 24 ml of pre-cooled (4 °C) was then
adding to the suspension, mixed by inversion and incubated on ice for 5 minutes.
During this time the Nucleobond® BAC 100 (Maxi) Column was equilibrated with
6 ml Buffer N2. The bacterial lysate was then cleared by filtration; a Nucleobond®
Folded Filter was placed in a plastic funnel and dampened with a few drops of
Buffer N2. The bacterial lysate was then loaded onto the filter and the flow-through
collected. The cleared lysate was then loaded on to the equilibrated column and the
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column emptied by gravity flow (DNA bound to the column). The column was then
washed twice with 18 ml Buffer N3 and the flow-through discarded. The BAC DNA
was then eluted from the column with 15 ml Buffer N5 pre-warmed to 50 °C and
collected in a 50 ml centrifuge tube (VWR). 11 ml room-temperature isopropanol
was then added and mixed to precipitate the eluted plasmid DNA and centrifuged at
18,000 RCF (Beckman Coulter Avanti J-25) for 30 minutes at 4 °C. The supernatant
was then carefully discarded and the DNA pellet washed with 1 ml 70% ethanol and
the pellet transferred to a 1.5 ml Eppendorf tube. The DNA was pelleted again by
centrifugation at RT and washed once more with 500 µl 70% ethanol. The ethanol
was then removed and the pellet dried at RT. Once dry, the pellet was re-suspended
in 200 µl ddH2O and the DNA concentration determined by Nanodrop.
2.7.4 Extraction of HPV16 plasmid DNA
The extraction of HPV16 plasmid DNA was carried out using the GenElutetextsu-
perscriptTM Plasmid Miniprep kit (Sigma Aldrich) according to the manufacturer’s
instructions. Briefly, the bacterial pellet (from 2.7.2) was completely re-suspended
in 200 µl Resuspension Solution before the addition of 200 µl Lysis Solution. The
solution was mixed by inversion and incubated on ice for up to 5 minutes. 350 µl
Neutralisation/Binding Solution was then added and the solution mixed by inversion
before being spun in a table-top microcentrifuge (Eppendorf 5415 D) at maximum
speed for 10 minutes. The GenElute Miniprep Binding Column was then prepared
by insertion into a provided microcentrifuge tube, followed by the addition of 500
µl Column Prep Solution, spinning at maximum speed for 1 minute, and the flow-
through discarded. The cleared lysate (supernatant) from the previous step was then
transferred to the column and spun at maximum speed for 1 minute. The column
was then washed with 750 µl Wash Solution. The DNA was eluted from the col-
umn in 50 µl pre-warmed (65 °C) ddH2O and the DNA concentration determined by
Nanodrop.
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2.8 Generating directly labelled DNA probes by
nick translation
2.8.1 Nick translation
The nick translation reaction contained: 2 µg DNA (in 54 µl), 10 µl 10x NTB
(1 M Tris-HCl, pH 7.5, 1 M MgCl2, 10 mg/ml BSA fraction V), 10 µl DTT (0.1
M) (Thermo Fisher Scientific), 8 µl d(GAC)TP mix (0.5 mM each), 2 µl dTTP
(0.5 mM), 12 µl aminoallyl-UTP (0.5 mM, Sigma), 2 µl DNA polymerase I (10
U/µl, New England Biolabs), 2 µl DNase I (1:25 dilution with 1X buffer, Roche).
The reaction mixture was incubated at 16 °C for 2 hours and then placed on ice.
Following incubation, 1 µl was run on a 2% agarose gel and the DNase I inactivated
by heating the reaction mixture to 75 °C for 5 minutes. The amine-modified DNA
was then purified using a QIAquick PCR Purification kit (Qiagen) and eluted in
100 µl ddH2O. The DNA was precipitated by the addition of 10 µl NaOAc (3M, pH
5.2) and 250 µl 100% ethanol and incubation at -20 °C overnight. After, the sample
was spun at maximum speed for 30 minutes and 4 °C and the resulting DNA pellet
washed with 100 µl 70% ethanol. The pellet was then re-suspended in 6 µl ddH2O
and 1 µl used to determine the concentration by UV-Vis spectroscopy (Nanodrop).
2.8.2 Coupling fluorescent dye
Fluorescent labelling of the probe is achieved by chemical coupling of dye (see table
2.13). 5 µl amine-modified DNA (max. 2 g) was heated to 95 °C for 5 minutes and
snap cooled on ice. 3 µl NaB labelling buffer (0.2 M sodium bicarbonate pH 8.3,
Sigma) was added and mixed. To this, the amine-reactive dye reconstituted in 2 µl
DMSO was added, the solution mixed and incubated in the dark at RT for 1 hour.
Following incubation, 40 µl ddH2O was added and the labelled probe purified using
the QIAquick PCR purification kit, with two column washes with buffer PE and the
DNA eluted in 50 µl ddH2O. The probe concentration and labelling efficiency was
determined by UV-Vis spectroscopy (Nanodrop) and use of an algorithm written by
Dr Daniel Bolland, Babraham Institute.
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2.8.3 Probe precipitation
To precipitate the probes required for DNA FISH, 20 ng of each directly labelled
probe required per slide was mixed with 2 µl human cot-1 DNA (6 µg), 1 µl single
stranded DNA from salmon sperm testes (9.7 µg) and the volume adjusted to 100 µl
with ddH2O. 10 µl 3 M NaOAc and 275 µl ethanol was then added and the solution
mixed by inversion and incubated at -20 °C for at least 1 hour. After incubation, the
precipitation reaction was spun at maximum speed (14,500 RCF) for 30 minutes at 4
°C and the pellet washed with 70% ethanol. The dried pellet was then re-suspended
in 5 µl formamide and incubated at 37 °C, shaking at 1,000 rpm protected from light.
After 30 minutes, 5 µl pre-made dextran sulphate mix (20% dextran sulphate in 2x
SSC) buffer was added and put back on the heated shaker for a further 10 minutes.
The probe was mixed thoroughly before pipetting onto the coverslip.
2.9 DNA FISH
The slides (from 2.7.1) were taken from storage at -20 °C and put into 20% glyc-
erol/1X PBS to equilibrate to RT for at least 20 minutes. 3x freeze/thawing cycles
were then performed in liquid nitrogen. One slide at a time was submerged in liq-
uid nitrogen using forceps for 5–6 seconds or until the characteristic popping sound,
and placed on a paper towel to defrost. The opaque frozen glycerol thawed before
repeating the freeze/thaw cycle for a total of 3 times in liquid nitrogen. Following
completion of all the necessary slides, all were washed twice in 1X PBS for 5 min-
utes each before incubation in 0.1 M HCl for 30 minutes at RT. Following this, the
slides were again washed twice in 1X PBS for 5 minutes at RT before the slides were
equilibrated in 50% formamide/2X SSC for 10 minutes at RT. The slides were put
in 1X PBS immediately before adding the probe to the cells.
10 µl probe was pipetted on to the centre of a 22 x 22 mm coverslip and protected
from any light source. One at a time, slides were removed from 1X PBS and any
excess liquid around the cell spot was dried using a paper towel. The coverslip was
then quickly inverted onto the slide covering the cell spot and sealed with rubber
cement (Fixogum, Marabu) and the slides protected from light at all subsequent
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stages of the protocol. Once all coverslips had been added, the slides were placed on
a heat block at 78 °C for exactly 2 minutes before being transferred to a light-tight
humidified chamber and incubated at 37 °C overnight (at least 16 hours).
The following day the rubber cement was peeled off and the slides placed in 2X
SSC for 15 minutes to enable the coverslips to loosen. The slides were then washed
in the following series of washes; 50% formamide/2X SSC at 45 °C for 15 minutes,
0.2X SSC at 63 °C for 15 minutes, 2X SSC at 45 °C for 5 minutes, 2X SSC for 5
minutes and finally 1X PBS for 5 minutes, both at RT. The slides were then stained
in a DAPI solution (1 µg/ml) for 2 minutes at RT and de-stained in 1X PBS for 5
minutes. The slides were once again fixed in a 3.7 % formaldehyde/1X PBS solution
for exactly 5 minutes at RT before being quenched in 155 mM glycine for at least 30
minutes to remove the autofluoresence of the formaldehyde. The slides were washed
in 1X PBS for 5 minutes at RT before mounting a 22 x 50 mm coverslip using 30
µl ProLong® Diamond Antifade Mountant (Life Technologies) and sealing with nail
varnish.
Figure 2.2: Workflow for probe labelling and DNA FISH (Bolland et al.
2013)182
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2.10 DNA FISH analysis
2.10.1 Microscope analysis
All FISH slides were analysed at the Babraham Institute using their facilities, with
supervision from Olga Mielczarek (PhD student, Corcoran Lab, Babraham Institute).
Successful probe hybridisation was determined by first looking at the slides using an
Olympus FV1000 confocal microscope. Once a successful FISH reaction had been
confirmed, the slides were transferred to a MetaSystems Metacyte connected to Zeiss
Axio Imager Z2 microscope for more detailed analysis; the Metacyte scans the slide
and automatically images fields of view with multiple cells, capturing the fluorescent
signals across twenty focal planes. For this experiment a 3-probe assay of wavelengths
488 (green), 555 (red) and 647 (far red) was programmed.
2.10.2 Determining probe distance
Following Metacyte analysis the data was transferred to a computer where the data
was analysed using Metafer 4 v3.11.2 software. Metafer performs an automated anal-
ysis of fluorescence signals including the identification of the number of fluorescent
spots per cell and distance between signals. A total of ∼1500 cells per slide were
captured using the Metacyte; cells containing human BAC probes ≠ 2 and HPV
probe ≠ 1 were discarded from the subsequent analysis of the 3D distances between
probes. The x, y and z coordinates between all 3 probes were exported and analysed
using a customised Perl script (Felix Krueger, Babraham Institute). The Perl script
identified the 3D distances between each probe in each individual cell (8 combina-
tions in total), i.e. red1/green, red2/green, far red1/green etc. The chromosome of
interest was identified by the presence of a green signal (HPV probe), and the dis-
tance between the red signals (ARL15 probe) to the HPV integrant was determined
by identifying the smallest distance between red1/green and red2/green. The small-
est distance represents a cis interaction between the HPV probe and the ARL15
site on the integrated allele whilst the longer distance is in trans in relation to the
ARL15 site on the unintegrated allele. The same analysis was performed on the far
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red signals (control probe) and the distance between HPV-ARL15 and HPV-control
compared.
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Chapter 3
HPV16 oncogene expression levels
during early cervical
carcinogenesis are determined by
the balance of epigenetic
chromatin modifications at the
integrated virus genome
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3.1 Introduction
Previous work carried out by the Coleman group characterised a panel of seventeen
W12 integrant clones that were isolated from a mixed cell population in a non-
competitive manner. In contrast to the current dogma of cervical carcinogenesis,
the study showed that in comparison to episome-containing cells, HPV16 integration
does not necessarily lead to a competitive growth advantage, nor does it always in-
crease the expression levels of the virus oncogenes183. Additionally, the genome copy
number was compared to the individual HPV16 expression levels of each of the inte-
grant clones to determine the level of transcription per DNA template copy. Across
the seventeen clones examined, the range of E6 and E7 transcript level per template
varied by approximately 17-fold and 16-fold, respectively183. This data indicated
that the difference in the level of transcription from integrated HPV genomes is not
dependent on virus copy number; clones containing a high DNA copy number dis-
played relatively low levels of expression per template and vice versa. However, there
were a number of examples where clones containing the same and/or similar virus
DNA copy number showed significant differences in the levels of E6/E7 expression
per template (Figure 3.1).
Initial investigations into possible reasons for the significant variation in the level
of virus oncogene transcripts per template showed that epigenetic differences in the
virus chromatin influenced the level of transcription from the virus early promoter.
The study indicated that post-translational modification (PTM) of histone tails is a
mechanism by which the expression of the viral oncogenes is controlled183.
In order to provide a tractable system, and to avoid any complexity caused by het-
erogeneous changes in cells containing concatemerised integrants, clones with genome
copy number less than or equal to four were analysed. From this group, two clones
with high levels of expression per template (F and A5), two with medium levels (D2
and H), and one with low levels of expression per template (G2) were selected. The
three groups of clones, each with statistically different levels of oncogene expression,
were used as comparators to one another in the analysis of epigenetic regulation of
the integrated HPV16 DNA genome.
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Figure 3.1: A plot of mean E6/E7 expression per template versus template
copy number per cell across the W12 integrant clones183. Individual clones
are represented by black circles.
As previously discussed, individual marks as well as patterns of PTMs of histone
tails are associated with varying levels of transcription from gene promoters. By in-
vestigating whether the abundance and distribution of hallmark PTMs correlate with
the levels of HPV16 transcription, this investigation aimed to elucidate whether this
type of epigenetic regulation has a direct influence on expression of the virus onco-
genes in pre-malignant cervical keratinocytes. Both characteristic methylation and
acetylation marks have been examined and include marks that are associated with
active transcription: H3K4me3, predominantly found at gene promoters; H3K4me1,
found at all enhancer elements; and H3K27ac, a PTM associated with the subset of
active enhancers184. To balance this, hallmark PTMs that result in transcriptional
repression were also examined, namely H3K9me2, H3K27me2 and H3K9me3.
In addition to the analysis of the abundance of hallmark PTMs associated with
the integrated HPV genome, this study sought to determine functional significance of
enzymes responsible for laying down these marks with particular focus on acetylation
of histone tails (H3ac, H3K27ac, H2AK5ac). As previously mentioned, the covalent
attachment of an acetyl-moiety onto lysine residues present on histone tails results in
specific epigenomic patterns that correlate with active transcription. This study will
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focus of the activity of two type A HATs: p300 (EP300) and TIP60 (Tat-interacting
protein 60 kDa; also known as KAT5). p300 is a global HAT that is able to efficiently
acetylate the amino-terminal tails of all four-core histones, whereas TIP60 is more
selective, primarily targeting the tails of histone H4 and H2A for acetylation185, 186.
Additionally, it has been shown that somatic mutations in the p300 and TIP60 ORFs
occur in a number of malignancies187, 188, 189. Mutations that result in augmented
HAT activity lead to the increased expression of the viral oncogenes, which, in turn,
accelerate disease progression and as such HATs p300 and TIP60 represent potential
targets for the control of transcription from the integrated HPV16 early promoter.
This part of the investigation aimed to determine epigenetic modifications to the
integrated HPV16 genome that might affect the levels of transcription from the virus
early promoter. Fundamental to the level of transcription of any gene is the activity
of RNAPII. As previously discussed, the conversion from the paused/poised version
of the enzyme to the actively elongating form is mediated by the kinase CDK9 within
the P-TEFb complex; dysfunctions in the CDK9-related pathway have been shown
to be related with several malignancies including advanced solid tumours, leukemia
and lymphomas190.
In the first part of this chapter, the abundance and distribution of hallmark PTMs
and RNAPII, and its associated forms, across the viral genome were characterised
by performing chromatin immunoprecipitation (ChIP) assays followed by RT-qPCR
analysis of the integrated viral genome. Secondly, the functionality of p300 and
TIP60 HATs as well as CDK9 in the context of P-TEFb were probed by depletion
and inhibition with siRNAs and small molecule inhibitors, respectively.
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3.2 Results
3.2.1 Genetic mutation of the HPV16 LCR is not responsi-
ble for the differential oncogene expression of the W12
integrant clones.
Since the aim of this study was to investigate whether changes to the epigenetic
landscape of the HPV16 genome are responsible for the differential viral expression
in clones from the polyclonal W12 cell line, genomic sequencing of the LCR of all
W12 clones was carried out to determine any mutations and dismiss the possibility of
aberrant transcription factor binding and consequent differential virus gene expres-
sion. Polymerase chain reaction (PCR) of the LCR genomic region and subsequent
sequencing was carried out on twelve different integrant clones derived from the W12
Series2 cell line, two early passage W12 episomal cell lines as well as SiHa cells and
compared to the published W12E DNA sequence (GenBank: AF125673.1). Two
forward and two reverse orientation primers spread across the HPV16 LCR genome
were used to amplify viral DNA to the required concentration for DNA sequencing
(20 ng/100 bp in 10 µl) (Figure 3.2 A). Optimisation of PCR conditions for the
amplification of 7045F-223R was carried out using a range of MgCl2 concentrations
and primer annealing temperatures. This indicated that 62.5 °C and 2.5 mM MgCl2
were the most favourable conditions based on product band intensity and these con-
ditions were carried forward (Figure 3.2 B). Full length PCR products (7045F-223R)
were only produced at the required concentration for sequencing for W12 cell lines
Par1, Par2, A5 and G2 (Figure 3.2 C; lanes 1, 2, 4 and 8, respectively); hence it was
decided to use primer pairs 7045F-7681R (Figure 3.2 D) and 7555F-223R (Figure
3.2 E) to re-amplify the LCR of all lines. DNA samples obtained by gel extrac-
tion were then sequenced and the data overlaid to compare the sequences of each
clone. Analysis indicated there were no genetic mutations in the W12 clones, apart
from a single nucleotide deletion in one of the seven integrant copies of the viral
genome in clone R2 (Figure 3.3). In addition, differences in the SiHa genomic se-
quence compared to W12E correlated with the published SiHa sequence (GenBank:
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AF001600.1/AF001599.1) (Appendix 1). The lack of a genomic mutation after anal-
ysis of the LCR sequence of the W12 clones indicated that genetic factors did not
differentially influence viral expression across the clones.
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Figure 3.2: Amplification of the long control region (LCR) by PCR across
a panel of 14 W12 integrant clones. A) Diagram showing the location of PCR primer
sets specific for the HPV16 LCR region and the amplified product length. Numbers refer to the
location of the 5 end for the forward primer relative to the start of the annotated HPV16 genome.
B) Optimisation of conditions for PCR of HPV16 LCR using primers 7045F-223R. PCR reactions
were conducted at a range of temperatures; 1=50.0°C, 2=52.5°C, 3=55.0°C, 4=57.5°C, 5=60.0°C,
6=62.5°C at three different concentrations of MgCl2 (1.5, 2.5 and 3.5 mM) for 50 PCR cycles. M
is a marker (100 bp ladder), and each 50 µl PCR sample was run on a 1 % agarose gel. PCR
reaction of the LCR of numerous W12 cell lines using primers (C) 7045F-223R, (D) 7045F-7681R
and (E) 7555F-223R. PCR reactions were conducted at 62.5°C with a 2.5 mM concentration of
MgCl2 using different W12 cell lines; 1=W12 Par1, 2=W12 Par2, 3=W12 Cl. 3, 4=W12 Cl. A5,
5=W12 Cl. D2, 6=W12 Cl. E3, 7=W12 Cl. F, 8=W12 Cl. G2, 9=W12 Cl. H, 10=W12 Cl. H2,
11=W12 Cl. J3, 12=W12 Cl. Q, 13=W12 Cl. R2, 14=W12 Cl. S2. Control reactions included;
15=SiHa, 16=NCx/6, 17=W12 Par1 (no primers) [neg ctrl], 18=reaction specific primer pair (no
DNA) [neg ctrl], 19=W12 Par1 (E6-E7) [pos ctrl]. Targets were amplified using primer pairs for 50
PCR cycles. 20 µl of each sample was loaded onto a 1 % agarose gel.
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Figure 3.3: Genomic sequencing of the long control region (LCR) of W12
clone R2. A) DNA sequence called computationally by the program Chromas Pro;
bases determined by the height of each peak. B) Chromatogram produced by Sanger
sequencing the PCR product generated across the LCR of the HPV16 genome. C)
DNA sequence of the frame shift caused by the apparent deletion of a thymine residue
at position 7491. A - green, T- red, C - blue, G - black.
3.2.2 HPV16 oncogene expression from the W12 integrant
clones depends upon the level of association of acti-
vating or repressive chromatin marks.
Having identified that the cause of differential HPV16 expression in the W12 inte-
grant clones was not due to a genetic mutation in the LCR of the viral genome, the
aim was then to assess the epigenetic environment of the W12 integrant clones with
viral genome copy number less than four (F, A5, D2, H, G2), which have a wide
variation in E6/E7 transcript abundance per template between them. In the first
instance, chromatin immunoprecipitation reactions were performed using antibodies
specific to active histone post-translational modifications (PTMs) to quantify levels
at the integrated virus genome. ChIP analysis showed that higher virus oncogene
expression per template was associated with greater levels of H3K4me3 across the
early genes E6, E7 and E1, a hallmark of transcriptional activity. Although the asso-
ciation of H3K4me3 with the HPV genome appeared to occur that the same position
in each of the W12 clones — the central LCR — the profiles of W12 clones F and
A5 altered slightly with the highest peak in F located over gene E6 and the highest
peak in clone A5 over E7. In W12 clone G2 the peak of H3K4me3 abundance over
E6 was much smaller than the highly expressing clones, and, in contrast to W12
clones F, A5, D2 and H the abundance of H3K3me3 appeared to be maintain across
E7 and E1 portions of the HPV16 genome. Additionally, the H3K4me3 PTM was
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absent from L1 gene in all five clones. (Figure 3.4 A).
The cells with high expression per template also showed enrichment of the histone
PTMs associated with gene enhancer/promoter regions H3K4me1 and H3K27ac (Fig-
ure 3.4 B and C). The H3K4me1 ChIP profiles of the highly expressing W12 clones F
and A5 were very similar with peaks over the central/3’ LCR and mid-way through
the early gene E1, however, the profiles for the medium expressing clones D2 and H
were very different. As with F and A5, two main peaks of H3K4me1 were observed
on W12 clone H, one over the LCR and the other over E7 — this is upstream of the
second peak observed in clones F and A5. In W12 clone D2 however, H3K4me1 was
more abundant over the 3’ end of the L1 gene remained high over the 5’ end of the
LCR. Abundance then sharply decreased at the central LCR and slowly increased
until a broad peak over E1. The profile of clone G2 was similar to that of F/A5,
however the level of the activating H3K4me1 mark was much reduced.
Whereas there were peaks of H3K4me1 distributed across the length of the virus
genome tested, the H3K27ac mark was found predominantly over the LCR and early
genes of each virus genome (Figure 3.4 C). The main deviation from this trend was
seen in clones A5 and D2, both of which had greater peaks of the H3K27ac at the
5’ end of E1, over the region of the E8 promoter (splice donor SD1302)191.
After determination of the association of active PTMs with the integrated HPV16
genome, ChIP analysis was also carried out using antibodies against hallmarks of
repressive chromatin. In this instance the opposite observation was made; lower
levels of expression per template were associated with higher levels of each PTM
tested, namely H3K9me2, H3K27me2 and H3K27me3 (Figure 3.5 A-C).
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Figure 3.4: Integrated HPV16 genome associations with active histone
post-translational modifications (PTMs). Level of association of the histone
PTM (A) H3K4me3, as well as the transcriptional enhancer marks (B) H3K4me1
and (C) H3K27ac. In each graph, the y-axis shows the relative levels of enrichment
normalised to host control target regions as indicated in italics under each panel. The
x-axis and underlying schematic show the region of the HPV16 genome analysed.
Data presented as mean ± SEM (n=2). In all panels, data for each of the five clones
are colour coded according to the key at the foot of the figure.
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Figure 3.5: Integrated HPV16 genome associations with repressive his-
tone PTMs. Level of association of the histone PTM (A) H3K9me2, (B) H3K27me2
and (C) H3K27me3. In each graph, the y-axis shows the relative levels of enrich-
ment normalised to host control target regions as indicated in italics under each
panel. The x-axis and underlying schematic show the region of the HPV16 genome
analysed. Data presented as mean ± SEM (n=2). In all panels, data for each of the
five clones are colour coded according to the key at the foot of the figure.
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3.2.3 Level of HPV16 integrant transcription per template
correlates with association of histone acetylation mod-
ifying enzymes
Acetylation of histone tails as a mark of transcriptional activation of the integrated
HPV16 genome was next focussed upon. In addition to previous H3K27ac, ChIP
analysis of general histone 3 acetylation level (H3ac) was performed (Figure 3.6 A).
Again, clones with higher expression per template were associated with higher levels
of H3ac, with the greatest abundance seen downstream of the transcription start
site over the E6 and E7 genes in all of the W12 clones. To begin investigations into
the enzymes responsible for writing acetyl-PTMs, the association of global histone
acetyltransferase (HAT) enzymes p300 and TIP60 with the virus genome was also
determined by ChIP. Analysis showed that the association of p300 was greatest at
the genomes of the high expressing clones, with lesser levels at the low expressing
clone G2 genome (Figure 3.6 B). Specifcally, in W12 clones F and A5 there was a
sharp peak of enzyme associated with the 3’ end of the LCR of the HPV16 genome
— virus early promoter (p97) — as well as smaller increases of p300 association over
the E6 and E7 loci and the 5’ end of E1 (E8 promoter). In contrast, the medium-
and low-expressing clones D2, H and G2 had reasonably consistent levels of p300
associated with the HPV16 genome, with a slight elevation of abundance across the
viral early promoter.
ChIP analysis of association of HAT TIP60 with the virus genome again showed
that clones with hisger expression per template were associated with higher levels
of the activating enzyme (Figure 3.6 C). The distribution profiles of the two highly
expressing clones F and A5 were quite different. Both clones had a peak of TIP60
abundance over the 3’ LCR, however in clone A5 this was slightly shifted and also
included the 5’ end of E6. Additionally in clone A5 there was a broad peak spanning
from the 3’ end of E7 to the centre of the E1 gene, encompassing the E8 promoter.
This peak was absent in the medium- and low-expressing clones D2, H and G2,
respectively.
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Figure 3.6: Integrated HPV16 genome associations with histone acetyla-
tion and HAT abundance. Level of association of the histone PTM (A) H3ac,
and associated HAT enzymes (B) p300 and (C) TIP60. In each graph, the y-axis
shows the relative levels of enrichment normalised to host control target regions as
indicated in italics under each panel. The x-axis and underlying schematic show the
region of the HPV16 genome analysed. Data presented as mean ± SEM (n=2). In
all panels, data for each of the five clones are colour coded according to the key at
the foot of the figure.
As such a clear association between enzymes that write activating chromatin
marks and the high-expressing clones had been identified, the opposite scenario was
then tested. ChIP analysis was performed on all five clones using an antibody spe-
cific for histone deacetylase 1 (HDAC1), an enzyme that removes acetyl groups from
histone lysine residues. The resultant deactelyation makes DNA less accessible to
RNA polymerase machinery; HDAC enzymatic activity is associated with repressed
chromatin and a lack of transcription126. In this instance, cells with low virus tran-
script levels per template (G2) showed much higher abundance of HDAC1 (Figure
3.7 A). To determine the effect of inhibiting enzymatic action of HDACs on the level
of viral transcription across the panel of W12 clones, cells were treated with the
class I/II HDAC-specific small-molecule inhibitor Trischostatin-A (TSA). After 16
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hours of treatment the relative levels of E6/E7 expression had increased in all of the
clones. The trend showed that de-repression of transcription from the viral genome
increased from the high-, medium-, low-expressing clones with a significantly greater
increase in E6/E7 transcript levels in clone G2 than in F (Figure 3.7 B).
Figure 3.7: Integrated HPV16 genome associations with HDAC abun-
dance/activity.(A) Level of association of the enzyme HDAC1. The y-axis shows
the relative levels of enrichment and normalised to host control target regions as
indicated in italics under each panel. The x-axis and underlying schematic show the
region of the HPV16 genome analysed. Data presented as mean ± SEM (n=2). (B)
Changes in HPV16 E6/E7 transcript levels following type I/type II HDAC inhibi-
tion with Trichostatin A (TSA) (n=3). Asterisks refer to comparisons with control
vehicle-treated cells set to 1. P -values (Students t-test): *P<0.05, error bars=SEM.
In all panels, data for each of the five clones are colour coded according to the key
at the foot of the figure.
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The abundance of HAT and HDAC enzymes at the integrated W12 genome bore
no relation to the total levels of enzyme in each clone. Western blot analysis of
protein abundance was conducted (Figure 3.8 A-C) and densitometric quantitation
indicated that, in the majority of cases, enzyme abundance in each individual clone
was similar to the five-clone average, which was set at one (Figure 3.8 E-G). Notable
deviations were the levels of p300 in clone G2, which was significantly lower than
the high- and medium-expressing clones; however this trend was the opposite for the
HAT TIP60. It is pertinent to note that alternative splicing of the gene encoding
TIP60 results in at least four different protein isoforms; isoform 2 (KAT5 2) encodes
a 513 amino acid protein (58.5 kDa) and is accepted as the canonical form of the
protein, it is this that was measured by Western Blot analysis. Microarray analysis
compared the total transcript abundance of each enzyme in the individual clones
compared with the episomal parental W12 cell line (Figure 3.8 I-K). Together this
showed that the total cellular amount of each enzyme was similar across the panel
of W12 clones regardless of levels of viral transcript per template, indicating specific
enzyme loading onto integrated virus chromatin.
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Figure 3.8: Overall protein levels per cell of enzymes detected by Western
Blot. Baseline levels were determined by (A-D) Western blot, (E-H) quantified using
Image J and (I-L) analysed by microarray. The enzymes assessed were: p300 (n=1)
(A, E, I), TIP60 (n=2) (B, F, J), HDAC1 (n=1) (C, G, K) and CDK9 (n=2) (D,
H, L). For each blot, levels of the target and loading control were quantified at
two or three different exposures and the mean values determined. The results were
normalised to the loading control and referenced to 5/(sum of individual values).
Where more than one blot was performed, a representative image is shown. (I-L)
Baseline levels were also determined by microarray analysis (A5 data not available).
For each panel the expression level fold change of each integrant clone was compared
to episomal W12par, which was set to 1. A.U. = arbitrary units. In all panels, data
for each of the five clones are colour coded according to the key at the foot of the
figure.
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To test the functional significance of HAT recruitment in determining levels of
HPV16 oncogene expression from integrated genomes, specific small molecule in-
hibitors and siRNAs were used to inhibit and knockdown the enzymes, respectively.
Cells with the highest and lowest level of virus early gene expression per template
(clones F and G2, respectively) were used in these analyses to simplify interpreta-
tion of the resulting data. In the first instance a serial dilution of p300-specific small
molecule inhibitor C646192 was carried out in order to find the lowest drug concen-
tration that produced a significant change to the E6/E7 mRNA levels of both clones,
F and G2, compared to vehicle-treated control (Figure 3.9 A and B). The use of the
lowest concentration of each drug limits the number of off-target effects caused by
small molecule inhibitor treatment. At the lower concentrations tested, viral onco-
gene expression of clone F was similar if not higher (although not significantly) than
control but was significantly reduced at 25 µM. Lower concentrations of C646 treat-
ment on G2 cells had a stronger effect on viral oncogene expression with 10 µM and
25 µM treatment both resulting in a significant decrease. A series dilution was also
performed for the TIP60-specific small molecule inhibitor MG149193 (Figure 3.9 C
and D). A drug concentration of 150 µM resulted in a significant decrease in E6/E7
mRNA levels in both clone F and G2, and as a result this concentration was carried
forward to future experiments.
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Figure 3.9: Histone acetyltransferase (HAT) small molecule inhibitor op-
timisation. qRT-PCR analysis of HPV16 mean E6/E7 transcript levels in W12
clone F (A, C) and W12 clone G2 (B, D) cells following treatment for 16 hours with
(top row) p300i (C646) and (bottom row) TIP60i (MG149), respectively, at the con-
centrations indicated. Resultant gene expression was referenced to vehicle-treated
cells (Ctrl bar), which was set to 1. Error bars=SEM, n=2. In all panels, data for
each of the two clones are colour coded according to the key at the foot of the figure.
To support the small molecule inhibitor studies, enzyme depletion through siRNA
transfection was employed. Using the specific protocol for W12 keratinocytes (as de-
tailed in section 2.1.7 in the Materials and Methods), a dilution series of p300- and
TIP60-specific siRNA was carried out. From the series, the lowest concentration
of siRNA (utilised to abrogate off-target effects) that produced consistent, signif-
icant gene knockdown by way of mRNA reduction was carried forward to future
experiments. W12 clones A5 and H were used in this experiment as F and G2 were
unavailable for use at this time. The dilution series ranged from 10-100 nM siRNA
and affects were determined using mRNA quantification of each enzyme, p300 (Fig-
ure 3.10 A and B) and TIP60 (Figure 3.10 C and D), compared to a non-targeting
control sample at the same concentration. Transfection results were most consistent
for W12 clone H; however, for both clones transfection with 10 nM siRNA resulted
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in significant knockdown of both targets (P<0.0001).
Figure 3.10: Optimisation of siRNA knockdown of enzyme target genes.
Target mRNA levels determined by qRT-PCR in W12 clones A5 and H follow-
ing treatment with (A, B) sip300 and (C, D) siTIP60, at the concentrations in-
dicated. The level of gene knockdown was referenced to cells treated with siNTC
(non-targeting control) at the appropriate concentration, which was set to 1 (Ctrl
bar). Error bars = SD, n=1. In all panels, data for each of the two clones are colour
coded according to the key at the foot of the figure.
Using siRNA at 10 nM, levels of p300 and TIP60 mRNA were depleted to similar
levels in W12 clones F and G2 (Figure 3.11 A and E). The protein abundance of
each enzyme following siRNA treatment was determined by Western blot analysis
and quantified using ImageJ software (Figure 3.11 B and F). siRNA treatment of
clone F did not produce as great a knockdown of enzyme protein compared with
clone G2; in addition, sip300 was slightly less efficient at reducing the amount of
protein than siTIP60. However, the reduction of each enzyme in both clones had a
significant impact on viral oncogene expression (Figure 3.11 C and G). Knockdown
of the HAT enzymes resulted in decreased levels of E6/E7 mRNA in both W12 F and
G2 compared to non-targeting control samples. Additionally, there were significantly
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greater reductions in viral oncogene expression in clone F compared with G2, despite
greater protein knockdown in clone G2. The differential sensitivity between clones F
and G2 was also observed following p300- and TIP60-specific small molecule inhibitor
treatment at 25 µM and 150 µM respectively (Figure 3.11 D and H).
Figure 3.11: Effects of histone acetyltransferase (HAT) depletion/inhibition
on HPV16 oncogene expression. Depletion/inhibition in W12 clones F and G2 of HAT
enzymes p300 (n=4) (upper row) and TIP60 (n=6) (lower row). The panels show levels
of depletion of target mRNAs (A, E), target protein (B, F) and HPV16 E6/E7 transcripts
(C, G) in siRNA-treated vs. non-targeting control (NTC)-treated cells. Panels (D and H)
show HPV16 E6/E7 transcript levels in cells treated with specific small molecule inhibitors,
vs. cells treated with vehicle only. (B, F) Protein samples from all replicate experiments
were combined for use in Western blot and specific protein bands were normalised to the
loading control (-tubulin) and referenced to NTC set to 1. Error bars=SEM. P -values
(Students t-test): *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. In all panels, data
for each of the two clones are colour coded according to the key at the foot of the figure.
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To ensure that the effects of small molecule inhibitors on virus transcription were
driven by direct changes to the genome chromatin structure, ChIP analysis of in-
hibitor treated samples was performed. W12 clone F was chosen for this experiment
as enzymatic inhibition had a resulted in the greatest decrease in viral oncogene ex-
pression. The use of small molecule inhibitors was necessary as the chromatin yield
from siRNA treated samples was too low. p300 is known to specifically mediate the
acetylation of H3K27, hence this PTM was used to detect changes as a result of
enzyme inhibition. The abundance of H3K27ac associated with the HPV16 genome
in the C646 treated sample was very significantly reduced compared with control
(Figure 3.12 A and B). In slight contrast to Figure 3.4 C, the H3K27ac profile of
the control treated W12 clone F cells was broader over the E6 and E7 loci and less
restricted to the LCR. There was also significant removal of the activating histone
mark H2AK5ac, specifically associated with the TIP60 enzyme, following inhibitor
treatment (Figure 3.12 C and D). These data indicate that the effects on viral tran-
scription as a result of enzyme inhibition were a direct effect of changes in chromatin
structure.
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Figure 3.12: Effects of histone acetyltransferase (HAT) inhibition on the
abundance and distribution activating chromatin PTMs in W12 clone
F. Levels of association of H3K27ac (A, B) following p300 specific small molecule
inhibition (C646), and H2AK5ac (C, D) following TIP60 small molecule inhibition
(MG149), both for 16 hours. In each graph (A and C), the y-axis shows the relative
levels of enrichment normalised to host control target regions as indicated in italics
under each panel. The x-axis and underlying schematic show the region of the HPV16
genome analysed. Data presented as mean ± SD (n=1). Panels B and D show an
alternative representation of data from A and C; high-low bar graphs with the mean
value represented by a centre line.
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3.2.4 HPV16 transcript levels per template correlate with
active RNA polymerase II (RNAPII) level and acti-
vating complex P-TEFb
The role of RNA polymerase II (RNAPII) was next assessed in determining the
differential viral oncogene expression seen in the integrated W12 clones with copy
number less than four. Initially, the abundance and association of total RNAPII
with the HPV16 genome was analysed by ChIP and no overall differences were seen
across the high-, medium-, and low-expressing clones in total loading (Figure 3.13
A). However, cells with lower virus expression per template showed a significantly
greater association with the poised/paused or stalled form of RNAPII, Serine 5
phosphorylated (Ser5P), particularly across the early genes (E6, E7 and E1) (Figure
3.13 B). Conversely, cells with higher expression per template showed higher amounts
of the active/elongating form of RNAPII, Serine 2 phosphorylated (Ser2P), across
the virus LCR and early genes (Figure 3.13 C).
The positive transcription elongation factor (P-TEFb) complex is essential to
switch paused RNAPII to its actively transcribing form. P-TEFb is comprised of
Cyclin T1 and its kinase partner CDK9, which is responsible for the phosphoryla-
tion of the C-terminal domain repeats at Ser2. ChIP analysis of these components
showed that there were also higher levels of both proteins associated with W12 clones,
with high E6/E7 transcription per template (Figure 3.14 A and B). CDK9 protein
quantification revealed that, as with acetyl-associated enzymes p300 and TIP60 and
HDAC1, basal levels were similar across the panel of W12 clones (Figure 3.8 D).
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Figure 3.13: Integrated HPV16 genome associations with RNA poly-
merase II (RNAPII). Level of association of (A) total RNAPII, (B) RNAPII-
Ser5P (poised/paused) and (C) RNAPII-Ser2P (active/elongating). In each graph,
the y-axis shows the relative levels of enrichment normalised to host control target
regions as indicated in italics under each panel. The x-axis and underlying schematic
show the region of the HPV16 genome analysed. Data presented as mean ± SEM
(n=2). In all panels, data for each of the five clones are colour coded according to
the key at the foot of the figure.
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Figure 3.14: Integrated HPV16 genome associations with the components
of the P-TEFb complex. Level of association of (A) CDK9 (n=3), and (B) cyclin
T1 (not determined for clones A5, H and D2) (n=1). In each graph, the y-axis shows
the relative levels of enrichment normalised to host control target regions as indicated
in italics under each panel. The x-axis and underlying schematic show the region of
the HPV16 genome analysed. Data presented as mean ± SEM. In all panels, data
for each of the five clones are colour coded according to the key at the foot of the
figure.
The functional significance of CDK9 recruitment in determining levels of HPV16
oncogene expression was tested by depletion and inhibition of the enzyme in W12
clones F and G2. Transfections were carried out with CDK9-specific siRNAs at 10
nM (Figure 3.15 A-D) and resulted in similar knockdown of CDK9 mRNA to approx-
imately 20% compared to the non-targeting control (Figure 3.16 A). Residual CDK9
protein following siRNA treatment was analysed by Western blot and quantified
(Figure 3.16 B). Treatment with siRNA CDK9-6 caused slightly greater reduction
of CDK9 protein than CDK9-5. Depletion of CDK9 produced significantly greater
reductions in viral oncogene expression in clone F (higher levels of virus transcript
per template) than in clone G2 (lower levels of virus transcript per template) (Fig-
ure 3.16 C). The differential sensitivity between clone F and G2 as a result of CDK9
enzyme depletion mirrors that seen upon depletion of the HATs p300 and TIP60.
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Figure 3.15: Optimisation of siRNA knockdown of CDK9 enzyme. Target
mRNA levels determined by qRT-PCR in W12 clones A5 and H following treatment
with (A, B) siCDK9 5, (C, D) siCDK9 6 at the concentrations indicated. The level of
gene knockdown was referenced to cells treated with siNTC (non-targeting control)
at the appropriate concentration, which was set to 1 (Ctrl bar). Error bars = SD,
n=1. In all panels, data for each of the two clones are colour coded according to the
key at the foot of the figure.
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Figure 3.16: Effects of CDK9 depletion/inhibition on HPV16 oncogene
expression. (A-C) Depletion of CDK9 using siRNAs (n=2), showing the levels
of target mRNA (A) and protein (B), together with the changes in HPV16 E6/E7
transcript levels (C), in siRNA-treated vs. non-targeting control (NTC) -treated
cells. (D) The effect of CDK9 inhibition on the E6/E7 transcript levels of W12
clone F cells following treatment with Flavopiridol for 16 hours vs. cells treated with
vehicle only (set to 1) (n=2). Protein samples from all replicate experiments were
combined for use in the Western blot and specific protein bands were normalised to
the loading control (β-tubulin) and referenced to NTC, which was set to 1. Asterisks
refer to comparisons with control vehicle-treated cells set to 1. Error bars = SEM.
P -values (Students t-test): *P<0.05, ***P<0.001. In all panels, data for each of the
two clones are colour coded according to the key at the foot of the figure.
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To ensure the transcript level changes were a direct effect of CDK9 inhibition,
the ChIP profiles of RNApolII (and its associated forms) as well as hallmarks of
activating and repressive chromatin structure were compared. CDK9-specific small
molecule inhibitor Flavopiridol generated an 87% reduction in E6/E7 transcript lev-
els in W12 clone F compared with a vehicle-only treated control (Figure 3.16 D)
and chromatin from both samples was used for ChIP analysis. Flavopiridol treat-
ment produced no significant change in overall levels of CDK9 associated with the
integrated HPV16 genome (Figure 3.17 A and B). Despite no overall change in abun-
dance, the association profile of CDK9 with the HPV16 genome changed as a result
of flavopiridol inhibition; the peak over the viral early promoter was reduced and an
additional peak over the early gene E6 was present when compared to the control
sample.
Flavopiridol treatment of W12 clone F cells resulted in a significantly reduced
level of total RNAPII and this was particularly pertinent downstream of the virus
early promoter (Figure 3.17 C and D). Interestly, the abundance of total RNAPII
across the integrated LCR region was very different when the two samples were
compared. In the control sample, the major peak of total RNAPII over the 3’ of the
LCR (p97) was t totally absent in the flavopiridol treated sample, with a peak over
the 5’ LCR (E2BS3 and 4) seen instead.
CDK9 inhibition resulted in a significant reduction in the active form of RNAPII,
Ser2P; levels were near baseline over the promoter region of the integrated virus LCR
and early genes (Figure 3.17 E and F). As with total RNAPII, a peak over the 5’
LCR was seen in the flavopridol treated sample indicating that the polymerase is
becoming stalled in this area upon CDK9 inhibition.
The abundance and distribution of PTMs were also affected by CDK9 inhibition.
The amount of histone PTM of transcriptional activation, H3K4me3, was dramati-
cally reduced, most noticeably over the p97 and E8 promoter (Figure 3.16 G and H).
This was mirrored by a significantly increased level of H3K9me2, a mark of consti-
tutive heterochromatin and transcriptional repression, across the integrated genome
(Figure 3.17 I and J).
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Figure 3.17: Effects of CDK9 inhibition on the abundance and distribu-
tion of hallmark PTMs in W12 clone F. Level of association of the enzymes
CDK9 (A-B), total RNAPII (C-D), RNAPII Ser2P (E-F), as well as the active PTM
H3K4me3 (G-H) and repressive PTM H3K9me2 (I-J) following treatment with spe-
cific CDK9 small molecule inhibitor Flavopiridol for 16 hours. In each graph (A, C,
E, G, I), the y-axis shows the relative levels of enrichment normalised to host control
target regions as indicated in italics under each panel. The x-axis and underlying
schematic show the region of the HPV16 genome analysed. Data presented as mean
SD (n=1). Panels B, D, F, H, J (right column) show an alternative representation
of data from left column; high-low bar graphs with the mean value represented by a
centre line. Abbreviations: Flav = Flavopiridol, Ctrl = control.
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3.3 Discussion
The LCR of the HPV16 genome is known to be the region with the most genetic
variation194. Numerous studies have identified a high number of nucleotide varia-
tions between cell lines and tissue samples from different geographical locations and,
most notably, with clinical severity195, 196. As such, investigations into the genomic
sequence of a panel of fourteen W12 integrant clones was conducted to determine
whether genomic mutations could be responsible for the ∼16-fold difference in vi-
ral oncogene transcript levels183. The genome sequences of the episome-containing
W12 (W12E) and the HPV16-positive cervical cancer (SiHa) cell lines are published
(GenBank: AF125673.1 and AF001599.1/AF001600.1, respectively) and were used
as comparators for the LCR sequence of the integrant clones. Known mutations of
the LCR of SiHa include a single nucleotide substitution from adenosine to thymine
at position 7,519 and a 38 base pair deletion of nucleotides 7754-7791197; both were
detected by the PCR amplification of the LCR and subsequent sequence analysis
indicating adequate accuracy and robustness of the methods employed. Analysis of
the LCR sequence showed extensive sequence homology between the W12 integrant
clones. A single mutation was found in clone R2, which contains seven copies of
the viral genome183. Although the computerised base call of a thymidine residue at
position 7,491 matched the W12E reference sequence, further scrutiny of the chro-
matogram for this clone indicated a potential deletion of this nucleotide in 1/7th
of the population resulting in a frame shift of the affected population (Figure 3.3).
Mutations within the many transcription factor-binding sites located in the LCR of
the HPV16 virus can impact viral expression. For example, single nucleotide poly-
morphisms (SNP) in the binding sites of the repressive transcription factor YY1
have been shown to disrupt the binding of associated proteins198, 199. In contrast,
a SNP in the binding site of the activating transcription factor AP-1 increases the
binding affinity of associated proteins; both mutations result in increased activity
of the HPV16 p97 promoter200. However, the mutation in the sub-population of
W12 clone R2 does not occur within a transcription factor binding site, nor does it
lead to a functional change in the transcript, therefore is unlikely to affect the viral
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expression of this clone. It is clear that genetic mutation and resultant changes to
the binding affinity of transcription factors to the regulatory region of viral DNA is
not responsible for the differential expression of viral oncogenes E6 and E7 across
the W12 integrant clones, certainly those with a genome copy number less than 4,
the focus of this study (F, A5, D2, H, G2).
Having established that changes to the genetic sequence of the regulatory region
of the viral genome are not responsible for the wide range of viral oncogene ex-
pression per template, investigations into epigenetic mechanisms of gene regulation
were conducted. Previous work carried out by the Coleman group indicated that
the post-translational modification of histone tails was a mechanism by which the
expression of the viral oncogenes E6 and E7 are controlled183. In the present study,
an increased number of hallmark PTMs representative of active and repressed chro-
matin have been analysed to generate a broader picture of the epigenetic landscape
at the integrated HPV16 genome. Moreover, the design and use of additional primers
along the length of the HPV16 genome mean that the abundance and distribution
of PTMs have been analysed at a greater resolution to produce more in-depth data
and facilitate more robust conclusions.
Levels of HPV16 expression were positively associated with higher abundance of
histone PTMs that marked transcriptionally active chromatin. However, the this
analysis found that the distribution profiles of H3K4me3 and H3K4me1 differ. For
H3K4me3, there is a broad association over the early region of the viral genome
with the greatest abundance at the oncogenes E6 and E7; this is compared with
discrete peaks over the early LCR and E1 regions of the viral genome for the histone
modification H3K4me1. It is likely that the relative distribution or abundance of
the enzymatic writers (histone methyltransferases) and their cofactors responsible
for each mark results in the alternate profiles201.
Conversely, viral oncogene expression levels were negatively associated with re-
pressive chromatin marks. The abundance of repressive marks were particularly low
across the LCR region of the HPV16 genome in each of the five clones; this is to
be expected as the regulatory region remains structurally more open compared with
the rest of the genome to facilitate transcription factor binding and the recruitment
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of transcriptional machinery to the virus early promoter (p97). For W12 clone G2
the highest levels of repressive chromatin marks were found over the E6 and E7 gene
bodies indicating particularly firm repression of transcription of the viral oncogenes.
Interestingly, the di-methylated form of H3K27 was much more abundant than the
equivalent tri-methylated mark. This is likely a result of the global reduction of
H3K27me3 in high-risk HPV-infected cells; expression of virus oncogene E7 leads
to transcriptional induction of demethylase enzymes KDM6A and 6B151. In addi-
tion to removing methyl-moieties from histone tails, the demethylases delocalise the
polycomb repressive complex 2 (PRC2), the writer of the H3K27me3 mark151, 202. In
combination with the increased abundance of repressive PTMs, investigations con-
ducted by Dr. Cinzia Scarpini showed that the overall levels of endogenous CpG
DNA methylation were also greatest at the virus genome of the low-expressing W12
clone203. DNA methylation is an additional layer of epigenetic regulation and results
in the stable repression of transcription through direct and indirect mechanisms204.
Additionally, histone acetylation associated positively with levels of HATs exam-
ined, namely p300 and TIP60. A link between the HAT p300 and cervical malignancy
has previously been identified with a positive correlation between p300 expression
levels in HPV16 infected cells, and disease progression from CIN1 to 3 has been
demonstrated; levels of p300 in cervical cancer cell lines SiHa and CaSki are greater
when compared to HPV negative keratinocytes NHEK and RT3SB205. Additionally
16 % of SCCs are associated with somatic mutations in the p300 coding sequence97.
In our system we found that p300 was particularly abundant at the LCR of the viral
genome in the highest expressing clones per template, F and A5, indicated by a sharp
peak in the region; this is likely a result of AP1 dependent, contact-driven recruit-
ment of p300 required for the transcription of the HPV genome206. As with p300,
there is greater association of TIP60 with the viral genome of the highly expressing
W12 clones F and A5, represented by a broad peak over the LCR and viral early
genes. The increased level of association is likely due to the preferential binding
of the TIP60 chromodomain to H3K4me1207, which is also found associated with
these regions of the HPV16 genome and is also reflective of the elevation of TIP60
in transcribed regions and at the promoters of active genes137.
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It has been previously shown that p300 can activate HPV gene expression206, 205, 208;
however, in addition to this, across the panel of W12 clones a functional, dose-
dependent relationship with p300 was observed (Figure 3.9). Cells with high virus
expression per template (clone F) showed a significantly greater sensitivity to equiva-
lent levels of p300 depletion or inhibition compared with those with low virus expres-
sion per template (clone G2) (Figure 3.11 A-D). Observations following the depletion
and inhibition of TIP60 mirrored those seen with p300 indicating the importance of
functional HATs for effective transcription of the HPV16 genome (Figure 3.11 E-H).
HAT inhibition not only had a significant effect on viral oncogene expression but
also resulted in a dramatic change in the abundance and distribution of activating
chromatin marks along the HPV16 genome. The H3K27 and H2AK5 residues are
preferentially acetylated by p300209 and TIP60210, respectively; small molecule inhi-
bition of each enzyme reduced the amount of each mark associated with the HPV16
genome to near baseline levels compared with vehicle-treated control (Figure 3.12).
Interestingly, despite HATs usually being associated with the activation of tran-
scription, there is evidence that TIP60 acts as a transcriptional repressor of integrated
HPV18. In Hela cells, TIP60 binds to the HPV18 LCR in a YY1-dependent manner
and subsequently recruits the bromodomain containing cellular repressor Brd4 to
the enhancer/promoter; as such TIP60 is targeted by the HPV18 viral oncogene E6
for degradation211. However, in contradiction to this model, there was no associa-
tion between levels of TIP60 and the transcriptional repressor protein YY1 observed
in HPV16-positve W12 cells203. Further to this, previous work carried out by the
Coleman group indicated an activating role for TIP60 in the HPV16 system through
determination that viral expression decreased as a result of inhibiting TIP60 in W12
episome containing cells (data not shown). Although the reasons for opposing obser-
vations of TIP60 function between HPV18 and HPV16 are unclear, we have shown
that this is not due to the structural form of the virus genome (i.e. episomal vs
integrated) and it is likely that the mechanism of TIP60 recruitment is relevant. In
addition to binding to the HPV LCR in a YY1-dependent manner, TIP60 can also be
recruited to this region through a number of alternate mechanisms including interac-
tions with phosphorylated RNAPII137 or direct binding to the chromatin through its
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chromodomain. This can occur via the repressive PTM H3K9me3 at double stranded
breaks212 but also via the active marks H3K4me3213 and H3K4me1207, both of which
are found at greater levels at the HPV16 LCR in the highest expressing clones F and
A5 (Figure 3.4). Additionally, when combined with H3K27ac, as is the case in the
high expressing W12 clones, H3K4me1 is an indicator of active enhancers.
Moreover, whilst Brd4 commonly acts as a cellular repressor it has also been
shown to have dual functionality through its ability to interact with and recruit
P-TEFb, the cofactor required for RNAPII elongation214. As such, Brd4 plays a
positive role in RNAPII-dependent transcription through enhancing the recruitment
of the active P-TEFb complex to acetylated chromatin in the promoter region76. The
novel finding that TIP60 depletion and inhibition results in decreased viral expression
in HPV16-containing W12 cells is likely caused as a result of decreased levels of TIP60
binding to the viral promoter/enhancer; this in turn results in reduced levels of both
Brd4 and the subsequent P-TEFb recruitment causing diminished transcription of
the viral genome.
In direct contrast to p300 and TIP60, the abundance of HDAC1 at the HPV16
genome was negatively correlated with virus expression per template. HDAC1 was
detectable at the virus genome in all clones with slightly elevated levels at the LCR;
this is consistent with the previously described necessity for HDACs at gene promoter
regions to reset chromatin by the dynamic turnover of acetyl groups without which,
despite increased acetylation, gene induction is inhibited215, 216, 137.
In addition to alterations in chromatin structure as a result of post-translational
modifications to histones, transcriptional activation of a gene is predominantly de-
pendent on the activity of RNAPII217. As previously noted, the recruitment of
P-TEFb is required to phosphorylate the serine 2 residue on the C terminal domain
(CTD) of RNAPII, which is necessary for active transcription. The CDK9 enzyme
was functionally significant, as evidenced by a greater sensitivity to depletion in
cells with higher HPV16 gene expression per template. As with the HATs, selective
enzyme inhibition of CDK9 with Flavopiridol resulted in striking changes in the dis-
tribution of RNAPII and hallmark chromatin PTMs. Interestingly, in addition to
depleted levels of RNAPII associated with the viral genome, the distribution pro-
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files of total and Ser2P RNAPII altered in a similar fashion with the predominant
peak translocating away from the viral promoter (control) to the 5’-end of the LCR
(CDK9i). This suggests that CDK9 inhibition results in the stalling of RNAPII at
the E2BS4 — which loops and interacts with the E2BS1/2 at the viral early pro-
moter — resulting in the dramatic reduction of transcription from the viral early
promoter.
Conversely, although exhibiting very similar distribution profiles, the amount of
the repressive PTM H3K9me2 was increased following CDK9 inhibition. These data
illustrate that the genome is much less accessible to the transcription machinery and,
consequently, viral transcription is diminished. The importance of P-TEFb/CDK9
for transcription of the HPV16 genome adds to previous observations for the necessity
of this complex for the transcription of other viral genomes including Epstein-Barr
virus218 and the human immunodeficiency virus (HIV)219.
Observations presented in this chapter indicate that genetic mutation in the non-
coding LCR of the virus genome is not responsible for differential levels of HPV16
oncogene expression across the W12 integrant clones; rather the level of E6/E7 ex-
pression from the virus early promoter (P97) is determined by the balance of hallmark
histone PTMs characteristic of transcriptionally active or repressed chromatin. It is
interesting to consider the expression of HPV16 oncoproteins in terms of clinical
progression. Whilst it is known that the levels of HPV16 oncogenes are statistically
similar in lesions ranging from normal through LSIL to HSIL21, levels of dysplasia
and progression towards carcinoma increases. This can be attributed to the loss of
cell cycle control and the accumulation of genetic mutations as a result of pRb and,
even more importantly, p53 degradation. In this study, the W12 cells were derived
from a pre-malignant, low-grade cervical lesion. At this early stage of disease, the
levels of E6 and E7 expression — influenced by epigenetic modifications to the inte-
grated HPV16 genome — presumably contribute to the likelihood of progression of
a low-grade cervical lesion.
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4.1 Introduction
Regulation of gene expression and epigenetic control of the transcriptome extends
far beyond that of post-translational histone modifications. The human genome does
not exist as a one-dimensional polymer or function in a sequential fashion; rather, it
is folded in three-dimensional (3D) space. There is an increasing body of evidence
showing that the 3D genomic organisation of the nucleus has an important role in
determining gene expression patterns220. Gene expression is controlled by regulatory
elements that can be located several mega bases (Mb) away from their corresponding
gene promoters; this indicates that communication between distal gene enhancers
and promoters is essential for regulated gene expression221, 222.
Microscopic study of the nucleus, primarily with fluorescence in situ hybridisa-
tion (FISH) revealed many of the basic principles underpinning genomic organisation.
Early light and electron microscopy studies showed the separation of active euchro-
matin and inactive heterochromatin to distinct regions of the nucleus,223 and more
recently revealed the existence of distinct sub-nuclear organelles224, 225, 226, 227, 228.
FISH with chromosome paints revealed that chromosomes occupy distinct territo-
ries within the nucleus throughout interphase, with limited intermingling229, 230, 231.
Additionally, the positioning of each chromosome is not random but related to gene
density; small, gene-dense chromosomes (e.g. human chromosome 17, 19, 20) occupy
the 3D nuclear interior compared with gene-poor chromosomes (e.g. human chro-
mosome 18) that are located towards the nucleus periphery232, 233, 231. A correlation
between nuclear location and transcriptional output has also been determined by
microscopy studies; upon activation, individual gene loci have been shown to move
from the nuclear periphery and to preferentially associate with euchromatin in the
nuclear interior234. Despite important contributions to the understanding of genome
architecture, microscopic techniques are limited by their low-throughput nature. The
advent of chromatin conformation capture (3C) technologies has enabled a more sys-
tematic, genome-wide and high-throughput approach to study nuclear architecture.
Multiple chromosome conformation capture assays have been developed and pro-
vide a population-averaged impression of contact frequencies between genomic sites235.
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Each assay is based upon the principle that regions of interacting chromatin can be
cross-linked, cut using restriction enzymes, and re-ligated so that genomic sequences
in close physical proximity in the nucleus become linked to one another. The re-
sultant ligation junctions reflect the 3D organisation of the genome at the time of
fixation and can be used to infer chromatin structure (Figure 4.1)236, 235
Figure 4.1: Comparison of different 3C-based methodologies taken from
Davies, J. et al., 2017235. 3C libraries share the indicated steps and can then be
interrogated by the specific steps in the 3C protocol shown subsequently.
The original 3C method described in Dekker et al., 2002 is a powerful technique
to assess whether a region of interest interacts with a series of pre-specified genomic
fragments, and, as such, is termed a one-to-one approach. Following the re-ligation
of DNA fragments and the removal of crosslinks, contacts are analysed between
selected pairs of sequences. Prior knowledge, or strong hypotheses, of interacting ge-
nomic regions is required to generate the loci-specific primers required to amplify and
quantify ligation junctions. Initially, 3C technology was used to define the spatial
organisation of yeast chromosomes236 and later adapted to demonstrate long-range
gene regulation by the physical looping of an enhancer to its target gene at the
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β-globin locus237, 238. The technique has since facilitated the identification of long-
distance cis and trans physical contacts at multiple gene loci239, 240, 241; however,
this approach is limited to the confirmation of suspected interactions rather than
identifying novel ones in an unbiased way. The improved access and affordability of
next generation sequencing (NGS) meant that future generations of progressively un-
biased, high-throughput, 3C-based methods were developed with increasing genomic
resolution; these include 4C (‘one-to-all’ approach)242, 243, 5C (‘many-to-many’ ap-
proach)244 and Hi-C (‘all-to-all’ approach)245, 246 (Figure 4.1).
Whilst 4C and 5C have been instrumental in furthering our knowledge and under-
standing of nuclear architecture and its role in genome regulation,247, 248, 249, 242, 221, 250
Hi-C is unique in its ability to generate contact maps between all parts of the genome.
The modifications to the original protocol used to generate 3C libraries include: the
fill-in of restriction enzyme digested DNA fragments with biotin-labeled nucleotides;
blunt-end ligation; further DNA fragmentation using sonication; and a streptavidin
pull down of ligated fragments. Adaptations to 3C library generation result in the
concentration of the informative ligation junctions representative of the 3D inter-
actions across the genome, which are subsequently sequenced from both ends by
paired-end sequencing246. The resolution of resultant Hi-C maps is determined by
the restriction site density as well as depth of sequencing, and has increased from a
scale of 1 Mb246 to single kilobase resolution251. As such, Hi-C has been used to re-
fine our understanding of genome-wide compartments of open and active and closed
and inactive genomic regions246; to extensively describe the principles of chromo-
some looping251; as well as to identify a further layer of nuclear organisation termed
topologically associating domains (TADs)252. Typically, TADs are one megabase in
size and represent chromosomal units within which DNA sequences preferentially
contact one another and form the framework within which promoters can find their
respective enhancers and vice versa 253. However, the production of quality Hi-C
data for large mammalian genomes requires the sequencing and mapping of several
billion reads per sample. In order to significantly reduce the number of sequencing
reads required to generate contact maps of equivalent resolution, capture Hi-C was
generated. An additional hybridisation selection of chosen loci, e.g. gene promoters,
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specifically enriches Hi-C libraries for the chosen loci and the DNA elements that
they contact in 3D254, 255, 256.
Based upon similar methodology to capture Hi-C, Peter Fraser and Stefan Schoen-
felder (Babraham Institute) invented sequence capture of regions interacting with
bait loci (SCRiBL) Hi-C. Using SCRiBL Hi-C, all interactions between elements
within a capture region as well as between the capture region and the rest of the
genome are identified (Figure 4.2).
Figure 4.2: Cartoon illustrating the principles of Sequence Capture of Re-
gions interacting with Bait Loci (SCRiBL) Hi-C A. The 3D interactions (red
double headed arrow) within a capture region and short- and long-range interactions
between the capture region and the rest of the genome. B. HPV16 genome (bold
red line) integrated into the host is the designated capture region. 3D interactions
between the virus and host are identified.
This chapter outlines how SCRiBL Hi-C has been adapted to enrich for the
HPV16 genome in the W12 integrant clone system. The need for significant enrich-
ment of Hi-C libraries is particularly pertinent due to the relatively tiny size of the
viral genome in comparison to the host. In the first part, Hi-C libraries from which
genome-wide contacts can be determined are generated; the second part, describes
the design and production of HPV16-specific baits that are used to capture only the
ligation fragments containing the virus genome. The successful generation of SCRiBL
Hi-C libraries will enable a much broader analysis of the epigenetic regulation of viral
transcription of the W12 clones.
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4.2 Materials and Methods
4.2.1 Hi-C protocol (SCRiBL)
An undigested library (used in capture-seq experiment) and Hi-C libraries (SCRiBL)
were generated concurrently with any alterations for the generation of the undigested
library indicated in the text below. At each stage the reaction volumes and the
processes for both the Hi-C and undigested libraries were kept equal so that as far
a possible the samples were treated the same. For each W12 clone used in this
experiment there are two biological replicates; the cells for each replicate were fixed
and frozen on the same day but the generation of subsequent libraries occurred
separately for each replicate. This work was carried out in collaboration with Marco
Michalski from the Babraham Institute.
4.2.2 Part I: Generation of Hi-C libraries
Cell culture and crosslinking of chromatin
W12 clones were grown in monolayer culture as previously described in Chapter 2.
Cells were analysed at the lowest available passage (p) after cloning (F p6, G2 p12,
NCx/6 p5, A5 p5, D2 p8 and H p6) in order to minimise any effects of genomic in-
stability caused by deregulated HPV16 oncogene expression. W12 cells of each clone
were seeded into four 15 cm2 plates and grown to 80–90% confluence (approximately
30 million cells in total), and fixed in EGF positive culture media supplemented with
methanol-free formaldehyde (Agar Scientific) to a final concentration of 2% for 10
minutes at room temperature with gentle agitation. Crosslinking was quenched by
the addition of ice-cold glycine (VWR International) to a final concentration of 125
mM. Plates were incubated at room temperature for 5 minutes on a rocker followed
by 10 minutes at 4 °C. The adherent W12 cells were then scraped from the culture
plate using disposable cell scrapers and the resultant cell suspensions from two plates
were pooled into one 50 ml Falcon tube i.e. there were two Falcon tubes per cell line,
representing two biological replicates with 15 million cells each (Figure 4.5). The
Falcon tubes were then spun at 720 RCF in an Eppendorf 5810R centrifuge for 10
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minutes at 4 °C. The supernatant of each 50 ml Falcon tube was discarded, the pellet
of each was carefully resuspended in 10 ml ice-cold PBS and transferred to a 15 ml
Falcon tube. The 15 ml Falcon tubes were then spun at 720 RCF for 10 minutes at 4
°C, and the supernatant was discarded. The pellets were then flash frozen in liquid
nitrogen and stored at -80 °C.
Cell lysis and chromatin digestion
The cell pellets were thawed on ice before resuspension in 1 ml ice-cold lysis buffer
(10mM Tris-HCl pH 8 (Sigma), 10 mM NaCl, 0.2% IGEPAL® CA-630 (Sigma), pro-
tease inhibitor cocktail tablet (EDTA-free) (Roche). Cells resuspended in 1 ml lysis
buffer were then added to 49 ml ice-cold lysis buffer in a 50 ml Falcon, and the tubes
were inverted four times to mix. The tubes were then incubated on ice for 30 minutes
with occasional mixing. Following lysis, nuclei were pelleted by centrifugation at 650
x g for 5 minutes at 4 °C and the supernatant was discarded. Next, the pellets were
resuspended in 1.25x NEBuffer 2; briefly, 500 µl 1.25x NEB2 were used to resuspend
the pellets, this was followed by the addition of a further 400 µl 1.25x NEBuffer 2
to fully disperse the pellets by gentle pipetting and cells were transferred to a 1.5 ml
Eppendorf tube. The final volume was then measured and made up to 1.25 ml with
the addition of 1.25x NEBuffer 2 to the cell suspension, and divided between five
1.5 ml Eppendorf tubes (250 µl and 5-6 million cells in each). Each of the aliquots
were made up to a final volume of 358 µl with 1.25x NEBuffer 2, the chromatin was
solubilised by the addition of 11 µl 10% SDS (0.3% final concentration) (Promega)
and incubated at 37 °C for 60 minutes with shaking at 950 rpm. SDS-solubilisation
removes non-crosslinked proteins and opens the chromatin, making it accessible for
restriction endonuclease cleavage. SDS was quenched by adding 75 µl 10% Triton X-
100 (1.7% final concentration) (Sigma) to each tube and the nuclei were incubated at
37 °C for 60 minutes with shaking at 950 rpm. Restriction digestion was performed
by the addition of 800 units of the restriction endonuclease MboI (32 µl 25 U/µl,
New England Biolabs) per tube (5 million cells). One Eppendorf tube was kept as
undigested material and 32 µl dH2O were added to this tube instead of MboI. All
tubes were incubated at 37 °C overnight with shaking at 950 rpm.
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Biotin marking of DNA ends and blunt end ligation (Hi-C samples only)
Following overnight incubation the four Eppendorf tubes containing digested DNA
were placed on ice. The restriction fragment ends were filled in and the DNA ends
marked with biotin by adding: 1.5 µl of each 10 mM dCTP, dGTP, dTTP, 37.5 µl
0.4mM biotin-14-dATP (all Thermo Fisher Scientific) and 10 µl 5U/µl Klenow (DNA
polymerase I large fragment, New England Biolabs) to each tube. Each solution was
then mixed and incubated for 75 minutes at 37 °C with shaking at 700 rpm. Following
incubation all tubes were placed on ice.
Blunt-ended DNA fragments cross-linked together in chromatin complexes were
then ligated following the in-nucleus ligation protocol previously described257, with
minor modifications. Prior to ligation, excess salts and enzymes were removed by
centrifugation (600 x g for 5 minutes at 4 °C) and the supernatant was discarded.
Each cell pellet was then resuspended in 995 µl 1x T4 DNA ligase buffer (New Eng-
land Biolabs) supplemented with BSA (100 µg/ml final concentration). The ligation
was carried out using 2000 units (5 µl) T4 DNA ligase (400U/µl, New England Bi-
olabs) per 5 million starting material of cells. The reaction was then placed at 16
°C for 4 hours followed by 30 minutes at room temperature. Following the ligation
of DNA fragments in close 3D proximity, DNA crosslinks were reversed and proteins
were degraded by the addition of 25 µl 10 mg/ml Proteinase K (Roche) per tube
and the chromatin was incubated at 65 °C overnight with shaking at 900 rpm. At
this stage, the undigested DNA samples were treated the same way, after adjusting
the volume by adding 556 µl TLE (10 mM Tris pH 8.0, 0.1 mM EDTA).
DNA purification
Each reaction mixture was cooled to room temperature before the addition of 10
µl of 10 mg/ml RNaseA to each Eppendorf and incubated at 37 °C for at least 60
minutes, shaking at 600 rpm. The DNA was then purified by a phenol and two
phenol-chloroform extractions. Material from the four digested samples (for each
replicate) were pooled into a 50 ml Falcon tube and the undigested libraries made
up to 4 ml with TLE in a 50 ml Falcon. To both Falcon tubes, 4 ml (1:1 ratio) phenol
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pH 8.0 (Sigma) was added and vortexed for 1 minute to mix. The tubes were spun
for 10 minutes at 3500 rpm at room temperature and then the aqueous phase was
transferred into a new tube. A back extraction of the original phenol was used for
optimum recovery of DNA; briefly, 2 ml TLE were added to any remaining aqueous
liquid and phenol left behind in the original Falcon. Again, the tubes were vortexed
to mix and spun for 10 minutes. The entire aqueous phase was then added to the
Falcon tube from the previous step. The DNA extraction was repeated twice using
phenol pH 8.0: chloroform (Sigma) following the steps as previously described. The
DNA was then precipitated by adding 1/10th the total volume of 3 M sodium acetate
pH 5.2 and 2.5 x the total volume of ice-cold 100% EtOH (VWR Chemicals), and
the tubes were incubated overnight at -20 °C.
The tubes were then spun for 30 minutes at 4 °C at 3500 rpm, DNA pellets were
washed three times with 70% ethanol and then resuspended in 100 µl (Hi-C DNA)
and 25 µl (undigested DNA) TLE respectively (25 µl per 5 million cells starting
material). The DNA concentrations of a dilution series (1:500, 1:1000 and 1:2000
dilutions) were measured using the Quant-iT PicoGreen assay (Life Technologies) as
per the manufacturer’s instructions.
Quality control of Hi-C libraries
Quality control reactions were carried out to analyse the Hi-C marking and ligation
efficiency. To determine the efficiency of digestion, fill-in and subsequent ligation
of DNA in the Hi-C libraries a PCR reaction was carried out using two forward
primers (IDT) designed around MboI restriction sites of the RPL13A locus. The
PCR reaction mix included: 200 ng template DNA, 0.125 µl Hot Start Taq DNA
polymerase (New England Biolabs), 2.5 µl 10X Taq reaction buffer (New England
Biolabs), 2 µl dNTP mix (2.5 mM), 1 µl RPL13A B forward primer (10 M), 1
µl RPL13A G forward primer (10 µM) (Table 4.1) and dH2O to 25µl. The PCR
cycling conditions were the following: 95 °C for 15 minutes, followed by 38 cycles
of 94 °C for 30 seconds, 53.9 °C for 30 seconds, 72 °C for 1 minute followed by a
final amplification at 72 °C for 7 minutes. The reaction products were then run on a
1.5% agarose gel. Subsequently the PCR products from four reactions were purified
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(Qiagen purification kit) and spilt into two; one sample digested with the restriction
enzyme ClaI and the other one was left untreated. For this digestion reaction, 750
ng PCR product were incubated with the restriction enzyme ClaI (20 U), 2 µl 10X
Cut Smart buffer made to 20 µl with dH2O and incubated for 2 hours at 37 °C. Both
samples were then run on a 1.5% agarose gel.
The detection of expected interactions in the Hi-C libraries was also conducted
by designing primers that would generate a specific 3C product. PCR reactions were
set up as before, replacing the primers, which were used before, with RPL13A D2J
forward and RPL13A D2J reverse (10 mM) (Table 4.1). The PCR cycling conditions
were the same as before, but the reaction consisted of 35 cycles and had an annealing
temperature of 62 °C. Again, the products were run on a 1.5% agarose gel and the
DNA bands in undigested and Hi-C libraries were compared.
Biotin removal from un-ligated ends (Hi-C libraries only)
To remove biotin-dATP from any non-ligated fragments ends, 40 µg of DNA from
each Hi-C library was incubated with T4 DNA polymerase (NEB). Briefly, eight
reactions containing: 5 µg DNA, 1 µl 10mg/ml BSA, 10 µl 10x NEBuffer 2, 2 µl 10
mM dATP, 2 µl 10 mM dGTP and 5 µl (15U) T4 DNA polymerase (New England
Biolabs) in a total volume of 100 µl with dH2O were set up, mixed and incubated at
20°C for 4 hours. As there was no biotin to be removed in the undigested libraries
and a smaller quantity of DNA was required, 3 x 5 µg DNA aliquots (15 µg total)
were made to an equivalent volume with dH2O and also placed at 20 °C for 4 hours.
Following incubation, biotin removal in the Hi-C samples was then stopped by the
addition of 2 µl 0.5 M EDTA pH 8.0 (Invitrogen) to each aliquot. Two Hi-C reactions
were then pooled together to make a total amount of DNA ∼10 µg per sample, and
all three undigested reactions (15 µg) were pooled. DNA was extracted using phenol
pH 8.0:chloroform (1:1) and was subsequently precipitated with sodium acetate pH
5.2 and 100% ethanol as described previously (see DNA Purification). Following
overnight incubation at -20 °C samples were spun and the DNA was washed in 70%
EtOH. Each pellet was then resuspended in 130 µl dH2O.
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DNA fragmentation and size fractionation
130 µl of each sample was added to a Microtube AFA fibre pre-slit tube (LGC
Genomics), and DNA was sheared to an average size of 400 bp using the Covaris
E220 Sonicator (settings: duty factor 10%, peak incident power 140 (W), cycles per
burst 200 and time 55 seconds).
End repair and ‘A’ tailing
Sonication randomly breaks the DNA into fragments and the subsequent end repair
step refills the ends of these broken DNA fragments. Following sonication the 130
µl samples were transferred to fresh 1.5 ml Eppendorf tubes and the volumes were
adjusted to 180 µl by the addition of the following: 18 µl 10x T4 DNA ligase buffer,
18µl dNTP mix 2.5 mM, 6.5 µl T4 DNA polymerase, 6.5 µl T4 polynucleotide kinase
(NEB), 1.3 µl Klenow DNA polymerase (5 U/µl, NEB). All samples were then in-
cubated at room temperature for 30 minutes. The DNA was then purified using the
QIAquick PCR Purification Kit (Qiagen) according to the manufacturer’s instruc-
tions. The DNA was eluted from each column in a fresh 1.5 ml Eppendorf with 30
µl TLE.
The addition of a single dATP to the repaired 3’ end was required to facilitate the
ligation of sequencing adapters that are required for downstream Next Generation
Sequencing. To add dATP, 5 µl 10x NEB2, 11.5 µl 1 mM dATP, 3.5 µl Klenow
(exo-) (New England Biolabs) were added to the DNA and mixed (50 µl total). The
reactions were incubated at 37 °C for 30 minutes after which the Klenow (exo-) was
inactivated by incubating at 65 °C for 20 minutes before cooling on ice. The two
Hi-C samples were then pooled (100 µl total) and the undigested samples were made
up to 100 µl with dH2O, both in Eppendorf LoBind 1.5 ml microcentrifuge tubes
(Sigma).
Double-sided SPRI-selection
DNA fragments ranging in size between 250-500 bp were isolated by a double-sided
size selection using AMPure XP beads (Beckman Coulter) by performing sequential
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Solid Phase Reversible Immobilisation (SPRI) bead selections. Briefly, 0.6x (60 µl)
SPRI beads were added to the 100 µl DNA, mixed thoroughly by pipetting and
vortexing and incubated at RT for 15 minutes to allow DNA with high molecular
weight to bind to the beads. The tubes were then placed on a magnetic separator
and the supernatant was transferred into a fresh 1.5 ml LoBind tube. During the
first incubation the SPRI beads were concentrated for the next size selection. 80 µl
of beads per reaction were placed in a LoBind tube, put on a magnetic separator and
all but 35 µl of the supernatant was removed. The 35 µl concentrated SPRI beads
were added to the 160 µl supernatant from the previous step (1.14x), the sample
was vortexed and incubated for 15 minutes to allow all DNA >200 bp to bind. The
beads were then washed twice with 500 µl fresh 70% EtOH and dried at 37 °C for
2–3 minutes. The DNA was eluted from the beads with 50 µl TLE. A further 250
µl TLE was subsequently added to the Hi-C samples only to make a total of 300 µl
(required for the next step). Samples were stored at -20 °C until required.
Streptavidin pull-down of biotinylated HiC ligation products (Hi-C sam-
ples only)
In order to minimise loss of DNA during the streptavidin pull-down of biotinylated
Hi-C ligation products, all steps were carried out in LoBind tubes and with LoBind
pipette tips. The pull down of biotin-marked ligation junctions was carried out using
Dynabeads MyOne Streptavidin C1 beads (Life Technologies), which were prepared
in the following way before use; for each wash the beads were resuspended in the
appropriate buffer, transferred to a new tube and place on a rotating wheel for
3 minutes. Briefly, 150 µl C1 beads per sample were placed in a fresh Eppendorf,
placed on the magnetic rack and the supernatant was removed. The beads were then
washed twice with 400 µl Tween Buffer (5 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 1M
NaCl, 0.05% Tween). The beads were then washed with 300 µl of 2x No Tween
Buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 2 M NaCl) and the supernatant was
removed. The beads were then combined with 300 µl Hi-C DNA and incubated
at room temperature for 15 minutes with rotation. Following this, the beads were
reclaimed and resuspended in 400 µl 1x NTB (5 mM Tris-HCl pH 8.0, 0.5 mM
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EDTA, 1M NaCl). The suspension was then placed at 55 °C with shaking at 500
rpm for 5 minutes to improve the specificity of the pull down before the supernatant
was removed and the beads were washed in 100 µl 1x ligation buffer (New England
Biolabs). The reclaimed beads were then resuspended in 50 µl 1x ligation buffer and
transferred to a new tube.
Paired-end adapter ligation and library amplification
The undigested sample was defrosted on ice and 5.8 µl 10x ligation buffer were added
to the DNA. Custom SCRiBL adapters were ligated to the Hi-C and undigested li-
braries by the addition of 4 µl SCRiBL TruPE adapter mix (15µM) (Table 4.1)
and 4 µl NEB T4 Ligase (400 U/µl). Reactions were incubated at room tempera-
ture for 2 hours on a rotator; SCRiBL TruPE adapters were generated by annealing
SCRiBL TruPE adapter 1 and SCRiBL TruPE adapter 2 by decreasing the temper-
ature from 90 °C to 4 °C with ∆ -1 °C /minute. The undigested material was placed
at 65 °C for 15 minutes to inactivate the ligase enzyme and subsequently frozen at -20
°C. The beads from the Hi-C samples were recaptured, the supernatant was removed
and the beads were washed twice with 400 µl TB. The beads were subsequently
washed with 200 µl 1x NTB, 100 µl 1x NEBuffer 2 and then 50 µl 1 x NEBuffer 2.
Finally the beads were resuspended in 50 µl 1x NEBuffer 2 and transferred into a
new tube. Samples were stored at -20 °C.
Final quality control and library quantification
A test PCR amplification was run on both the Hi-C and undigested samples to
determine the number of PCR cycles required to generate enough material for capture
and sequencing. The following PCR reactions were set up; 2.5 µl DNA, 0.075 µl 100
µM PE PCR primer 1.0.33, 0.075 µl 100 µM PE PCR primer 2.0.33, 0.7 µl each 10
mM dNTP (x4), 0.3 µl Phusion polymerase (New England Biolabs), 5 µl 5X Phusion
HF buffer (New England Biolabs) and 14.25 µl dH2O. The PCR conditions were 98
°C for 30 seconds, followed by either 6, 9 or 12 cycles of 98 C for 10 seconds, 65 °C for
30 seconds, 72 °C for 30 seconds followed by 72 °C for 7 minutes. The PCR products
were then run on a 1.5% agarose gel against MassRuler DNA Ladder using 6X DNA
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loading dye (both Thermoscientific). The appropriate number of cycles for the final
amplification PCR was taken as the number immediately below that at which the
smear is just visible.
The final PCR amplification was performed as described above, but using the
whole Hi-C and undigested DNA libraries (20–30 25 µl PCR aliquots). Following
the PCR reaction, library products were pooled and the beads were reclaimed on
a magnetic rack. The PCR products in the supernatant were purified with 1.8x
volume AMPure XP beads and washed twice with 1 ml 70% EtOH before DNA was
eluted with 50 µl TLE. Samples of each library were sent to the Bioanalyser for
concentration and size distribution quantitation.
4.2.3 Part IIa: Generation of biotinylated RNA for target
enrichment (SCRiBL)
RNA baits were designed for the enrichment of the HPV16 genome in the Hi-C
samples generated in Part I.
Capture RNA bait library design
120-mer capture RNA baits were bioinformatically designed with custom perl script
from Simon Andrews (Babraham Institute) to both ends of MboI restriction frag-
ments overlapping the HPV-16 genome. Requirements for target sequences were as
follows: GC content between 25% and 65%, no more than two consecutive Ns within
the target sequences, and maximum distance to a MboI restriction site 330bp. For
short MboI fragments, where 120-mer RNA baits originating from both ends would
have overlapped (potentially interfering with optimal hybridization to Hi-C libraries),
only the coding strand was used for capture RNA bait design; if necessary the baits
were trimmed to minimum length no shorter than 97 nt. This resulted in the design
of 16 RNA bait sequences (Table 4.3) covering the MboI restriction fragment ends
of the entire HPV16 genome, with the exception of two fragments too short (18 and
63 bp, respectively) for capture RNA bait design.
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Zero Blunt® TOPO® cloning of gBlocks
DNA sequences encoding for the 16 RNA bait sequences, with different restriction
enzyme sites at each fragment end (5’ BglII and 3’ HindIII or SpeI, Figure 4.12)
were ordered as two gBlocks (Integrated DNA Technologies) and cloned into plas-
mid vectors using the Zero Blunt® TOPO® cloning kit with One Shot® TOP10
chemically competent cells according to the manufacturer’s instructions. Following
overnight incubation, plasmid DNA from gBlock clone 1.1 and 2.1 was isolated using
the QIAprep spin Miniprep kit (Qiagen) according to the manufacturer’s instruc-
tions. DNA was eluted in 50 µl Elution Buffer.
Digestion to cut out gBlock fragments from pCR-Blunt II-TOPO cloning
vector
To isolate the gBlock fragments from the cloning vector, digestion reactions with
restriction enzyme EcoRI were performed. 8.5 µg of each gBlock 1 and 2 were
incubated with 12 µl 10x CutSmart Buffer and 6 l EcoRI HiFi enzyme (both New
England Biolabs) for 2 hours at 37 °C. After incubation the mixtures were run on a
1% agarose gel and the bands containing the desired insert (∼1 kb) were cut out and
purified using the QIAquick Gel extract kit (Qiagen) according to the manufacturer’s
instructions. The DNA was eluted in 50µ l H2O per column and quantified by
Nanodrop.
Digestion of gBlock fragments and ligation of T7 sequencing adapters
DNA from both gBlocks was then further digested to release the fragments specific
to the HPV16 genome. The DNA from gBlock1 was incubated with restriction
enzymes BglII (10 U/µl) and HindIII (20 U/µl), whereas DNA from gBlock2 was
incubated with BglII (10 U/µl) and SpeI (10 U/µl). Each fragment contained a single
BglII cut site and enabled side specific ligation of a T7 promoter sequence adapter
(Table 4.1). T7 adapters were generated by annealing T7 promoter adapter 1 and
T7 promoter adapter 2; 20 µl each of both forward and reverse primers (100 µM)
were mixed with 60 µl oligo annealing buffer (10 mM Tris pH 8.0, 50 mM NaCl, 1
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mM EDTA) and placed in a PCR machine at 95 °C for 5 minutes. Following this
initial incubation the temperature was decreased at a rate of 1 °C per minute to 4
°C. Digestion with both restriction enzymes and adapter ligation was carried out in
one reaction simultaneously in the presence of BamHI (20 U/µl) to each reaction
in order to cut any unspecific adapter-adapter products that may be present. Two
reactions containing 700 ng gBlock1 or 850 ng gBlock2 DNA, 30 units BglII each,
100 units BamHI each, 5-fold molar excess of pre-annealed T7 promoter adapters,
and either 80 units HindII (NEB) or 40 units SpeI (NEB) were incubated at 37 °C
for 2 hours in 1x T4 DNA ligase buffer (NEB). Following this incubation 1200 units
T4 DNA ligase (NEB) were added to each reaction and incubated at 25 °C for 3
hours. The samples were then run on a 1% agarose gel and specific bands at 180 bp
were cut out and gel purified.
In vitro transcription
In vitro transcription was carried out using the T7 MegaScript kit (Ambion) with
biotin-labelled dUTP (Roche). Equimolar amounts of gBlock1 and gBlock2 purified
DNA was combined and used in in vitro transcription reaction; 2 µl 10X buffer, 5.5
µl DNA template (280 ng), 5 µl biotin-UTP (Roche), 1 µl unlabelled rUTP (100
mM), 1.5 µl rATP (100 mM), 1.5 µl rCTP (100 mM), 1.5 µl rGTP (100 mM) and 2
µl T7 enzyme mix. The reaction mixture was incubated at 37 °C overnight.
Purification of biotinylated RNA
To remove any remaining template DNA the samples were treated with 1 µl Turbo
DNase (Life Technologies) for 15 minutes at 37 °C. The RNA was then purified using
the MEGAclear kit (Ambion) following the manufacturer’s instructions. The RNA
was eluted in 50 µl elution solution. The size and integrity of the RNA was tested
by running 2 µl on a 2% agarose gel and the final concentration of RNA baits was
quantified by Nanodrop.
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4.2.4 Part IIb: Generation of biotinylated RNA for target
enrichment (Capture-seq)
The generation of RNA bait for the capture of undigested libraries was carried out
using a plasmid approach. The pSP64 HPV16 plasmid (Figure 4.11 A) contains
the linearised HPV16 genome, from which four consecutive, non-overlapping DNA
fragments spanning the length of the genome were produced. These were then in
vitro transcribed to RNA and fragmented to produce RNA baits for the capture
reaction.
Plasmid preparation
An overnight culture from a glycerol stock made from a single colony of plasmid
pSP64 HPV16 1.1 (Cinzia Scarpini) was prepared with 5 ml LB broth and 100 µg/ml
ampicillin and incubated at 37 °C with gentle shaking overnight. Following incu-
bation, plasmid DNA was extracted using QIAprep® Spin Miniprep Kit (Qiagen)
according to the manufacturer’s instructions. The quantity and purity of the DNA
was determined by Nanodrop analysis.
Plasmid integrity check
To check the integrity of the plasmid DNA a digest assay was performed using re-
striction enzymes BamHI (20 U/µl, New England Biolabs) and EcoRI HIFI (20 U/µl,
New England Biolabs), which cut the plasmid at two and three sites respectively.
For each restriction enzyme reaction 1 µg DNA, 1 µl restriction enzyme, 2.5 µl 10x
buffer (NEBuffer 3.1 for BamHI or Cutsmart for EcoRI, both New England Biolabs),
and 17.8 µl dH2O. Both reactions were incubated at 37 °C for 1 hour before being
run on a 1% agarose gel.
PCR amplification of HPV16 genome
To amplify the HPV16 genome four primer sets were designed across the entire W12E
genome. Plasmid DNA was diluted to 10 ng/µl and four PCR reactions were set
up, each with a separate primer pair (Table 4.1); 1 µl plasmid DNA (10ng/ul), 2 µl
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dNTP mix (2.5 mM), 10 µl Expand High Fidelity buffer (10x), 0.5 µl forward primer
(100 µM), 0.5 µl reverse primer (100 µM), 0.75 µl Expand High Fidelity enzyme
mix, 82.5 µl dH2O. A touchdown PCR was run to ensure specific amplification of
the DNA. The following PCR conditions were used: 94 °C for 5 minutes, followed by
13 cycles of 94 °C for 1 minute, 74–62 °C for 1 minute, 68 °C for 8 minutes, followed
by 22 cycles of 94 °C for 1 minute, 62 °C for 45 seconds, 68 °C for 8 minutes, and
then 68 °C for 10 minutes before cooling to 4 °C. PCR products were then run on a
1.5% agarose gel.
In vitro transcription with biotin-UTP
T7 promoter sequences were added to one side of the PCR product during the PCR
amplification described above, which enabled subsequent directional in vitro tran-
scription. Sequences were in vitro transcribed in the presence of biotin-UTP and
purified as described previously.
RNA fragmentation
An equimolar mix of the four full length (2,000 nt) RNA products was then frag-
mented to ∼150 nt for use in the capture reaction using a modified version of
the FGRS protocol for RNA-seq library preparation protocol (Iyer Lab, Lauren
Fairchild). Briefly, chemical fragmentation of the RNA occurred by combining 250
ng of RNA, 100 mM Tris pH 8.0 and 4 mM MgCl2 in 10 µl and incubating at 95 °C
for 8 minutes in a PCR machine. A total of 5 µg RNA was fragmented using this
method.
Precipitation of RNA
The fragmentation reactions were then pooled into 2 x 100µl samples and precipitated
using 1x volume (100 µl) ice-cold isopropanol and 1/10th volume (20 µl) ammonium
acetate Stop Solution (Ambion) and incubated at -20 °C for 2 hours. Following
incubation, the RNA was spun at 14,000 rpm at 4 °C for 20 minutes to pellet the
RNA. The pellet was then washed twice with 500 µl 75% ethanol and resuspended
in 20 µl dH2O. The resulting RNA was then quantified using the Nanodrop.
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4.2.5 Part III: Solution hybrid capture of Hi-C library
Hybridisation of Hi-C library with biotin-RNA target bait
The amount of Hi-C library DNA or genomic DNA library captured was determined
by the concentration of each library and ranged from 500–2000 ng. To prepare the Hi-
C library (pond) for capture with RNA baits the appropriate volume was transferred
into a 1.5 ml LoBind Eppendorf tube and concentrated using a vacuum concentrator
(Savant SPD 2010, Thermo Scientific). After evaporation of all liquid, the Hi-C
DNA pellet was resuspended in 5 µl dH2O and transferred into a fresh LoBind
Eppendorf. 2.5 µg mouse cot-1 DNA (Invitrogen) and 2.5 µg sheared salmon sperm
DNA (Ambion) were added as blocking agents. To prevent concatemer formation
during hybridisation 1.5 µl blocking mix (300 µM) were added (equimolar mix of
four oligo blockers: (P5 b1 for 33, P5 b1 rev 33, P7 b2 for, P7 b2 rev) (Table 4.1),
resulting in a 10 µl reaction mixture. This was resuspended thoroughly, transferred
into PCR strip tubes (Agilent 410022), closed with a PCR strip tube lid (Agilent
optical cap 8x strip) and kept on ice until use.
A master mix of the 2.23x hybridisation buffer was then prepared; 167.25 µl 20x
SSPE (Gibco, 11.15x final), 66.9 µl 50x Denhardts (Invitrogen, 11.15x final), 6.69 µl
500 mM EDTA (Gibco, 11.15 mM final), 6.69 µl 10% SDS (Promega, 0.223% final)
and 52.47 µl H2O. The hybrisation buffer was mixed thoroughly and heated to 65
°C for at least 5 minutes. 30 µl were then aliquoted per capture reaction into a PCR
strip, closed with a PCR strip tube lid and kept at room temperature.
Biotinylated RNA baits were used in a ratio of 1:12 to Hi-C libraries (25 ng
biotinylated RNA baits per 300 ng Hi-C library). The baits were prepared by trans-
ferring 25 ng of biotinylated RNA into a 1.5 ml LoBind Eppendorf tube, and made
up to a volume of 5.5 µl with H2O. Subsequently, 30 units (1.5 µl) SUPERase-In
(Ambion, 20 U/µl) were added (7 µl total), mixed, transferred into a PCR tube,
closed with a strip tube lid and kept on ice. Biotinylated RNA baits for capture
DNA-Seq were used in a ratio of 1:3.33 (300 ng RNA baits per 1,000 ng genomic
DNA library); these baits were prepared in the same way as above.
The PCR machine (PTC-200, MJ Research) was set to the following program; 95
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°C for 5 minutes, 65 °C forever. The PCR strip containing the pond Hi-C libraries
was transferred to the PCR machine in the position marked red (Figure 4.3 A), the
PCR program was started and the DNA denatured. Once the temperature returned
to 65 °C the PCR strip containing the hybridisation buffer was transferred to the
PCR machine in the position marked in blue (Figure 4.3 B) and incubated for 5
minutes. Following this, the final PCR strip containing the biotinylated RNA bait
was transferred to the PCR machine in the position marked in green (Figure 4.3 C)
and incubated for 2 minutes. After 2 minutes, 13 µl of hybridisation buffer were
pipetted into the 7 µl RNA baits (blue into green). This was immediately followed
by pipetting 10 µl of the Hi-C library into the hybrisation buffer:RNA mix (red
into green). The remaining PCR strip was closed with a new strip tube lid and the
reactions were incubated for 24 hours at 65 °C, in a total reaction volume of 30 µl.
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Figure 4.3: PCR machine set up for the hybridisation of RNA baits to
DNA libraries. PCR strip containing DNA (red) is placed in row D at 95 for 5
minutes. Once the temperature has cooled to 65 the PCR strip containing hybridi-
sation buffer (blue) is put in row B in the machine and incubated for five minutes.
After the PCR strip containing RNA (green) is added to row F and incubated for
2 minutes before 13 hybridisation buffer is added to the RNA (blue into green) im-
mediately followed by the transfer of 10 µl DNA library into the RNA mix (red into
green).
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Streptavidin-biotin pull-down and washes
Captured DNA/RNA hybrids were enriched using Dynabeads MyOne Streptavidin
T1 beads (Life Technologies). 60 µl T1 beads per captured library were aliquoted
into a LoBind Eppendorf and washed three times in 200 l binding buffer (BB: 1 M
NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA). With the streptavidin beads in 200 µl
BB the entire hybridisation reaction from the 24-hour incubation was transferred into
the beads and mixed. This was then incubated at room temperature on a rotating
wheel. After 30 minutes the beads were reclaimed on a magnetic separator and the
supernatant was discarded. The beads were then resuspended in 500 µl wash buffer
I (WBI: 1x SSC, 0.1% SDS) and incubated at room temperature for 15 minutes
with agitation every 2-3 minutes. Following incubation, the beads were once more
reclaimed and the supernatant was discarded. The beads were then resuspended
in 500 µl wash buffer II (WBII: 0.1x SSC, 0.1% SDS) pre-warmed to 65 °C, and
then incubated at 65 °C for 10 minutes with agitation every 2-3 minutes. This
was repeated for a total of 3 washes in WBII. The beads were next reclaimed, the
supernatant was discarded and the beads were resuspended in 200 µl 1x NEBuffer 2
and immediately transferred into a fresh LoBind Eppendorf tube.Tubes were placed
immediately back on the magnetic rack and the supernatant was removed. Finally
the streptavidin beads (with bound captured DNA/RNA) were resuspended in 30 µl
1x NEBuffer 2 and transferred into a fresh tube.
Post-capture PCR amplification of SCRiBL Hi-C libraries
To determine the optimal number of PCR cycles for SCRiBL Hi-C library amplifica-
tion, test PCRs were set up as previously described with PCR cycle numbers tested
9, 12 and 15. The amount of amplified DNA was then checked by running the entire
reaction on a 1.5% agarose gel. Again, the number of cycles chosen for the final PCR
amplification of the SCRiBL library was determined by choosing the number of PCR
cycles immediately before the appearance of a smear on the gel. For the final PCR
amplification, multiple reactions were set up so that the entire volume of SCRiBL
Hi-C library was used (2.5 µl in each PCR reaction). In the final reaction primer
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pairs consisted of one TruSeq adapter reverse compliment and the TruSeq universal
adapter (Table 4.1). Each primer pair introduced a library-specific barcode required
for accurate sequencing of each library.
The samples from the complete PCR reaction were pooled, placed on a magnetic
separator and the supernatant transferred into a fresh LoBind Eppendorf tube. The
beads were resuspended in 20 µl 1x NEBuffer 2 and kept at -20 °C as a back up.
The volume of supernatant containing the captured library was determined and was
then purified by performing sequential SPRI bead selections at 1x and 1.8x volume
(Beckman Coulter). The captured libraries were finally eluted from the beads in 20
µl TLE. Before sequencing, the quality and quantity of all libraries were checked by
Bioanalyzer (Agilent) and Kapa Q quantitative PCR (Kapa Biosystems).
Paired-end Next Generation Sequencing
Two biological replicate Hi-C and capture Hi-C libraries were prepared for each
of the cell lines. Sequencing was performed on Illumina HiSeq 2500 generating
50bp paired-end reads (Sequencing Facility, Babraham Institute). CASAVA soft-
ware (v1.8.2, Illumina) was used to make base calls and reads failing Illumina filters
were removed before further analysis. Output FASTQ sequences were mapped to
the human reference genome (GRCh37/hg19) containing the HPV16 genome as an
extra chromosome and were filtered to remove artefacts using the Hi-C User Pipeline
(HiCUP)
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Table 4.1: Details of oligonucleotides used in the synthesis of SCRiBL
Hi-C libraries
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4.2.6 Bioinformatic analysis performed by Jack Monahan
HiCUP & SeqMonk
Sequence data was obtained from Illumina HiSeq paired-end sequencing. Using
the HiCUP Pipeline258, paired-end capture Hi-C (cHi-C) fastq files were mapped
with Bowtie 2259 to a human GRCh37 reference containing an HPV16 pseudo-
chromosome. HiCUP removes invalid and artefactual di-tags by overlaying the di-
tags on an in silico restriction digest of the reference. The resulting BAM files con-
tained putative di-tags for use in subsequent analyses. SeqMonk (Somin Andrews,
Babraham Bioinformatics) was used to quantitate and visualise the density of di-tags
contained in the BAM files. The HPV16 sequence and annotation files were down-
loaded from the European Nucleotide Archive (http://www.ebi.ac.uk/ena/data/view/K02718).
ENCODE Annotation for NHEK260 was obtained from Ensembl release 75261.
Circos
The raw cHi-C fastq files were converted to fasta format and BLAST262 was used to
search the HPV16 genome for reads mapping to it. The partner human reads were
determined and the 2 sets of reads were mapped to the GRCh37 reference containing
the HPV16 pseudo-chromosome using Bowtie 2. The BAM outputs were converted
to BED format and modified to be compatible with the circular visualisation tool
Circos 263. The HPV16 genome was split into bins of 500 bp and the count per bin
determined from the chimaeric human-HPV16 di-tags. The counts, the HPV16 MboI
restriction map and gene coordinates were annotated on the Circos plots.
GOTHiC
The HiCUP output was converted to format compatible with the Bioconductor
package GOTHiC 254, 264. To find significant interactions between distal locations
GOTHiC implements a cumulative binomial test based on read depth. This was
used to identify regions of the human genome in contact with the HPV16 pseudo-
chromosome at a resolution of 1kb. Di-tag mappings were visualised with Circos
after filtering the previous Circos input by the GOTHiC determined interactions.
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Breakpoint Mapping with USearch
The precise sites of HPV16 integration in the W12 cell lines were identified by se-
quencing undigested Hi-C libraries. The raw fastq files were converted to fasta for-
mat and BLAST was used to search for reads mapping to the HPV16 genome. From
these, the corresponding human tag were determined. Fast clustering of the reads
with USearch 265, based on an sequence identity score of 0.65, identified clusters of
sequences in the human and HPV16 derived reads. Consensus sequences from non-
singleton clusters were obtained by aligning the clustered reads to each other using
Clustal Omega 266. The breakpoints were inferred from these consensus sequences
and validated by Sanger Sequencing267.
From the validated integration sites, custom chimaeric references were generated
for each W12 line. Due to the existence of tandem amplifications in some of the
regions of integration, two versions of the chimaeric human-HPV16 chromosomes
were generated. In the first case, the HPV16 provirus was 5’ of a single amplified
human sequence. For the second, the provirus was placed 3’ of the amplified human
sequence. For another W12 line, ‘H’, there is a deletion in the region of integration
and this was reflected in the chimaeric chromosome.
Juicer and Juicebox
Using the specific chimaeric references, Hi-C contact maps at different resolutions
were generated from raw Hi-C fastq files using the Juicer Pipeline268. Juicer con-
structs a compressed contact matrix from pairs of genomic positions located in close
proximity in 3D space. The Hi-C contact maps were imported into Juicebox 269 for
visualisation.
HiCUP (2nd time) & FourCSeq
HiCUP alignment and filtering was repeated on the cHi-C using the chimaeric ref-
erences. The di-tags were subsequently filtered to remove those that did not have
a tag in the captured region (i.e. the HPV16 provirus). cHi-C approximates a
multiplexed Circularized Chromosome Conformation Capture (4C) experiment with
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multiple viewpoints. However due to the relatively low number of captured di-tags
per HPV16 MboI fragment, the entire provirus had to be treated as a single 4C view-
point. The tag counts per HPV16-interacting fragment were determined and these
counts were supplied to the Bioconductor package FourCSeq270. To find significant
interactions between the viewpoint and fragments, FourCSeq applies a variance sta-
bilising transformation to the counts and calculates a distance-dependent monotone
fit.
Z-scores are derived from the fit residuals of the fragments selected by the fit.
Significance is dependent on genomic distance from the viewpoint and takes into
account the agreement between replicates. An asymmetric fit, allowing for differences
between the regions upstream and downstream of the provirus was used. Significant
fragments were those with z-scores greater than 2 in both replicates and an adjusted
p-value of less than or equal to 0.05 in at least one replicate.
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4.3 Results
4.3.1 Modifications to the ‘Sequence Capture of Regions In-
teracting with Bait Loci’ (SCRiBL) protocol for pro-
duction of Hi-C and captured libraries from the W12
clones.
The aim of the collaboration with Peter Fraser’s group (Babraham Institute) was to
adapt their protocol for producing SCRiBL Hi-C libraries toward use on the panel
of integrated HPV16 W12 clones. The experimental aims were two fold and ran
concurrently; to determine areas of the host genome that the integrated HPV16
genome was in contact with in three dimensions (3D), and, to identify both 5’ and 3’
virus-host junctions in each of the W12 clones tested. The key experimental stages
of generating SCRiBL libraries are outlined in Figure 4.4, and are described in detail
in the Methods section (Chapter 4.2).
Important adaptations to the original protocol for producing SCRiBL libraries
for the W12 integrant clones (with viral genome copy number less than four: F,
A5, D2, H, G2) were the use of the 4-cutter restriction enzyme MboI, with cut site
GATC, and the generation of biotinylated RNA baits specific to the HPV16 genome.
The major distinction between the generation of libraries required for SCRiBL Hi-C
and those used for breakpoint identification was the digestion of chromatin with a
suitable restriction enzyme. Digestion with MboI was not required for the generation
of libraries used for breakpoint identification; as such these libraries were named
undigested throughout the course of this work. For each W12 clone tested, two
biological replicates of both libraries were produced (Figure 4.5).
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Figure 4.4: Schematic overview of the experimental processes required to produce
Sequence Capture of Regions interacting with Bait Loci (SCRiBL) libraries suitable
for next generation sequencing (NGS) on an Illumina platform.A) The generation of a
Hi-C library is divided into six main steps. (1) Initially cells were grown to 90% confluency and
fixed using methanol-free formaldehyde, preserving the 3D nuclear architecture of DNA. (2) The
subsequent chromatin was subject to a restriction enzyme digest and the resulting sticky ends filled
in with generic dNTPs and biotin labelled dATP. (3) Fragments in close proximity were ligated
together via blunt-end, in-nucleus ligation and the crosslinks between DNA fragments reversed. (4)
Ligated DNA was fragmented further by sonication centred at 400 bp and resultant DNA ends
were repaired. Size selection was performed to exclude fragments of the wrong size and a single
dATP added to the repaired 3’ end to allow sequencing adapters to be ligated at a later stage.
Streptavidin pull down of the remaining fragments from the Hi-C library ensured that only those
containing biotin-incorporated DNA were carried forward. (5) Illumina sequencing adapters were
then ligated to the 3 dATP and a pre-capture test PCR carried out to determine the number
of amplification cycles required to generate the final Hi-C library. (6a) Hi-C libraries were then
sent for paired-end sequencing or (6a) used in a hybridisation reaction with specifically designed
biotin-labelled RNA baits. B) Generation of RNA baits. (7) DNA complementary to the capture
region was designed using the IDT gBlock approach. DNA fragments were then released via DNA
restriction digest. (8, 10) T7 promoter adapters were then ligated to the DNA fragment ends to
facilitate in vitro transcription with biotin-labelled dUTP. (11) The RNA baits were then incubated
with the DNA Hi-C library in a hybridisation reaction. C) Generation of the final SCRiBL library.
(12) Biotin-labelled hybrid DNA:RNA was captured via a pull down with streptavidin beads, and
(13) a post-capture PCR reaction performed to determine the number of ampflication cycles required
to generate the final SCRiBL library. (14) Each library was then placed on the Illumina platform
for 100 bp, paired-end NGS.
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Figure 4.5: Diagram indicating the experimental set up of Hi-C library
generation for the W12 clones. A) A single 15 cm2 plate of either F p6, G2 p12,
NCx p5, A5 p5, D2 p8 or H p6 at 80–90% confluence was used to seed four additional
15 cm2 plates. B) At 90% confluence, cells were fixed with formaldehyde and two 15
cm2 plates were combined into one 50 mL Falcon tube to provide cellular material for
one biological replicate. Cellular material was then separated from the supernatant
by centrifugation. C) The chromatin pellet was washed with PBS and transferred
into a 15 mL Falcon tube before a second centrifugation step. D) Following cell lysis,
the cell solution was divided equally between five 1.5 mL Eppendorf tubes. Four were
used for the generation of a Hi-C library for use in SCRiBL, and one was kept as an
undigested library and was used in the capture-seq experiment.
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4.3.2 Short-range interactions of W12 clone Hi-C libraries
are detected using chromosome conformation capture
(3C) assays.
Quality control checks give a strong indication of whether a Hi-C library will be
successful; as such, forward primers were designed across the RPL13A host genomic
control locus to detect short-range interactions generated by unique ligation events in
the Hi-C libraries (Figure 4.6 A). The RPL13A genomic locus was divided according
to MboI restriction sites and the fragments labeled alphabetically. Forward primers
within a number of fragments were designed, and two forward primers were paired
in a subsequent PCR reaction. The use of two primers in the same orientation
meant that PCR products were only detectable in libraries previously digested with
MboI where ligation had occurred (Hi-C). PCR reactions with primer pairs B:I and
B:G resulted in expected 394 bp and 319 bp products respectively using W12 clone
F Hi-C template DNA (Figure 4.6 B). An annealing temperature of 53.9 °C was
carried forward and the number of PCR cycles increased to amplify the strength of
the band. Use of the B:I forward-forward primers resulted in Hi-C specific products;
the strongest band was produced using W12 G2 Hi-C DNA template compared
to a minimal amount of 394 bp-specific product from the NCx or W12 F Hi-C
libraries (Figure 4.6 C). In contrast, use of the B:G forward-forward primers in the
PCR reaction resulted in an abundance of the 319 bp-specific ligation product in
all three Hi-C libraries (Figure 4.6 D). Although there were additional 3C ligation
products generated by both primer pairs, fewer were made using the B:G primers;
moreover, any additional products were further from the band of interest making
detection of the desired product more reliable. Consequently, the B:G forward-
forward primers designed across the RPL13A locus were used for the detection of
short-range interactions in all subsequent W12 Hi-C libraries.
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Figure 4.6: Detection of short-range interactions in the W12 clone F Hi-C
library.A) Diagram showing the generalised principle of using two forward primers
designed across the RPL13A locus (control region) according to MboI restriction
sites (indicated by dashed line) to determine short-range interactions in the W12
clone F Hi-C library. Primers are depicted as green arrows. B) Optimisation of
conditions for PCR of Hi-C library using primer pairs B:G and B:I. PCR reactions
were carried out at a range of temperatures; 1=53.9 °C, 2= 52.7 °C and 3=52 °C for
35 cycles. Each 25 µl PCR sample was run on a 1.5% agarose gel. White arrowheads
indicate the PCR products of interest; B:G = 319 bp, B:I = 394 bp. PCR reaction
of NCx undigested and Hi-C, W12 F undigested and Hi-C and W12 G2 undigested
(Un) and Hi-C libraries (Hi-C) using (C) B and I forward primers and (D) B and G
forward primers. PCR reactions were carried out at 53.9 °C for 38 cycles. Each 25
µl PCR sample was run on a 1.5% agarose gel. Black arrowheads indicate the B:I
and B:G specific PCR products.
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For robustness, an alternative method for detecting short-range interactions in
Hi-C libraries was utilised (Figure 4.7 A). The RPL13A genomic locus was again
divided into fragments according to MboI restriction sites and labeled alphabetically.
Forward primers spanning two restriction fragments were designed, each containing
a 5’-GATCGATC-3’ sequence. This eight-nucleotide sequence was generated from
blunt-end, in-nucleus ligation of MboI restriction fragments and was present in Hi-C
libraries. A reverse primer in the same fragment as the 3’-end of the forward primer
was designed and the combined pair used to generate specific PCR products. No
PCR product should be generated using an undigested library as the forward primer
will not be complementary to template DNA and should not anneal.
PCR reactions were carried out testing three alternative primer pairs; similar
amounts of PCR product were produced regardless of W12 F DNA template with
primer pairs B:H and C:H; 369 bp and 373 bp, respectively. However, although some
product was formed using undigested material with primers D:J, product formation
was much more specific to the Hi-C sample (Figure 4.7 B). An abundance of PCR
product in both the undigested and Hi-C libraries for the B:H and C:H primer pairs
was likely due to the unspecific binding of the forward primer as a result of a low
annealing temperature (55 °C) and a high GC content (64%) compared with D:J
primer pair (38%). Optimisation of PCR conditions for Hi-C specific amplification
of the D:J 401 bp product was carried out at a range of primer annealing temperatures
(Figure 4.7 C). An annealing temperature of 62 °C and 35 cycles of amplification
was carried forward when testing for short-range interactions in all W12 clone Hi-C
libraries (Figure 4.8 A-D). Specific, short-range interactions were detected in the Hi-
C libraries of all clones and no product was formed in the undigested counterpart;
this was a clear indication of successful library generation.
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Figure 4.7: Alternative method of detecting short-range interactions in
the W12 F Hi-C library.A) Diagram showing the generalised principle of pairing a
forward primer, designed to span an MboI restriction site (indicated by dashed line)
of the RPL13A locus (control region), with a reverse primer in a different segment
to determine short-range interactions in a Hi-C library. Resultant PCR products
are specific to digested Hi-C material. Primers are depicted as arrows; forward
orientation = green, reverse = red. B) PCR of short-range interactions in W12 F
undigested (Un) and Hi-C samples using primer pairs: B forward and H reverse
(B:H), C forward and H reverse (C:H), and D forward and J reverse (D:J). PCR
reactions were conducted at 55 °C for 35 cycles; 20 µl of the resultant PCR sample
was run on a 1.5% agarose gel. C) Optimisation of conditions for PCR using primers
B:H, C:H and D:J. PCR reactions were conducted at a range of temperatures; 1=58.1
°C, 2=60 °C, 3=61.2 °C and 4=62 °C for 35 cycles; 10 µl of the resultant PCR sample
was run on a 1.5% agarose gel.
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Figure 4.8: Detection of short-range interactions in each W12 clone Hi-C
library.PCR reactions of undigested (Un) and Hi-C libraries with D:J primers; NCx,
W12 F and W12 G2 replicate 1 (A) and replicate 2 (B), W12 A5, W12 D2 and W12
H replicate 1 (C) and replicate 2 (D). Each PCR reaction was conducted at 62 °C
for 35 cycles; 10 µl of the resultant PCR sample was run on a 1.5% agarose gel.
4.3.3 Verification of in-nucleus ligation efficiency of W12
clone Hi-C libraries by PCR digest assay.
An additional quality control was carried out before proceeding with the generation
of Hi-C libraries; the ligation efficiency of in-nucleus ligation was verified by PCR
digest assay. Successful fill-in and ligation of two MboI sites (GATCGATC) creates a
site for the restriction enzyme ClaI (ATCGAT) (Figure 4.9 A). Hi-C DNA was used
as a template for PCR reactions using the previously optimised B:G forward-forward
primers (Figure 4.9 D). Following amplification, half of the PCR reaction mixture
was incubated with ClaI for 2 hours at 37 °C. The products of the PCR and digestion
reactions were compared by agarose gel electrophoresis. Every Hi-C sample showed
the specific B:G PCR product (319 bp). In contrast, in the ClaI digested samples
this product band was cut into two alternative bands of 220 bp and 100 bp (Figure
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4.9 B-D). The ligation efficiency was estimated by quantifying the intensity of the
cut and uncut bands using Image J software. The ligation efficiency was high in all
W12 Hi-C libraries ranging from 71.1% (W12 clone A5 rep I) to 94.2% (W12 clone
G2 rep I); this was also suggestive of successful library generation.
Figure 4.9: Determination of ligation efficiency in each W12 clone Hi-C library.
A) Diagram showing that the product of blunt-end ligation of MboI restriction fragments
constitutes a ClaI restriction site. PCR reactions with BG primers and ClaI digestion
reactions of NCx, W12 F and W12 G2 replicate 1 (B) and replicate 2 (C), W12 A5, W12
D2 and W12 H replicate 1 (D) and replicate 2 (E). For each clone, the Hi-C lane is loaded
with the 750 ng PCR product produced using the B:G forward primers at 59.3 °C for
38 cycles. The ClaI lane contains digestion products following incubation of 750 ng PCR
product with 20 U ClaI restriction enzyme for 2 hours at 37 °C. All samples were run on
a 1.5% agarose gel. The ligation efficiency for each library is shown under each gel.
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4.3.4 Determination of conditions for final PCR amplifica-
tion of W12 clone Hi-C libraries.
Following stages 4 and 5 of Hi-C library generation (Figure 4.4 A), a test PCR was
carried out to determine the number of amplification cycles required to generate
sufficient DNA material for the subsequent hybridisation reaction and NGS as well
as an appropriate level of library complexity. PCR reactions were carried out using
PE primers 1.0 and 2.0 (Illumina) at 65 °C for 6, 9 or 12 cycles (Figure 4.10 A-D). A
smear of 300-500 bp was produced using NCx, W12 F and W12 G2 material (Figure
4.10 A and B), whereas the smear produced from W12 A5, W12 D2 and W12 H
samples was slightly higher, centered around 500 bp (Figure 4.10 C and D). The
DNA concentration of the undigested libraries was higher than the Hi-C equivalent;
this was due to the loss of material of the Hi-C samples as a result of the extra
processing steps required for library generation. For example, the smear produced
following PCR with 6 amplification cycles of undigested NCx template DNA was
similar to that produced by 12 cycles of amplification of NCx Hi-C DNA template.
The necessary number of PCR amplification cycles for Hi-C libraries was decided by
choosing one fewer number of cycles than that at which a smear was visible; this was
constant across samples generated at the same time, i.e. NCx, F and G2 = 8 cycles
and A5, D2 and H = 9 cycles.
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Figure 4.10: Test amplification of Hi-C and undigested libraries to de-
termine the number of PCR amplification cycles required to generate
sufficient material and library complexity. 2.5 µl DNA from the Hi-C (A and
C) or undigested libraries (B and D) of each clone were combined with Illumina
primers PE 1.0 forward and PE 2.0 reverse for either 6, 9 or 12 cycles (as indicated)
at 65 °C. Each 25 µl PCR sample was run on a 1.5% agarose gel against a 100 bp lad-
der. The number of cycles chosen to generate the final Hi-C or undigested libraries
are shown under each gel.
4.3.5 Generation of RNA baits for capture-sequencing to
detect virus-host breakpoints in the W12 clones.
A key experimental aim was to accurately identify the virus-host breakpoint junctions
in the W12 clones. To do this, enrichment of the HPV16 genome sequence from the
undigested libraries, which had been fragmented by sonication only, was first used.
HPV16-specific biotinylated-RNA baits were made, and used to hybridise to W12
undigested DNA libraries (Figure 4.4 B, steps 7-11). Subsequent streptavidin bead
pull-down resulted in the sequencing of DNA fragments comprised at least partially
of HPV16 genome. Aligning host-virus DNA reads to the human genome identified
two peaks of reads that indicated both the 5’ and 3’ virus-host junctions.
The pSP64 plasmid, in which the W12E HPV16 genome is cloned (Cinzia Scarpini)
(Figure 4.11 A), was used to generate fragments of HPV16 DNA that were later in
vitro transcribed to RNA for use in the hybridisation reaction with the W12 clone
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undigested libraries. Initially the integrity of the plasmid DNA was checked by di-
gesting with either EcoRI or BamHI restriction enzymes (Figure 4.11 B). Digestion
with EcoRI resulted in three DNA fragments whereas BamHI resulted in two, both
indicative of the number of restriction sites in the pSP64 plasmid respectively. Four
sets of primers were designed to evenly cover the entire HPV16 W12E genome (see
Table 4.2).
Table 4.2: DNA primers spanning W12E genome
These were used to amplify the virus genome in a touchdown PCR reaction and
accurately produced the desired DNA products (Figure 4.11 C, Table 4.2). PCR
products of amplified HPV16 genome were combined in equimolar amounts to pro-
duce HPV16 template. In vitro transcription with unlabeled ribonucleotides (rUTP,
rATP, rCTP, rGTP) was trialed for a range of different reaction lengths (Figure 4.11
D). Samples were run against two different RNA molecular weight ladders to accu-
rately determine product length. A strong band centered on 2 kb with a smear of
different molecular weight products was produced in each of the in vitro transcription
reactions of both the HPV and control DNA templates. The greatest concentration
of HPV template RNA was produced after a reaction time of 18 hours, therefore
this condition was taken forward. In vitro transcription of each HPV RNA block
as well as an equimolar mix of all four was then carried out using biotin-UTP.
HPV DNA block3 was not loaded onto the gel properly due to an air pocket and
therefore reaction products are not clear. Despite this, a smear of RNA product
from 2 kb – 200 bp was produced for each individual block as well as for the ‘HPV
template’.
Following the generation of full-length biotin-labeled RNA complementary to the
HPV16 genome, chemical fragmentation with Tris pH 8.0 and 4 mM MgCl2 was
used to generated RNA baits approximately 150 bp in length (Figure 4.11 F). A
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fragmentation time of 8 minutes resulted in appropriately sized RNA baits and this
condition was used to generate a total of 5 µg biotinylated HPV16 RNA bait. After
purification, an aliquot of the fragmented RNA baits was run against another RNA
sample of known molecular weight (Marco Michalski) as well as two RNA ladders.
This ensured that the baits were an appropriate size for even coverage and optimal
hybridisation to the integrated HPV16 genome in the W12 clone undigested DNA
libraries (Figure 4.11 G).
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Figure 4.11: Generation of RNA baits for use in the capture-seq experiment with
undigested W12 clone DNA libraries. A) Diagram showing pSP64 HPV16 plasmid design.
HPV16 genes are indicated with red arrows and the restriction enzyme cut sites labelled on the
outside of the circularised genome (EcoRI = green; BamHI = yellow.) B) Plasmid integrity check.
Purified plasmid DNA was incubated with EcoRI or BamHI for 1 hour at 37 °C and the products run
on a 1% agarose gel. C) PCR amplification of the HPV16 genome. Four sets of primer pairs were
used to amplify the viral genome in a touch down PCR reaction. The PCR reaction was conducted
at 74-62 °C for 13 cycles followed by 22 cycles at 62 °C. PCR products were run on a 1.5% agarose
gel; HPV16 DNA block1: 2000 bp, HPV16 DNA block2: 1956 bp, HPV16 DNA block3: 1950 bp,
HPV16 DNA block4: 2066 bp. D) In vitro transcription of the HPV16 genome trial. An equimolar
mix of the full length DNA generated from each primer pair was combined to generate the HPV16
template, ptri-Xef RNA (Ambion) was used as a control. Various incubation times of in vitro
transcription with unlabelled rUTP were tested; 4, 6 and 18 hours at 37 °C. The reaction products
were run on a 1.5% agarose gel against a 100 bp DNA ladder, single-stranded (ss) RNA ladder
and a low-range RNA ladder. E) In vitro transcription of the HPV16 genome with biotin-labelled
dUTP. In addition to the equimolar mix, each HPV16 DNA block was individually transcribed with
biotin-labelled dUTP at 37 C overnight (18 hours). Resultant RNA was run on a 1.5% agarose
gel; HPV16 RNA block3 was not loaded properly and can therefore not be seen on the gel. F)
HPV16 RNA bait fragmentation. 250 ng of full length HPV16 template RNA from each primer
pair was incubated with 4 mM MgCl2 and 100mM Tris pH 8 at 95 °C for 0 to 10 minutes. Reaction
products were run on a 1.5% agarose gel. G) The size of the HPV16 purified RNA baits was checked
compared to a known reference (MCMV, supplied by Marco Michalski) by running both on a 1.5%
agarose gel.
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4.3.6 Design and generation of RNA baits for the produc-
tion of W12 clone SCRiBL libraries.
To identify 3D interactions between genomes of the integrated virus and the host, it
was necessary to enrich the W12 clone Hi-C libraries for the HPV16 genome. This
was done by hybridising biotinylated RNA baits specific for the HPV16 genome to
Hi-C DNA libraries. The approach taken to generate appropriate RNA baits was
different to that used in the capture-seq reaction; it was essential for the RNA baits
used for SCRiBL to hybridise to the ends of MboI digested DNA fragments of the
Hi-C libraries. As such, the virus genome was also fragmented according to MboI
restriction sites (GATC) (Figure 4.13 A).
gBlock® Gene Fragments from Integrated DNA Technologies (IDT) were de-
signed to generate biotinylated RNA baits for the capture of HPV16 genome within
the Hi-C DNA libraries, the principle of which is illustrated in Figure 4.12 A-D. In
the first instance ∼120 bp long sequences of DNA complementary to the 5’-end of
HPV16 genome MboI digested fragments were identified (Table 4.3). These DNA
sequences were constructed into gBlocks® flanked by two restriction enzymes, ei-
ther BglII/HindIII (gBlock1) or BglIII/SpeI (gBlock2) (Figure 4.12 E and F). Both
gBlocks® were isolated following Zero-Blunt® TOPO® cloning and the reaction
products visualised (Figure 4.13 B). The 1.2 kb and 1 kb products of gBlock1 and
gBlock2, respectively, were cut from the gel and purified; the band at 4 kb in each
sample represented the cloning vector and was not required. Double digestion of
both isolated gBlocks® with the appropriate restriction enzymes released the ≈120
bp DNA sequences, to which T7 promoter adapters required for in vitro transcrip-
tion were ligated. Reaction products from the digestion and ligation reaction were
visualised and the specific 180 bp product (≈130 bp DNA fragment + 50 bp T7
adapter) extracted and gel purified for in vitro transcription (Figure 4.13 C). As
well as the desired 180 bp product band, there were additional bands at 360 bp and
100 bp; these represented products comprised of two DNA fragments and two T7
adapters, and two adapters ligated together, respectively. In vitro transcription with
biotin-UTP generated a tight band of RNA baits at 130 bp, which were used for the
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capture of HPV16 fragments in the W12 clone Hi-C libraries (Figure 4.13 D).
Table 4.3: MboI restriction sites within the HPV16 genome and RNA
baits for SCRiBL
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Figure 4.12: HPV16-specific RNA bait generation using the IDT gBlock
approach for use in capture reaction to produce W12 SCRiBL libraries.
A) Diagram depicting the gBlock design of 120 bp HPV16 DNA fragments encom-
passed by enzyme-specific restriction sites; gBlock1 contained restriction sites for
BglII and HindIII whereas restriction sites for BglII and SpeI surrounded HPV16
DNA fragments in gBlock2. B) Digestion of each gBlock with the two specific re-
striction enzymes resulted in release of the HPV16 DNA fragments. C) T7 promoter
adapters, required for in vitro transcription of template DNA, were ligated to the
BglII site of the digested gBlock fragments. D) An equimolar mix of the two gBlock
fragments were combined and the HPV16 DNA fragments in vitro transcribed to
RNA using T7 RNA polymerase and biotin-UTP. E) Genomic sequence for gBlock1
design, F) Genomic sequence of gBlock2 design (coordinate details given in Table
4.2).
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Figure 4.13: Generation of HPV16 RNA baits for use in SCRiBL experi-
ments. A) Diagram showing the MboI restriction sites (red) and the coordinates of
gBlock1 and gBlock2 (orange and purple dashed lines, respectively) marked on the
circularised HPV16 genome. B) Isolation of gBlock fragments from the Zero Blunt®
TOPO® cloning vector. Cloning vectors containing gBlock1 and gBlock2 were in-
cubated with EcoRI for 2 hours at 37 °C and the reaction products run on a 1%
agarose gel. White arrowheads indicate the excised gBlock product. C) gBlocks 1
and 2 were digested with two specific restriction enzymes to release individual HPV16
DNA sequences; gBlock1 was incubated with BglII and HindIII and gBlock2 with
BglII and SpeI for 2 hours at 37 °C. This was followed by ligation of preannealed T7
sequencing adapters to the individual HPV16 fragments by incubation at 25 °C for 3
hours. Reaction products were then run on a 1% agarose gel. D) Equimolar amounts
of each gBlock were combined, and the HPV16 fragments in vitro transcribed with
biotinylated-dUTP. Following RNA purification, 2 µl of the reaction product was
run on a 2% agarose gel to check the size of the RNA fragments (baits). The white
arrowhead indicated the expected RNA product at 130 bp.
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4.3.7 Enrichment of HPV16 genome from W12 clone Hi-C
libraries through capture with biotinylated RNA baits.
After the hybridisation reaction and streptavidin pull down on RNA/DNA hybrid
complexes (steps 11 and 12, Figure 4.4 C), a test PCR was carried out to determine
the number of amplification cycles required to generate enough material for genomic
sequencing but not to introduce excessive library complexity. PCR reactions of the
SCRiBL libraries were carried out using PE primers 1.0 and 2.0 (Illumina) at 65 °C
for 9, 12 or 15 cycles (Figure 4.14 A and C). Smears of ∼300–800 bp were produced
after 12 and 15 amplification cycles, although these were very faint in the NCx, F
and G2 replicates; the final number of amplification cycles chosen was one directly
below that at which a smear was visible, hence the final F and G2 libraries had
an additional amplification cycle compared with A5, D2 and H (11 vs. 10). The
PCR conditions for the captured undigested libraries were also determined using PE
primers 1.0 and 2.0 (Illumina) at 65 °C for an increased number of cycles; 17, 20,
or 23 cycles (Figure 4.14 B and D). A smear centered on 400 bp was produced
using all W12 clone undigested DNA as PCR template and the final number of
PCR amplifications determined similarly to the SCRiBL libraries. Both the Hi-C
and undigested NCx libraries were not sequenced and a final library not generated,
hence the amplification cycle number determination was not necessary.
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Figure 4.14: Post-capture test amplification of W12 SCRiBL and undi-
gested libraries to determine the number of PCR amplification cycles
required to generate sufficient material for NGS and library complexity.
The PCR conditions required for the generation of the final SCRiBL Hi-C libraries
and captured undigested libraries was determined. The RNA/DNA hybrid ’catch’
was amplified by PCR with 9, 12 and 15 (A and C) or 17, 20 and 23 cycles (B and
D) amplification cycles at an annealing temperature of 65 °C. Reaction products
were run on a 1.5% agarose gel. The number of PCR amplification cycles chosen to
generate the final libraries is shown under each gel.
4.3.8 Quality assessment of SCRiBL library NGS using the
HiCUP pipeline.
After completion of the 100 bp, paired-end sequencing run of each of the SCRiBL
libraries, mapping and quality control checks were conducted using the Hi-C User
Pipeline (HiCUP) (Bioinformatics, Babraham Institute). HiCUP is a series of Perl
scripts which perform different tasks including the truncation, mapping, filtering
and de-duplication of the forward and reverse sequences generated by sequencing
(Figure 4.15 A). Initially the raw number of sequence reads were compared (Figure
4.15 B). The number of reads varied from 5.25 x 107 (A5 SCRiBL rep I) to 9.81
x 107 (G2 SCRiBL repI); this rudimentary check indicated that each sequencing
run had been successful. The total number of mapped pairs was determined as a
percentage of the total number of reads; additional filtering of the ‘mapped pairs’
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identified ‘valid pairs’, and this was also shown as a percentage of the total number
of reads (Figure 4.15 C). The percentage of total mapped reads was fairly consistent
across all of the libraries (25.7–39.9%), however the percentage of valid reads was
much higher in SCRiBL libraries of D2 rep II, G2 repI and G2 repII (24.9, 34.0
and 26.1%, respectively) compared to the 6.0% average of the seven other libraries.
Identification of ‘valid’ pairs meant that ‘invalid’ pairs present in each library could
be further characterised (Figure 4.15 D). Whilst no pairs containing a contiguous
sequence of the wrong size were identified in any library, the percentage of read
pairs containing religation events (8.1–27.5%) and dangling ends (2.7–52.0%) were
the most common cause of invalidity. A final quality control check was to determine
the cis:trans ratio of the valid reads (Figure 4.15 E). For all libraries the cis:trans
ratio was below 10% (5.4–9.5 %); this indicated that the proportion of valid reads
to be used for subsequent analysis were of high quality. Finally, a pilot SCRiBL
experiment was run to determine the optimal ratio of HPV16 genome-specifc RNA
bait to Hi-C library required in the (hybridisation step of the protocol) to maximise
the enrichment of HPV16-specific DNA and subsequent sequencing reads (Figure
4.16).
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Figure 4.15: Quality assessment of W12 clone SCRiBL libraries processed
using the Hi-C user pipeline (HiCUP). A) Schematic overview of the HiCUP pipeline.
For each library a FASTQ file is generated for the forward and reverse sequencing strands
(1). Hi-C ligation junctions are identified by locating reads comprising the GATCGATC
sequence and truncating the reads at this point (2). Truncated reads are then mapped to
the GRCh37 human, and W12E HPV16 reference genomes (3). Mapped reads are filtered to
remove common artefacts (invalid reads) (4). Putative PCR duplicates are then removed
from the valid reads to produce a final selection of reads that are used for subsequent
analysis (5). B) Bar-chart showing the number of raw reads obtained from each individual
sequencing run. C) Bar-chart showing the percentage of total mapped pairs (green) and
valid pairs (orange) compared with the total number of reads obtained for each W12
clone SCRiBL library. D) 100% stacked column chart showing the percentage of valid
and invalid pairs (same circularised, dangling ends, same fragment internal, re-ligation,
contiguous sequence and wrong size) compared with the total number of mapped pairs for
each W12 clone SCRiBL library. E) 100% stacked column chart showing the percentage of
close cis (<10 kbp), far cis (>10 kbp) and trans reads in each W12 clone SCRiBL library.
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Figure 4.16: Pilot SCRiBL experiment to determine the optimal RNA
bait concentration required to enrich the Hi-C libraries for the HPV16
genome A) Bar-chart showing the percentage of HPV16-specific sequencing reads
following hybridisation of samples of the W12 clone G2 Hi-C library with 1 ng, 5
ng, 25 ng and 125 ng RNA bait. B) Bar-chart showing the fold change enrichment
of HPV-specific reads following hybridisation compared to the W12 clone G2 Hi-C
library.
4.4 Discussion
The results presented in this chapter indicate that the SCRiBL Hi-C protocol (Peter
Fraser & Stephan Schoenfelder, Babraham Institute) can be successfully adapted to
generate Hi-C libraries, and ensure the capture and subsequent enrichment of the
HPV16 genome within the W12 integrant clones.
In the first part of this chapter, the methodology and validation techniques used
to generate W12 clone Hi-C libraries were described. The resolution of a chromosome
conformation capture assay is dependent on the frequency with which the restric-
tion enzyme fragments the genome271; this, in conjunction with the small ∼8 kb
HPV16 genome meant that the choice of appropriate enzyme was limited. As such,
the HPV16 genome was assessed for restriction enzyme cut sites; the 4-cutter MboI
(GATC) generated 11 fragments within the HPV16 genome and has previously been
shown to be used in the successful generation Hi-C libraries272. As a result, MboI
was chosen for the production of W12 clone Hi-C libraries. The use of a 4-cutter
restriction enzyme compared with more commonly used 6-cutter restriction enzymes
(HindIII273, 274, 256, BglII237 BamHI275 or EcoRI238 resulted in the generation of li-
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braries with a much higher level of complexity. Library complexity relates to the
number of possible interactions within a library produced for conformation capture.
Digestion of the human genome with a restriction enzyme with a 4 bp recognition
site results in approximately 16 million ∼256 bp fragments with the possibility of
up to 100 trillion unique pairwise interactions. This is a 100-fold increase in the
number of possible pairwise interactions between the ∼4 kb fragments generated by
a 6-cutter restriction enzyme245, 276. Given the enormity of theoretical interactions
within a library generated using a 4-cutter enzyme, it is impossible to capture all
interactions by sequencing alone, as such, the capture and enrichment of regions
of interest is required. Capturing the HPV16 genome fragments markedly enriches
their interacting fragments. Also, as a consequence, the overall library complex-
ity is reduced compared with the corresponding pre-capture Hi-C library, and the
identification of significant virus-host interactions at the restriction fragment level
is increased274. Additionally, it was important to take into account increased li-
brary complexity when producing final Hi-C libraries by PCR as over-amplification
resulted in the production of a greater percentage of invalid sequencing reads that
were discarded before downstream analysis.
Quality control analyses were based upon detecting short-range interactions in
Hi-C libraries following MboI restriction enzyme digest and in-nucleus ligation of
DNA fragments in close spatial proximity. Following the principles of 3C confor-
mation capture technology, primers were designed close to, and towards, the ends
of MboI restriction fragments of the known genomic locus RPL13A. The RPL13A
genomic locus was used as a control region as it had previously been shown to be
abundant and stably expressed in the W12 integrant clones183; alternative genomic
loci such as GAPDH and YHWAZ could also have been considered as these have also
been used as housekeeping genes to compare HPV16 transcripts across the panel of
W12 clones183, 203. In addition to the single control locus, optimal 3C PCR condi-
tions were determined using W12 clone F Hi-C material; clone F contains just one
copy of the integrated HPV16 genome and was considered the simplest system for
testing. The same primer pair and PCR conditions were carried forward for equiv-
alent quality control assays and were equally effective for each W12 integrant clone
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library. During the optimisation of the forward-forward primer 3C PCR assay, prod-
ucts other than the specific product were generated. These represent additional 3C
interaction products whereby the two specified DNA fragments are not directly lig-
ated together but have extra DNA fragments ligated between them. DNA fragments
generated by a 4-cutter restriction enzyme (e.g. MboI) have an average length of∼256 bp; as such, a ladder of products spaced by 256 bp is predicted and is observed
following the PCR of ligated fragments.
After restriction enzyme digest of DNA, fragments in close proximity were lig-
ated together within preserved nuclei (in-nucleus ligation); the efficiency of which
was determined by PCR digest assay. Until recently, re-ligation of digested frag-
ments has occurred in dilute solution to prevent non-specific ligation due to chance
inter-molecular collisions277, 246. However, more recent investigations indicate that
carrying out the ligation step within preserved nuclei lead to superior results such
as reducing technical noise as represented by the decrease in trans-chromosomal in-
teractions, as well as improving reproducibility257. To determine the efficiency of
the in-nucleus ligation step for each of the W12 clone Hi-C libraries, the specific
B:G product of blunt-end ligation was digested with the restriction enzyme ClaI.
The efficiency varied from 71.1–94.2% across the panel of W12 libraries, however
this variation does not indicate superiority, and will not have inferred a technical
advantage of any library over the other. It is possible to observe a maximum of
four interactions from one individual fragment per cell (both ends of the fragment
per allele) and as previously mentioned there are 16 million potential interactions
per fragment in a library generated using a 4-cutter restriction enzyme. Therefore,
assuming 100% ligation efficiency, it would be possible to detect all ligation interac-
tions starting with just four million cells (4∧4 = 16). For the generation of each W12
Hi-C library, the ligation step was carried out with a starting material of ∼fifteen
million cells; despite a maximum loss of efficiency of 28.9% all possible interactions
are still recovered ((15 × 0.711)∧4>16). In reality, the number of real interactions
is much fewer than the theoretical maximum due to such factors as distance decay
whereby the probability of an interaction occurring decreases the further the linear
distance between the two genomic fragments276.
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Subsequent sonication of ligated DNA products produced fragments of approx-
imately 400 bp in length. Size selection to remove fragments with much larger or
smaller lengths resulted in libraries with a more uniform size distribution (300–500
bp); this minimised any bias that can arise in subsequent amplification steps of the
protocol271. The final stage of the generation of Hi-C libraries was to determine the
appropriate number of amplification cycles required; a balance between producing a
sufficient concentration of DNA for the capture step and subsequent sequencing and
not introducing additional library complexity was struck. Testing a range of ampli-
fication cycles allowed for each library to be assessed individually and the number of
amplification cycles chosen was one fewer than that at which a smear was first visible.
The second part of this chapter describes how HPV16-specific RNA baits were
derived to enrich the W12 clone Hi-C libraries for the virus genome (generation of
SCRiBL Hi-C libraries). Capturing DNA fragments comprised of hybrid HPV16
and host DNA facilitated the identification of viral-host interactions, the results of
which are far-reaching and include insights into the effect of HPV16 integration on
host gene expression, or vice-versa, via long-range interactions from gene enhancer
or promoter sequences in 3D.
The capture of Hi-C libraries according to predetermined regions of interest, such
as cancer risk loci and gene promoters, has been conducted in an increasing number
of studies273, 256, 255, 274, 278; however enriching a Hi-C library for an integrated viral
genome is novel. The enrichment of the HPV16 genome represents a uniquely small
capture region (∼8 kb); previous capture Hi-C (cHi-C) experiments have captured
much larger whole chromosomal regions ranging from 350–750 kb in length273. As
a result of the small capture region and increased library complexity generated by
using MboI, the ratio of Hi-C library to biotinylated RNA bait could not simply
be replicated from published studies. Consequently, the optimal DNA:RNA bait
ratio for HPV16 genome enrichment was determined using the W12 clone G2 Hi-C
library hybridised to biotinylated RNA baits at a range of different concentrations.
It was shown that a quantity of 25 ng of biotinylated-RNA baits per 300 ng Hi-C
library produced the most favourable enrichment of HPV16-containing reads — 4.6
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fold change — compared with uncaptured Hi-C library (Figure 4.16).
gBlock® Gene Fragments from IDT were designed to generate biotinylated RNA
baits for the capture of the HPV16 genome within W12 clone Hi-C libraries. RNA
bait fragments were designed to have similar GC content (25–65%) and were of uni-
form size (∼120 bp); this prevented hybridisation and amplification bias, respectively,
in subsequent reaction stages of the protocol. In order to produce RNA baits for
the hybridisation reaction it was necessary to in vitro transcribe the isolated DNA
gBlock® fragments; this process required the ligation of a T7 promoter adapter
to each DNA fragment. To ensure controlled and specific ligation, T7 promoter
adapters were designed with a compatible, cohesive end (BamHI overhang) to that
of the 5’-end of DNA fragment (BglII overhang). Ligation of the two DNA molecules
generated a new restriction site (5’-GGATCT-3’) that could not be cleaved by either
enzyme used in the digestion reaction.
Following the capture of HPV16:host hybrid sequences from W12 Hi-C libraries,
the PCR conditions for the generation of the final SCRiBL libraries were determined
using custom PE PCR primers 1.0.33 and 2.0.33. Test PCRs indicated that the post-
capture DNA concentration of the HPV16-negative NCx library was lower compared
with the W12 integrant clones regardless of equal starting concentrations, illustrating
that the biotinylated-RNA baits successfully enriched for DNA fragments containing
the HPV16 genome. Additionally, the NCx cell line was used as a negative control
throughout the process of making the SCRiBL libraries; however, due to the costs
involved this library was not sequenced. The final W12 SCRiBL libraries were gen-
erated using Illumina sequencing adapters, required for the binding of DNA libraries
to a flow cell for next generation sequencing (NGS) on the Illumina HiSeq 2500 ma-
chine. Primer pairs consisted of one TruSeq Indexed adapter (reverse compliment)
and the TruSeq universal adapter (both Illumina); the resulting DNA fragments lig-
ated between the two sequencing adapters are termed ‘di-tags’. Consideration was
given to the TruSeq Indexed adapter used to generate each library to allow for the
multiplexing of three SCRiBL libraries per sequencing lane279. Libraries were se-
quenced to produce 100 bp paired-end reads. Paired-end sequencing enables both
ends of the DNA fragments to be sequenced — as the distance between each paired
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read is known, alignment algorithms can map the reads to a reference genome more
precisely280.
Resulting output FASTQ sequences were mapped to the human reference genome
(GRCh37/hg19) containing the HPV16 genome as an extra chromosome, and were
also filtered to remove experimental artefacts using HiCUP by Jack Monahan (EBI-
EMBL). Assessing the number of raw reads obtained for each library indicated that
each sequencing run had been successful given a theoretical maximum of 150–180
million read-pairs per lane as well as three libraries multiplexed per lane (Illumina
2013). Slight differences between the numbers of raw reads per SCRiBL library
may be as a result of variable binding efficiencies to the sequencing flow cell. Fol-
lowing read mapping, the percentage of valid and invalid pairs was identified and
the libraries filtered accordingly; even a small number of invalid di-tags could lead
to incorrect conclusions being drawn concerning genomic structure. Invalid reads
include sequences representing Hi-C artefacts and other uninformative di-tags and
are excluded from downstream analyses; invalid reads comprised mainly of artefacts
produced when a sequenced read pair maps to a single restriction fragment (‘same
circularised’, ‘same fragment dangling ends’, ‘same fragment internal’), di-tags of
the ‘wrong size’ identified by the mapped reads positioned too far away from the
putative restriction enzyme cut-site than allowed by the experimental size-selection
step, and ‘contiguous sequences’ generated by the re-ligation or incomplete digestion
of fragments (Figure 4.17)258.
HiCUP analyses of individual W12 SCRiBL libraries exposed variations in the
percentage of valid reads; the percentage of valid reads for the D2 SCRiBL II,
G2 SCRiBL I and G2 SCRiBL II libraries were much higher (28.3% mean) than
the remaining seven (6.0% mean). Interestingly, the separation of W12 D2 and G2
from F, A5 and H coincides with integrated viral copy number; an increased per-
centage of valid reads is seen in the W12 clones containing three or four copies of
the HPV16 genome whereas the percentage of valid reads remains stable among all
W12 clones tested with just one integrated copy of the viral genome. It is probable
that the increased numbers of di-tags containing HPV16 in W12 G2 and D2 SCRiBL
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Figure 4.17: Overview of experimental artefacts generated by the Hi-
C experimental protocol adapted from HiCUP: pipeline for mapping and
processing Hi-C data, Wingett S. et al., 2015258. Schematic shows the genome
digested into 5 restriction fragments. These fragments may subsequently ligate to
each other, or fragments derived from another chromosome, forming valid cis or trans
di-tags respectively (a). In contrast, re-ligation or incomplete digestion leads to the
generation of invalid contiguous sequences (b). Another common artefact occurs
when the sequenced read-pair maps to a single restriction fragment (c), (d) & (e).
Further, PCR may result in a fragment being copied multiple times (f). Di-tags are
also rejected when the mapped reads are positioned too far away from the putative
restriction enzyme cut-site than allowed by the experimental size-selection step (g).
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libraries map to more unique regions of the host genome which, as a percentage of
total reads, increase validity compared to the smaller number of HPV16 containing
di-tags generated in F, A5 and H. Additionally, the discrepancy of valid reads be-
tween biological replicates in W12 clone D2 highlights the necessity for at least two
replicates to produce robust data. Downstream analysis of the W12 SCRiBL Hi-C
libraries was conducted using data from valid read-pairs only; to ensure that libraries
could be directly compared, stringent normalisation of read numbers per library was
applied.
To address the second experiment of identifying the 5’ and 3’ virus-host junctions
in each of the W12 integration clones (with viral genome copy number less than four)
a HPV16 capture system, additional to that for the generation of SCRiBL Hi-C
libraries, was devised.
In order to identify the virus-host breakpoint, whole-genomic W12 DNA libraries
were captured with HPV16-specific biotinylated RNA baits that evenly covered the
whole virus genome; mapping the DNA sequence of viral-cellular junctions to the
human reference genome (GRCh37/hg19) containing the HPV16 genome as an extra
chromosome directly indicates the HPV integration site. Multiple studies have con-
ducted similar studies to determine the viral integration sites using tissue samples,
at different stages of carcinogenesis, for a range of HPV genotypes281, 282, 283, 101. In
each study, extracted DNA was prepared into a sequencing library and enriched for
the HPV genome via the hybridisation of HPV genome-specific probes; however, the
design and manufacture of HPV probes used was carried out by external companies
including MyGenostics Inc.281, 282, 283 or Roche NimbleGen Inc.101. In this investi-
gation the HPV probes were designed in-house; the generation of HPV16-specific
biotinylated RNA baits for use in our capture system was based upon isolating and
amplifying the W12E DNA genome from the pSP64 plasmid using primer pairs
evenly spaced across the HPV16 genome. The forward primer of each of the primer
pair was designed to incorporate the T7 promoter adapter sequence that enabled the
in vitro transcription of DNA to RNA. Gel electrophoresis analysis of the HPV16
RNA showed that, despite a pronounced band representing full length RNA (2 kb),
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numerous other RNA products were generated as represented by 300 bp–2 kb smear;
as such, the baits could only be used in qualitative experiments. The HPV16-specific
RNA was suitable for use in the capture-seq experiment but consideration should be
given as to whether they are appropriate for use in future, alternative experiments.
The methodology presented in this chapter lays the foundation for furthering our
understanding of HPV16 virus integration and associated selection of cells in the
field of papillomavirus biology. Viral genome integration represents a crucial step in
tumorigenesis27 and elucidation of integration events is an essential requirement for
understanding HPV-induced carcinogenesis. Coupled with SCRiBL Hi-C analyses,
further levels of virus and host genome regulation can be identified. Changes to gene
expression as a result of virus integration and long-range interactions may begin
to explain the mechanisms behind the growth advantage of particular cells present
across the cells of a polyclonal LSIL, and will be investigated in the next chapter.
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Chapter 5
Integrated HPV16 genomes
interact with host chromosomes
three-dimensionally (3D)
modulating nuclear architecture
and host gene expression.
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5.1 Introduction
The successful generation of both capture-seq and SCRiBL-Hi-C DNA libraries for
each of the W12 clones meant that the process of HPV16 integration and its effects
could be explored at both a genomic and epigenetic level.
As previously stated, HRHPV integration is seen in ∼85% of cervical SCCs and
is viewed as a key driver of squamous carcinogenesis2. Previous studies of clinical
samples and cell lines have used PCR-based approaches to map integration sites;
namely restriction site PCR (RS-PCR), rapid amplification of cDNA ends PCR
(RACE-PCR), including amplification of papillomavirus transcripts assay (APOT).
However, these virus-host breakpoint identification methods are limited by inher-
ent technical bias and, as such, the validity of results obtained by these techniques
is questionable. A number of different studies have now employed next genera-
tion RNA and/or DNA sequencing to more accurately determine the presence and
integration sites of virus genomes in HPV-associated malignancies across the hu-
man genome97, 98, 87, 176, 101, 100. Studies have demonstrated that HPV commonly
integrates into genomic ‘hotspots’, a number of which are associated with common
fragile sites (CFS)95, 284, 96 and, in addition, have shown that HPV can integrate di-
rectly into a gene — into both introns and exons — and can lead to varying changes
in host gene expression level87, 97, 98. Several mechanisms for host gene disruption
have been proposed, including: deletion or intragenic disruption of potential tu-
mour suppressor genes and upstream virus promoter insertion or amplification of
oncogenes97, amplification of the local region resulting in copy number variation
(CNV)176, or rearrangement and translocation of the integration locus elsewhere in
the host genome97, 100.
In addition, other studies have suggested that higher level transcriptional control
may be at play — there is a growing appreciation for how the three-dimensional
(3D) organisation of the genome contributes to the control of gene expression. HPV
integration into the flanking regions of genes, sometimes as far away as 500 kb,
has been found associated with large increases in gene transcription, specifically the
166
Integrated HPV16 genomes interact with host chromosomes in 3D
MYC proto-oncogene which is encoded for at the 8q24.21 locus. Haplotype resolved
RNA-seq data of the HeLa cell line showed that MYC is highly overexpressed from
the HPV18 integrated allele, which is also associated with higher levels of tran-
scriptionally active chromatin marks, transcription factors and RNAPII285. Analy-
sis of ‘chromatin interaction analysis with paired-end tag’ (ChIA-PET) sequencing
data demonstrated a long-range cis interaction between the integrated HPV18 pro-
moter/enhancer and the MYC gene285. Indeed, the HPV18-MYC 3D interaction has
been verified by chromosome conformation capture (Hi-C) analyses; in HeLa cells,
integration of HPV18 modifies normal chromatin loops present at, and around, the
8q24.21 locus such that virus and MYC sequences are in direct contact251. More-
over, CRISPR/Cas9 knockout of the integrated HPV18 fragment resulted in a 30%
decrease in MYC gene expression, providing experimental evidence supporting the
hypothesis that integrated HPV influences host gene expression via long distance
chromatin interactions286.
To date, next generation sequencing studies have primarily focused on the analy-
sis of advanced cervical SCCs that consist of clonal HPV integrant cells derived under
selective pressure. This study aimed to investigate naturally occurring HPV16 inte-
gration events that occur in premalignant cells isolated under non-competitive con-
ditions using the W12 clones; these data will elucidate whether characteristic virus
and host changes as a result of integration, such as long-range 3D interactions and
resultant host gene expression changes, are a typical feature of all HPV integrants
or whether they are restricted to cells with a selective growth advantage.
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5.2 Results
5.2.1 Integrated HPV16 genomes interact in 3D with host
chromosomes
Regions of the integrated HPV16 genome that interact in three dimensions with the
human genome were determined using GOTHiC software and visualised using the
Circos tool. Bioinformatic analysis including the mapping and aligning of sequence
reads was carried out in collaboration with Jack Monahan (EBI-EMBL). In each
panel (Figure 5.1 A-E), a single line within the circle represents a virus-host read
indicating a 3D interaction between the HPV16 genome and the host, and is coloured
according to the virus gene from which the read originates. The frequency of cis
interactions between the virus and the host is known to be greatest for host sequences
at the site of integration and to decrease with distance276. As such, analysis of the
SCRiBL Hi-C data simultaneously enabled the HPV16 integration locus in each of
the clones to be identified. For each clone a representative image of the biological
replicate libraries is shown.
In W12 clone G2 repII reads from across the virus genome were shown to interact
with the host, and came from all RNA baits designed around MboI restriction sites.
Although the distribution of the reads was fairly uniform, the greatest percentage
reads interacting with the host genome came from virus gene E7 (Figure 5.1 A left
panel). The integrated HPV16 genome interacts exclusively with chromosome 5;
when analysing the single chromosome view, there is a split between the bulk of
reads from the virus — indicating the integration site — and a subset of reads that
mapped to a separate region of the host. Given the large scale of the plot, this
indicates a long-range 3D interaction between the integrated virus in G2 and the
host (Figure 5.1 A right panel).
The number of virus-host reads that were captured and mapped for W12 clones
D2 (84.3%), F (11.2%), A5 (12.4%) and H (10.3%) were lower than for clone G2
arbitrarily set at 100%. As a result, there are reduced numbers of virus-host reads
in the circos plot analysis. In clone D2 the HPV16 genome also integrated into
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chromosome 5 of the host; the virus-host reads converge on a single point at the host
chromosome (Figure 5.1 B). The greatest percentage of virus-host reads in D2 come
from the restriction fragment that covers the 5’ half of the virus gene L1. For clone
H, the captured reads indicate that interactions between the virus and the host occur
from the early genes E6 and E7, E2 and L1, with the majority of reads coming from
the E2 portion of the virus genome (Figure 5.1 C left panel). Here, HPV16 integrates
into chromosome 4 and results in a large deletion of the host (∼170 kbp). The deletion
is illustrated by the separation of the virus-host reads in the chromosome-only Circos
view (Figure 5.1 C right panel). For each W12 clone there is consistently an absence
of reads originating from the virus genome between genes E1 and E2; this is a result
of the RNA bait design, which was based upon MboI restriction sites in the HPV
genome, rather than a true biological finding (see 5.3). Interestingly, we found that
W12 clones F and A5 had the same integration site, with virus-host reads converging
to the same region of chromosome 4 (Figure 5.1 D and E). Although virus-host reads
were identified across all possible regions of the virus genome, in both clones the
greatest percentage came from the 3’ section of E2. In all the W12 integrant clones
tested, the HPV16 genome was shown to interact with regions of host chromosomes
in cis ; there were no examples of the virus interacting in trans.
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Figure 5.1: Circos plots indicating 3D interactions between the integrated
HPV16 genome and host chromosomes across a panel of five W12 inte-
grant clones. Each line within each circle represents a virus-host read indicating
a 3D interaction between a region of the HPV16 genome and the host. Reads are
coloured to match the individual genes of the HPV16 genome: E6 = green, E7 =
orange, E1 = yellow, E2 = blue, E4 = red, E5 = pink, L1 = dark green, L2 =
light blue and the non-coding region = black. The left column contains circos plots
that comprise the HPV16 genome (orange) and the entire host genome, individual
chromosomes identified by different colours. The right column contains circos plots
that comprise the HPV16 genome (orange) and the single host chromosome where
3D interactions occur. The percentage of reads coming from different regions of the
virus is indicated by the histogram on the outside of the HPV16 genome, which is
split into 500 bp windows coloured red. The HPV16 RNA bait fragments using in
the capture-Hi-C experiment are indicated in blue on the outside of the circos plot.
In each Circos plot the absence of reads originating from HPV16 E1/E2 is due to
the RNA bait design, rather than a true biological finding. A) W12 G2 replicate II,
B) W12 D2 replicate I. Plots were generated using the Gothic program and are not
to scale.
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Figure 5.1: Continued. Circos plots indicating 3D interactions between
the integrated HPV16 genome and host chromosomes across a panel of
five W12 integrant clones. C) W12 H replicate I, D) W12 F replicate II and E)
W12 A5 replicate I. Plots were generated using the Gothic program and are not to
scale.
171
Integrated HPV16 genomes interact with host chromosomes in 3D
5.2.2 W12 integrant clone 5’ and 3’ virus-host breakpoints
identification at nucleotide resolution.
Analysis of the capture-seq experiment determined that for each clone, peaks of
virus-host reads mapped to two distinct sites of the host genome (data not shown;
these correlated with the results described in section 5.2.1). The identification of two
peaks, regardless of HPV16 genome copy number, demonstrated that there is only
one 5’ and one 3’ virus-host breakpoint in each of the W12 clones.
In order to validate the findings of the capture-seq experiment, primer pairs
consisting of one primer complementary to the virus genome and one to the host
genome flanking the virus-host breakpoint loci were designed in order to amplify the
virus-host chimaeric DNA for subsequent Sanger sequencing. For each W12 clone the
5’ and 3’ breakpoints were amplified and the size of the PCR products corresponded
to the original primer design (Figure 5.2 A-E left panel). Given successful PCR
amplification of the virus-host breakpoints, RT-qPCR primers were designed using
the same chimaeric DNA sequence used for PCR primer design. Each clone specific
5’ and 3’ breakpoint primer pair was tested on gDNA from the specific clone, and
gDNA from W12par1 (episomal) and the HPV-negative cell line NCx/6 as negative
controls to test the specificity of each breakpoint. For W12 clones G2, D2 and H,
both the 5’ and 3’ fusion transcripts were unique to the individual clones (Figure 5.2
A-C middle and right panels). Interestingly, however, while primer pairs specific to
breakpoints in W12 clones F and A5 confirmed the sequencing data, these primers
also produced a positive result, although relatively small amounts of product, in the
parental W12 cell line (Figure 5.2 D and E middle and right panels).
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Figure 5.2: Identification and specificity of the virus-host breakpoints across a
panel of five W12 integrant clones. Gels in the left column show the PCR amplification
products of W12 integrant clone-specific 5’ and 3’ virus-host breakpoints (lane 1 and 3,
respectively). PCR reactions were carried out at a range of temperatures (see below) for
50 cycles with a 1.5 mM concentration of MgCl2. (A) W12 clone G2; 5’ = 60 °C, 3’ =
52.1 °C, (B) W12 clone D2; 5’ = 55.4 °C, 3’ = 55.4 °C, (C) W12 clone H; 5’ = 56 °C, 3’
= 60 °C, (D) W12 clone F; 5’ = 59.3 °C, 3’ = 55.1 °C, (E) W12 clone A5; 5’ = 59.3 °C,
3’ = 55.1 °C. Control reactions included; negative controls which contained the PCR mix
without DNA (lane 2 and 4) and a positive control mix that contained E6-E7 primers (60
°C) (lane 5). The central and right columns indicate RT-qPCR analysis of the 5’ and 3’
virus-host breakpoints, respectively. Virus-host junctions in the specific integrant clones
were compared to the episomal (W12par1 p12) cell line and an HPV-negative cell line
(NCx/6).
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To pinpoint the exact break in both the virus and host genome at the site of
HPV16 integration in each of the W12 integrant clones, PCR amplified DNA was sent
for Sanger sequencing (Biochemistry, University of Cambridge). The resultant 5’ and
3’ breakpoint sequences for each clone were aligned using Nucleotide Blast against
both the W12E and the Hg19 human genome sequences to find the breakpoints in
the virus and the host at nucleotide resolution, respectively.
In W12 clone G2 the HPV16 genome is linearised by breaking the virus genome
in the E2 ORF [5’: 2,940 and 3’: 2,768] resulting in a loss of 173 bp and placing the
majority of the E2 gene (913 bp) upstream of the virus early promoter. Additionally,
the three copies of the HPV16 genome integrate into chromosome 5 — chromosome
band 5q11.2 — in an intergenic region of the host genome [5’: 52,681,626 and 3’:
52,655,805] (Figure 5.3 A).
The four HPV16 genomes in clone D2 are also integrated into chromosome 5, in
the region 5q34 [5’: 167,112,984 and 3’: 167,141,612]. Linearisation of the HPV16
genome occurs via breakage in the L2 [5’: 4,361] and E2 [3’: 3,272] ORFs, resulting
in a 1,089 bp deletion of the virus genome. Furthermore, the orientation of the virus
promoter opposes that of the transcription of the host gene TENM2 into which the
HPV16 genome has integrated (Figure 5.3 B).
In W12 clone H only a single copy of the HPV16 genome has integrated into
chromosome 4 — chromosome band 4q21.3 — within host gene MAPK10; moreover
transcription from the virus early promoter occurs in the same direction as transcrip-
tion of the host gene. Virus integration results in a large deletion of the host genome,
with the 5’ and 3’ host breakpoints separated by more than 170 kbp [5’: 86,983,196
and 3’: 87,153,458]. In addition, in comparison with the other W12 integrant clones
included in this study, a large proportion of the virus genome is also deleted; the
HPV16 genome is broken in the L1 [5’: 5,883] and E2 [3’: 3,751] ORFs, meaning
that the length of the integrated virus is 5,773 bp (Figure 5.3 C).
The Sanger sequencing data confirmed our initial finding that clone F and A5
have the same site of HPV16 integration. In both clones, a single copy of the virus
integrates into chromosome 4 — chromosome band 4q13.3 — within the host gene
RASSF6 [5’: 74,549,681 and 3’: 74,480,662]. Sanger sequencing also revealed an 18
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bp truncation and rearrangement of the HPV16 genome at the 3’ breakpoint whereby
a region of 54 bp (3,637 to 3,690) is inverted. The linearisation of the HPV16 genome
and resultant rearrangements occur within the E2 ORF [5’: 3,677 and 3’: 3,637] and
as a result places a portion of the E2 ORF upstream of the virus early promoter
(Figure 5.3 D).
Figure 5.3: Schematics showing host-virus junctions at the different integra-
tion sites. In all schematics, host chromosomal DNA is shown in blue and the orientation
indicated by the grey arrow above (5’ to 3’). Integrated HPV16 DNA is shown in orange,
with the viral oncogenes and LCR highlighted in red, and the direction of transcription
from the viral early promoter shown by an arrow from the URR. The location of the viral
breakpoint in base pairs is given above the junction, whereas the cellular DNA breakpoint
in base pairs is given below the junction. The genome copy number and length of the
integrated HPV16 genome is indicated in red above the schematic. When HPV16 has in-
tegrated into a host gene, the orientation is shown beneath the schematic. A) W12 clone
G2, B) W12 clone D2, C) W12 clone H and D) W12 clones F/A5. (Virus genome copy
number taken from Scarpini et al., 2014.)
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Identification of the exact virus-host breakpoints enabled the chimaeric sequence
to be aligned against the host (Hg19) and HPV16 (W12E) genome sequences across
this region. Regions of microhomology between the two sequences were highlighted;
often, nucleotides of both genomes directly adjacent to the breakpoint were homol-
ogous (Figure 5.4 A-D). In clone G2, at both the 5’ and 3’ breakpoints there was a
region of five homologous nucleotides, a feature that was also seen at the 5’ virus-host
breakpoint in clone D2 (Figure 5.4 A and B). In W12 clone H, a three-nucleotide
sequence was found at the 5’ and 3 breakpoints (Figure 5.4 C). In contrast, at
the 5’ breakpoint in F/A5 there were no adjacent homologous nucleotides; however
nucleotides at the 3’ breakpoint exhibited greater homology. A region of eight nu-
cleotides, separated into two groups of four by a single nucleotide was homologous
between the HPV16 and Hg19 DNA sequences (Figure 5.4 D). When the microho-
mology of 10 nt either side of the breakpoint was compared to that generated from
10,000 random shuﬄes of each sequence extended to 1,000 nt, the regions of micro-
homology that were significant included the G2 3’ breakpoint, H 5’ breakpoint and
F 5’ breakpoint.
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Figure 5.4: Regions of HPV16 and host sequence homology at the inte-
gration site. Figures show comparisons between the virus-host sequences obtained
by Sanger sequencing and the normal host and HPV16 genomic sequences, 25 nu-
cleotides either side of the breakpoint (indicated by a central dotted line). HPV16
DNA sequence = black, inverted HPV16 (HPV16i) DNA sequence = green, human
DNA sequence = blue, homologous nucleotides = red, underlined nucleotides = do
not match virus or host sequence, DNA fusion junctions denoted as ‘Jx’. Significant
levels of microhomology between host and HPV16 sequences were calculated by com-
paring the homology seen at the 10 nt directly either side of the breakpoint compared
to 1000 nt of extended sequence which was shuﬄed 10,000 times. *p <0.05.
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5.2.3 HPV16 integrates into regions of open and active host
chromatin.
For each clone the site of HPV16 integration was mapped onto the host (Hg19)
genome and aligned with ChIP-seq marks from the normal human epidermal ker-
atinocyte (NHEK; ENCODE datasets) cell line across a 5 Mb window from the in-
tegration locus (Figure 5.5 A-D). Marks of actively transcribed chromatin included
H3K27ac, H3K4me1, H3K4me2 and H3K4me3, whereas transcriptional repression
was denoted by the H2K27me3 mark. Areas of open chromatin were illustrated by
regions of DNaseI hypersensitivity and, additionally, binding sites of the boundary
element CTCF were also aligned across the integration locus.
The HPV16 genome in G2 integrates into an intergenic region that is abundant
in the activating histone modifications, particularly enhancer marks H3K27ac and
H3K4me1. Additionally concentrated DNaseI hypersensitivity marks indicate an
open chromatin structure at the site of HPV16 integration. Moreover, the lack
of repressive marks within this genomic region is striking (Figure 5.5 A). Similar
observations were made when evaluating the integration sites of clone D2 and F/A5
(Figure 5.5 B and D). Additionally, in clone D2, HPV16 integrates into the very large
host gene TENM2; the presence of a number of repressive marks downstream of the
integrated virus coincides with a large gene intron. In contrast to the aforementioned
W12 clones, in clone H the virus integrates into a region of the host genome absent
of either activating or repressive marks. However, the structure of the genome at this
site appears to be reasonably open, given alignment of the DNaseI hypersensitivity
sites (Figure 5.5 C). Interestingly, in all clones, the virus appears to integrate into
regions of the genome that contain or are close to CTCF sites.
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Figure 5.5: Analysis of host chromatin structure at the site of HPV16
integration. Each panel shows 5 Mb of the host genome across the integration loci,
with the virus integration site indicated by a black arrow (5’ and 3’ separated in
clone H due to deletion). Protein coding genes are shown in the first track and the
direction of each gene indicated by colour; red = 5’ to 3’, blue = 3’ to 5’. ChIP-
seq data from normal human epidermal keratinocyte (NHEK) cell line is aligned
with the host genome (taken from ENCODE). PTMs of active chromatin: H3K27ac,
H3K4me1, H3K4me2, H3K4me3 are coloured green; DNaseI hypersensitivity sites
are coloured blue; the repressive H3K27me3 mark is coloured red and CTCF sites
are coloured purple. A) W12 clone G2, B) W12 clone D2, C) W12 clone H, D) W12
clone F/A5.
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5.2.4 Short- and long-range 3D interactions occur between
the HPV16 and host genomes regardless of cell selec-
tion during early cervical carcinogenesis.
SCRiBL-Hi-C mapped sequence data were analysed and visualised using the Seq-
Monk program (Babraham Bioinformatics). Each peak in the viewer represents a
3D interaction between the integrated HPV16 genome and the host. The different
peak heights and colours refer to the normalised number of reads that correspond
to a particular interaction. The most populated reads in each of the data sets con-
sistently represented both the 5’ and 3’ virus-host breakpoints identified by capture
seq; close analysis of the HPV16 integration locus (100–200 kbp window) at high
normalised read depth revealed clearly defined peaks that matched the integration
breakpoints identified by Sanger sequencing (Figure 5.6 A (W12 G2), 5.8 A (W12
D2) and 5.9 A-C (W12 H, F, A5, respectively).
By increasing the size of the window across the integration locus (to 700 kb) and
decreasing the normalised read depth, additional distinct peaks of reads were visible
in clone G2 (Figure 5.6 B) and clone D2 (Figure 5.8 B). Multiple short-range (<500
kbp) 3D interactions occur between the integrated virus and the surrounding host
genome; at this scale interaction distances vary from 34–238 kbp. In figure 5.6 B
the short-range interaction loops in G2 were drawn from the HPV16 integration site
to regions of the host genome where peaks contained more than 44,000 normalised
reads. Of note, the interaction peaks in clone G2 appeared to align with CTCF sites,
with the majority additionally overlapping marks of enhancer regions (H3K27ac and
H3K4me1) and regions of DNaseI hypersensitivity (Figure 5.6 B). Expanding the
window further (5 Mb) illustrated a number of long-range (>500 kbp) 3D interactions
between the virus and the host. In figure 5.6 C the long-range interaction loops
were drawn to regions of the host genome where peaks contained more than 16,000
normalised reads. The furthest and most prominent peak was located at 53,520,000
within the first intron of host gene ARL15, approximately 900 kbp from the site of
HPV16 integration (Figure 5.6 C).
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Figure 5.6: Identification of short and long-range interactions between
integrated HPV16 and the host genome in W12 clone G2. A) SCRiBL-Hi-C
data 122.5 kbp across the HPV16 integration locus. The 5’ and 3’ breakpoints of the
virus are indicated by the tallest red bars and are labelled with black arrowheads.
B) SCRiBL-Hi-C data 700 kbp across the HPV16 integration locus. The black
line above the read peaks indicates the genomic window seen in panel A. Peaks
of reads indicate regions of the host interacting with the integrated virus in 3D.
Loops from the integration site to interacting regions of the host are shown beneath
the panel and have been drawn from the approxiate HPV16 integration site within
the amplified region to peaks containing more than 44,000 normalised reads. C)
SCRiBL-Hi-C data 5 Mbp across the HPV16 integration locus. The black line above
the read peaks indicates the genomic window of seen in panel B. Long-range 3D
interactions between the integrated virus and the host are indicated by peaks of reads
and highlighted by loops drawn beneath the panel and have been drawn from the
approximate HPV16 integration site within the amplified region to peaks containing
more than 16,000 normalised reads. In each panel the key indicates the normalised
read count. Additionally, protein-coding genes are shown in the first track of each
panel (genes coloured according to their orientation: red = 5’ to 3’, blue = 3’ to 5’),
followed by the alignment of ChIP-seq data from the NHEK cell line (ENCODE).
PTMs of active chromatin: H3K27ac, H3K4me1, H3K4me2, H3K4me3 are coloured
green; DNaseI hypersensitivity sites are coloured blue; the repressive H3K27me3
mark is coloured red and CTCF sites are coloured purple.
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To validate the finding of this long-range interaction to ARL15 in clone G2, 3D
fluorescent in situ hybridisation (FISH) was carried out. Three fluorescent DNA
probes were produced to hybridise to either the integrated HPV16 genome, ARL15,
or a control region of the genome that was the same linear distance in the opposite
direction from the integrated virus as the ARL15 probe (Figure 5.7 A). Only cells
containing one HPV16 signal and two copies of both the control and ARL15 probes
were analysed. A representative image is shown in Figure 5.7 B. Analysis of the
3D distances (x, y and z plane) indicated that in the integrated chromosome the
HPV16 probe and ARL15 interacting probes were significantly closer together than
the HPV16 probe and the control probe (Figure 5.7 C and D). Additionally, when
comparing the distances between the control probe and the ARL15 probe in both the
integrated and unintegrated chromosomes the two probes were significantly closer
together in the chromosome with HPV16 integrated (Figure 5.7 E and F). This
suggests that HPV16 integration affects host genome architecture, and that the long-
range interaction to gene ARL15 results in the two regions of DNA coming closer
together.
3D interactions between the integrated HPV16 genome and the host were also
identified in clone D2 (Figure 5.8 A and B). The majority of the interactions occurred
upstream of the integrated virus and are all within the large host gene TENM2,
over distances ranging from ∼49 to 527 kbp. The virus-host interaction loops in
D2 were drawn to regions of the host genome where peaks contained more than
6,000 normalised reads (Figure 5.8 B). Whilst the virus-host interactions closer to
the integrated virus align with marks of active and open chromatin, those further
from the virus appear to correlate less well with individual marks. Despite this, the
long-range interaction at 167,647,500 (the furthest from the integrated virus) does
align with a CTCF binding site.
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Figure 5.7: Validation of HPV16-host 3D chromatin interactions in W12
clone G2 by fluorescence in-situ hybridisation (FISH). A) Schematic detail-
ing the positions of the DNA probes used on the integrated and unintegrated alleles
of a portion of chromosome 5 in W12 clone G2. The ‘control probe’ hybridises to
a region of the host genome (51,676,020–51,873,551) and is coloured in purple, the
HPV16 probe is green, and the ‘interacting probe’ maps to the host gene ARL15
(53,473,886–53,584,235) is coloured in red. B) Representative image of the probes
hybridised to W12 G2 genome in a 3D FISH experiment. C and D) Analysis of
the 3D distance between both sets of FISH probes: HPV16:control (purple) and
HPV16:ARL15 (red) in the copy of chromosome 5 that contained the integrated
HPV16. Comparisons are shown in a box and whisker diagram (C) and a frequency
distribution graph (D). E and F) Analysis of the 3D distance between the ‘control’
and ‘interacting’ probes in both the integrated (green) and unintegrated (grey) al-
leles. Comparisons are shown in a box and whisker diagram (E) and a frequency
distribution graph (F). n=585; data presented as mean ± SEM; using unpaired,
two-tailed Students T-test: * p<0.05, **** p<0.0001.
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Figure 5.8: Identification of short and long-range interactions between
integrated HPV16 and the host genome in W12 clone D2. A) SCRiBL-Hi-
C data 122.5 kbp across the HPV16 integration locus. The 5’ and 3’ breakpoints of
the virus are indicated by the tallest red bars and are labelled with black arrowheads.
B) SCRiBL-Hi-C data 1.4 Mbp across the HPV16 integration locus. The black line
above the read peaks indicates the genomic window seen in panel A. Peaks of reads
indicate regions of the host interacting with the integrated virus in 3D. Loops from
the integration site to interacting regions of the host are shown beneath the panel and
have been drawn from the approximated HPV16 integration site within the amplified
region to peaks containing more than 6,000 normalised reads. For both panels the
scale bar indicates the normalised read count. Additionally, protein-coding genes are
shown in the first track (genes coloured according to their orientation: red = 5’ to
3’, blue = 3’ to 5’), followed by the alignment of ChIP-seq data from the NHEK
cell line (ENCODE). PTMs of active chromatin: H3K27ac, H3K4me1, H3K4me2,
H3K4me3 are coloured green; DNaseI hypersensitivity sites are coloured blue; the
repressive H3K27me3 mark is coloured red and CTCF sites are coloured purple.
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Figure 5.9: Virus-host breakpoints identified in clones H, F and A5 by
SCRiBL Hi-C. A) W12 H SCRiBL-Hi-C data 200 kbp across the HPV16 integration
locus. B) W12 F SCRiBL-Hi-C data 200 kbp across the HPV16 integration locus.
C) W12 A5 SCRiBL-Hi-C data 515 kbp across the HPV16 integration locus. In
each panel the 5’ and 3’ virus-host breakpoints are indicated by the tallest red bars
and are labelled with black arrowheads, while the scale bar indicates the normalised
read count. Additionally, protein-coding genes are shown in the first track (genes
coloured according to their orientation: red = 5’ to 3’, blue = 3’ to 5’), followed by
the alignment of ChIP-seq data from the NHEK cell line (ENCODE). PTMs of active
chromatin: H3K27ac, H3K4me1, H3K4me2, H3K4me3 are coloured green; DNaseI
hypersensitivity sites are coloured blue; the repressive H3K27me3 mark is coloured
red and CTCF sites are coloured purple.
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5.2.5 HPV16 integration can disrupt local host genome ar-
chitecture and affects the expression of host genes ad-
jacent to the integration site.
The Hi-C libraries (generated as part of the SCRiBL protocol – prior to the HPV16
sequence capture element) of clone G2 and D2 were sequenced and mapped against
the human Hg19 genome in order to evaluate the nuclear architecture of the host and
to determine whether any changes to host chromosome interactions are caused as a
result of HPV16 integration. The integration site of clones G2 and D2 are distinct
and, as such, they act as a control for one another.
A 5 Mb map of Hi-C data from clone G2 across the HPV16 integration locus
reveals clearly defined regions of interacting host DNA up to ∼1 Mb (approximately
the size of a topologically associating domain (TAD)) (Figure 5.10 A). Analysis of D2
Hi-C data across the same genomic locus reveals a predominantly similar structure
of host architecture (Figure 5.10 B and C). Moreover, upon aligning the publically
available TAD boundary information for IMR90 and hESC cell lines (Dixon et al.,
2012252), it is clear that all 3D interactions between integrated HPV16 and the host
in clone G2 occur within a TAD (Figure 5.11).
The nuclear architecture of clones G2 and D2 was additionally evaluated 2.5
Mb either side of the D2 HPV16 integration site (Figure 5.10 D-F). As with G2,
both clones exhibit similar host architecture across the region and the majority of
clearly defined 3D interactions between the virus and the host occurred within a
TAD boundary (Figure 5.12).
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Figure 5.10: Changes in host genome architecture and gene expression
as a result of HPV16 integration in W12 clones G2 and D2. A) W12 G2
Hi-C map, 5 Mb across the G2 integration locus (Chr5: 50,000,000–55,000,000).
The HPV16 integration site is annotated with a black arrowhead. B) W12 D2 Hi-
C map, 5 Mb across the G2 integration locus (Chr5: 50,000,000–55,000,000). C)
Chart plotting the insulation scores of W12 G2 (blue line) and W12 D2 (red line),
5 Mb across the G2 integration locus (Chr5: 50,000,000–55,000,000). D) W12 G2
Hi-C map, 5 Mb across the D2 integration locus (Chr5: 164,600,000–169,600,000).
E) W12 D2 Hi-C map, 5 Mb across the D2 integration locus (Chr5: 164,600,000–
169,600,000). The HPV16 integration site is annotated with a black arrowhead. F)
Chart plotting the insulation scores of W12 G2 (blue line) and W12 D2 (red line), 5
Mb across the G2 integration locus (Chr5: 164,600,000–169,600,000).
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Figure 5.11: Changes in host genome architecture and gene expression
as a result of HPV16 integration in W12 clone G2. A) Comparative Hi-C
map of G2 vs. D2 control. Blue dots represent host-host interaction sites that occur
less frequently in G2, while red dots represent interactions that are stronger in G2
compared with D2. B) W12 G2 SCRiBL Hi-C data showing 3D interactions between
the integrated virus and the host, CTCF sites (purple) are aligned in the top track.
The scale bar indicates the normalised read count and a black arrowhead indicates the
HPV16 integration site. C) Aligned protein coding track (genes coloured according
to their orientation: red = 5’ to 3’, blue = 3’ to 5’) above an alignment of TAD
boundaries from the publically available IMR90 (human lung fibroblast) cell line
(Dixon et al. 2012). D) Chart indicating the relative expression of W12 G2 protein-
coding genes 2.5 Mb either side of the HPV16 integration site. The chart indicates
the log fold-change of host gene expression in the clone of interest compared with a 6-
clone integrant average. Significant changes in host gene expression are indicated by
genes coloured green, non-significant expression changes are coloured grey (p<0.05,
negative binomial Wald test).
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Changes to host gene expression were evaluated by using available duplicate RNA-
seq data for seven W12 integrant clones: A5, B, D2, F, G2, H and R2. Bioinformatic
analysis of RNA-seq data was conducted in collaboration with Anton Enright (EBI-
EMBL). The expression of the protein coding host genes 2.5 Mb either side of the
HPV16 integration site were compared with the control 6-clone average to determine
whether host gene expression changed as a result of integration. In each of the W12
clones analysed (G2, D2, H, F and A5) significant changes to protein coding host
gene expression — both over and under expressed — were seen across the entire 5
Mb region (Figure 5.11 D (W12 G2), 5.12 D (W12 D2), 5.13 D (W12 H), 5.14 D
(W12 F) and 5.15 D (W12 A5)). Most notably, where HPV16 had integrated within
a host gene, the expression of that gene was consistently upregulated; the change
for TENM2 expression in clone D2 was 4.79-fold greater than the 6-clone average,
MAPK10 expression was increased by 4.47-fold and RASSF6 increased by 1.62- and
1.64-fold in clone A5 and F, respectively. In addition, the HPV16-host 3D interaction
to the first intron of ARL15 in clone G2 led to increased expression of the gene with
a 0.30-fold increase compared with the 6-clone average (p<0.05) (Figure 5.11 D).
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Figure 5.12: Changes in host genome architecture and gene expression
as a result of HPV16 integration in W12 clone D2. A) Comparative Hi-C
map of D2 vs. G2 control. Blue dots represent host-host interaction sites that occur
less frequently in D2, while red dots represent interactions that are stronger in D2
compared with G2. B) W12 D2 SCRiBL Hi-C data showing 3D interactions between
the integrated virus and the host, CTCF sites (purple) are aligned in the top track.
The scale bar indicates the normalised read count and a black arrowhead indicates the
HPV16 integration site. C) Aligned protein coding track (genes coloured according
to their orientation: red = 5’ to 3’, blue = 3’ to 5’) above an alignment of TAD
boundaries from the publically available IMR90 (human lung fibroblast) cell line
(Dixon et al. 2012). D) Chart indicating the relative expression of W12 D2 protein-
coding genes 2.5 Mb either side of the HPV16 integration site. The chart indicates
the log fold-change of host gene expression in the clone of interest compared with a 6-
clone integrant average. Significant changes in host gene expression are indicated by
genes coloured green, non-significant expression changes are coloured grey (p<0.05,
negative binomial Wald test).
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Figure 5.13: Host gene expression changes across the 5 Mb HPV16 integration
loci in clones H. A) SCRiBL-Hi-C data track with aligned protein-coding genes shown
beneath; genes coloured according to their orientation: red = 5’ to 3’, blue = 3’ to 5’.
TAD boundaries from the publically available IMR90 (human lung fibroblast) cell line
(Dixon et al. 2012) are aligned beneath. B) Chart indicating the relative expression of
W12 H protein-coding genes 2.5 Mb either side of the HPV16 integration site. The chart
indicates the log fold-change of host gene expression in the clone of interest compared
with a 6-clone integrant average. Significant changes in host gene expression are indicated
by genes coloured green, non-significant expression changes are coloured grey (p<0.05,
negative binomial Wald test). For each panel the scale bar indicates the normalised read
count.
Figure 5.14: Host gene expression changes across the 5 Mb HPV16 integration
loci in clones F. A) SCRiBL-Hi-C data track with aligned protein-coding genes shown
beneath; genes coloured according to their orientation: red = 5’ to 3’, blue = 3’ to 5’.
TAD boundaries from the publically available IMR90 (human lung fibroblast) cell line
(Dixon et al. 2012) are aligned beneath. B) Chart indicating the relative expression of
W12 F protein-coding genes 2.5 Mb either side of the HPV16 integration site. The chart
indicates the log fold-change of host gene expression in the clone of interest compared
with a 6-clone integrant average. Significant changes in host gene expression are indicated
by genes coloured green, non-significant expression changes are coloured grey (p<0.05,
negative binomial Wald test). For each panel the scale bar indicates the normalised read
count.
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Figure 5.15: Host gene expression changes across the 5 Mb HPV16 inte-
gration loci in clones A5. A) SCRiBL-Hi-C data track with aligned protein-coding
genes shown beneath; genes coloured according to their orientation: red = 5’ to 3’,
blue = 3’ to 5’. TAD boundaries from the publically available IMR90 (human lung
fibroblast) cell line (Dixon et al. 2012) are aligned beneath. B) Chart indicating the
relative expression of W12 A5 protein-coding genes 2.5 Mb either side of the HPV16
integration site. The chart indicates the log fold-change of host gene expression in
the clone of interest compared with a 6-clone integrant average. Significant changes
in host gene expression are indicated by genes coloured green, non-significant ex-
pression changes are coloured grey (p<0.05, negative binomial Wald test). For each
panel the scale bar indicates the normalised read count.
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To further investigate the effect of HPV16 integration on host gene expression,
the variance in gene expression in the genomic regions adjacent to the HPV16 in-
tegration site was compared with that of the whole chromosome. Analysis of the
gene expression variance was carried out in collaboration with Anton Enright (EBI-
EMBL) and was performed using the RNA-seq datasets from W12 clones G2, D2, H,
F, A5, B and R2. Host genes — including both protein-coding and non-coding genes
— either side of the HPV16 integration site were grouped into bins, each containing
five genes. The range and variance of gene expression of each bin was plotted against
the mean level of gene expression across the whole chromosome indicating that across
the W12 clones expression of genes in this regions was highly variable (Figure 5.16
A, C, E, G and I). In each of the clones analysed (G2, D2, H, F and A5), the variance
in gene expression of multiple bins within genomic regions adjacent to the HPV16
integration site were highly significant (p<0.05 and p<0.001), indicating that inte-
gration of HPV16 has a direct influence on host gene expression at and around the
integration site (Figure 5.16 B, D, F, H and J). Notably, significant changes to the
variance in host gene expression were felt within bins directly at the site of virus
integration (W12 A5: Fig. 5.16 J) or within bins very close to this region (≤6 bins).
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Figure 5.16: Variance in host gene expression across the host genomic
region containing the HPV16 integration site in W12 clones G2, D2.Each
left panel indicates the range and variance of host gene expression in W12 integrant
clones [A) W12 G2, C) W12 D2, E) W12 H, G) W12 F, I) W12 A5], focussing on
100 genes either side of the HPV16 integration site. For each clone, gene expression
levels were compared with those in six other clones, based on the full dataset from
clones G2, D2, H, F, A5, B and R2. In each panel, the HPV16 integration site
is centred on bin 0. Each bin contains five genes, with no overlap between bins.
The box and whisker plots illustrate the range of gene expression levels within each
bin, with the bar indicating median values, the box the IQR and the whiskers the
range. The mean gene expression across the whole chromosome is indicated by the
solid blue line, while the mean level of gene expression across individual bins is
shown by the dotted blue line. The mean variance of gene expression across the
whole chromosome is indicated by the solid red line, while the mean level of gene
expression across individual bins is shown by a dotted red line. Each right hand
panel shows the significance of the variance in gene expression within each bin. Each
point represents a five-gene bin, corresponding to those in the left-hand panels. The
horizontal lines indicate the significance of the variance in each bin, compared with
the variance in gene expression across the whole chromosome (above the dashed red
line, p<0.05; above the dashed pink line, p<0.01).
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Figure 5.16: Continued. Variance in host gene expression across the host
genomic region containing the HPV16 integration site. E and F) W12 H, G
and H) W12 F and I and J) W12 A5.
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5.2.6 HPV16 integration results in virus-host fusion tran-
scripts
Evaluation of RNA-seq data aligned to the human Hg19 reference genome for clone
G2 revealed the presence of a number of virus-host fusion transcripts that originated
from the virus early promoter. The fusion transcripts were generated by splicing
from either the 225 or 879 splice donor sites in the HPV16 genome into either the
52,664,903 or 52,665,662 cryptic splice acceptor sites in the host; this occurs as a
result of the loss of splice acceptor sites in the virus due to genome truncation during
the integration process. In addition, transcription across the virus-host breakpoint
junction itself was identified. All virus-host transcripts are summarised in Figure
5.17 A and C. To test the abundance of each fusion transcript in clone G2, RT-
qPCR primer pairs were designed according to the Hg19 coordinates produced by
RNA-seq. In clone G2 the 225-52,665,662 fusion transcript was most abundant; the
levels of the breakpoint and 879-52,664,903 fusion transcripts were similar; and the
relative abundance of the 879-52,664,903 transcript was extremely low (Figure 5.17
B). To determine the specificity of the fusion-transcripts, the same primer pairs were
tested in clone A5 — a W12 integrant with a different site of HPV16 integration —
and the episomal W12par1 cell line; in both control cell lines G2 fusion transcripts
were not identified. As a positive control, the level of E6/E7 (E6all) mRNA, which
includes all transcripts produced from the virus early promoter, was tested in each
of W12 cell lines.
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Figure 5.17: Differential splicing of virus-host fusion transcripts in W12
clone G2. A) Table summarising the the fusion transcripts between HPV16 and the
host in clone G2 identified by RNA-sequencing. B) The abundance of each virus-host
splice transcript analysed by RT-qPCR in clone G2, clone A5 and W12parI (episo-
mal). Four mRNA transcripts were identified: RNA-seq breakpoint read (yellow);
one read from the virus splice donor site at 225 bp to host acceptor site at 52,665,662
(green); and two reads from the virus splice donor site at 879 bp to host acceptor
sites at 52,664,903 (pink) and 52,665,662 (orange). The abundance of each transcript
was compared to a positive ’E6all’ control (blue), which captures all viral transcripts
from the early promoter. C) Schematic of the virus-host fusion transcripts illustrat-
ing the virus splice donor sites (red triangles) and host acceptor sites (inverted blue
triangles) in integrated W12 clone G2. The virus genome and host DNA are repre-
sented by red and blue lines, respectively and the virus-host breakpoints indicated
with a black line. Spliced transcripts are coloured to match the RT-qPCR analysis
in B. Diagram to scale.
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5.3 Discussion
Using a panel of W12 integrant clones, the results presented in this chapter illustrate
that the HPV16 genome integrates into distinct regions of the host resulting in minor
changes to host gene expression. Moreover, 3D interactions between the integrated
HPV16 genome and the host genome have been identified. These data indicate
consequences of HPV16 integration that are a typical feature of all HPV integrants
and are not restricted to cells with a selective growth advantage.
In the first part of this chapter, the identification of the 5’ and 3’ virus-host
breakpoints of five W12 clones (F, A5, D2, H and G2) were described at nucleotide
resolution. It is important to note that the HPV16 integration sites in four out of five
clones identified in this study differ from those that have been previously published
in Dall et al., 2008104; the discrepancies are summarised in Table 5.1.
Table 5.1: W12 integrant clone integration sites.
The techniques used to elucidate the virus-host breakpoints in 2008, namely Re-
striction Site PCR (RS-PCR) and Amplification of Papillomavirus Oncogene Tran-
scripts (APOT), were the most appropriate to use at the time; however, they are
less sensitive and less accurate than next generation sequencing employed in this in-
vestigation. Additionally, and in contrast to previous findings, the results from this
study revealed that the HPV16 integration site in W12 clones F and A5 are identi-
cal. Although both clones were isolated from the same mixed population of episomal
W12 cells (W12Ser2 p12) (Figure 1.6 C), it is likely that clone A5 is a precursor
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of clone F. Differences between the two clones are identified following continuous
culture; after just twelve passes, clone F acquires additional genomic imbalances and
has increased levels of HPV16 oncogene E6 and E7 expression when compared with
clone A5 (unpublished data Cinzia Scarpini/Mark Pett). Despite having the same
integration site, F and A5 have been treated as distinct clones in the host gene ex-
pression analysis of this investigation due to their phenotypic differences, including
the rate of cell growth183 and distinct patterns of host gene expression detected by
subsequent RNA-seq analysis. Furthermore, the F/A5 5’ and 3’ virus-host junctions
were found to be present in the W12 parental (episomal) cell line (Figure 5.2 D and
E middle and right panels); this suggests that that across a mixed population, a
small percentage of W12parI cells already harboured integrants.
Analysis of the HPV16 integration sites in the W12 clones showed that in the
majority of cases the virus integrates within the coding region of a host gene; RASSF6
(Ras association domain family member 6; W12 F/A5), MAPK10 (mitogen-activated
protein kinase 10; W12 H) and TENM2 (Teneurin transmembrane protein 2; W12
D2). Previous studies evaluating the HPV integration sites of cervical cancer samples
have also indicated the region directly upstream of RASSF6287 and MAPK10101
as sites of integration. This is consistent with data that illustrates that HPV16
integration sites are located in host genes significantly more often than is expected;
additionally in cases where the virus has integrated into an intergenic region of the
host, the virus-host breakpoints are significantly closer to genes than predicted by
chance284 — the target region must be a transcriptionally competent area of host
chromatin that can support viral oncogene expression. Preferential integration into
gene-rich areas of the host genome is complemented by evidence that demonstrates
in cervical SCC HPV16 preferentially integrates into regions of open and active
chromatin, determined by the associated of integration sites with regions of DNaseI
hypersensitivity and H3K4me3 methylation, respectively288, 289. The alignments of
hallmark PTMs from the NHEK cell line across a window 2.5 Mb either side of
the integration site of each W12 clone (Figure 5.5) correlates with these previous
findings, indicating that this occurs regardless of subsequent cell selection. ChIP-
seq data from NHEKs was determined the most appropriate publically available
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comparator for the W12 clones as epidermal keratinocytes, being a target of HPV
infection, were the only non-infected keratinocyte cell line available from ENCODE.
Evaluation of the integrated HPV16 genome revealed that the E2 ORF is most
commonly disrupted as a result of linearisation of the virus episome. Although in-
tegration does not always lead to a large deletion of the HPV16 genome — deletion
ranged from 36 bp (clone F/A5) to 2,131 bp (clone H) — disruption of the E2 ORF is
sufficient for the protein regulator of the virus early promoter not to be transcribed;
indeed, in clones G2, F and A5 a portion of the E2 ORF is placed upstream of the
virus early promoter. The integration events seen in the W12 clones are representa-
tive of the earliest model of HPV integration that promotes oncogenesis by disrupting
the E2 gene, alleviating E2 transcriptional repression of the HPV promoter and thus
driving oncogene expression; however, as will be discussed, these integration events
may also promote oncogenesis in a number of different ways including the formation
of hybrid (viral-host) transcripts that are more stable than viral E6/E7 transcripts as
well as the disruption of cellular genes and their flanking sequences, directly altering
their expression and the expression of genes adjacent to the integration site290.
Data from the capture-seq experiment and subsequent breakpoint verification
(Figure 5.2) revealed that, regardless of virus genome copy number, only one 5’ and
3’ virus-host breakpoint exists in each clone. The observation of fewer breakpoints
than the viral copy number has previously been reported and led the authors to
hypothesise that the discrepancy is due to the amplification of viral integrants and
flanking genomic sequences leading to redundant, identical breakpoints176. By eval-
uating the positions of the 5’ and 3’ breakpoints relative to the host genome it was
deduced that there are two distinct mechanisms in which HPV16 integrates into the
host genome in the W12 clones. Clone H is an example of direct integration of a
single virus genome that results in a deletion of the human genome. In this model,
the virus episome is linearised by two double strand breaks and inserts directly in the
host (Figure 5.18 A). In W12 clones F and A5, a single copy of the virus integrates
into the host genome via a looping mechanism. Looping results in the duplication
of a portion of the host genome adjacent to the integrated virus, and the 5’ and
3’ virus-host junctions appear reversed when aligned to the human genome (Figure
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5.18 B). Finally, clones G2 and D2 are examples of when multiple copies (n) of the
HPV16 genome integrate via a looping mechanism in to the host, which results in
amplification (n+1) of the adjacent region of the host (Figure 5.18 C). A summary
of the virus and host genomes in each of the W12 clones is shown in Figure 5.19.
Figure 5.18: Mechanisms of HPV16 integration in the W12 integrant clones. A)
Schematic illustrating the direct integration of the HPV16 genome (red) into the host (blue).
Chequered regions indicate DNA that is deleted and/or broken during the integration process.
B) Schematic illustrating a looping mechanism of integration of the HPV16 genome (red) into the
host (blue). Chequered regions indicate DNA that is deleted in the integration process. HPV
integration results in duplication of the host region labelled ‘B’, which flanks in the integrated
virus on both 5’ and 3’ virus-host junctions. C) HPV16 integration via the looping mechanism can
result in both the amplification of the virus genome and local regions of the host DNA. Schematic
illustrates the fusion virus-host DNA linear organisation after insertion of three copies of the HPV16
genome. In all panels, different regions of the host have been labelled alphabetically and coloured
in different shades of blue.
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Figure 5.19: Summary of HPV16 integration in the W12 integrant clones.
A) One copy of the HPV16 genome directly integrates into clone H resulting in a
large deletion of host DNA. B) A single copy of HPV16 integrates via the looping
mechanism in clone F/A5, which causes a duplication of the host region ‘B’. C) Four
copies of the HPV16 genome are integrated in clone D2 resulting in the amplification
of host region ‘B’. D) Three copies of the HPV16 genome are integrated in clone G2
resulting in the amplification of host region ‘B’. In all panels, the HPV16 genome is
coloured red and different regions of the host have been labelled alphabetically and
coloured in different shades of blue. A red arrow denotes the virus early promoter;
host gene promoters are illustrated with a black arrow.
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Analysis of the nucleotide sequences of both the virus and the host at each break-
point in the W12 clones adds to the existing body of evidence that suggests HPV inte-
gration likely occurs through microhomology-mediated repair mechanisms291, 282, 87.
Interestingly, although a number of breakpoints have at least five out of ten homolo-
gous nucleotides at the breakpoint (G2: 5’, D2: 5’ and F: 3’) they were not called as
significant despite other breakpoints with the same (G2: 3’) or fewer (H: 5’ and F: 5’)
homologous nucleotides having a p-value <0.05 (Figure 5.4). This is a result of the
analysis that compares the microhomology of the ten nucleotides directly adjacent to
the breakpoint to that of the immediate flanking region (1,000 nt) rather than to ran-
domly selected parts of the genome; this analysis includes corrections for local biases
of AT rich regions, a consideration that has not been made in current publications
that comment on microhomology at the HPV-host integration breakpoints.
The second part of this chapter focussed on identifying 3D interactions between
the integrated virus and host genomes. A technical factor that affects the appearance
of individual Circos plots and further analysis of the SCRiBL-Hi-C data is the number
of sequencing reads that have at least one end that maps to the HPV16 genome. The
number of captured reads varied dramatically between W12 clones, which is reflective
of the integrated viral genome copy, and also between replicates of the same clone
indicating the importance of performing biological replicates. Combining replicate
datasets resulted in removing library complexity; as such, the biological replicate of
each clone with the greatest number of virus-host reads have been analysed in this
thesis. Quality control checks throughout library preparation, and comparing the
SCRiBL-Hi-C data for both replicates, indicate that the results obtained are very
similar; however, the replicate with greater read depth enables more information and
robust conclusions to be drawn. Moreover, for W12 clones G2 and D2 where both the
Hi-C and SCRiBL-Hi-C datasets were obtained, the enrichment of HPV-containing
reads was vast and ranged from 170-fold (W12 D2 rep II) to 320-fold (W12 G2 repI)
(data not shown).
In W12 clones containing more than one copy of the virus genome, both short-
(defined as <500 kbp) and long-range (>500 kbp) interactions between the integrated
virus and regions of the host were identified. The significance of distal enhancer-
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promoter contacts via chromatin looping has been demonstrated by the generation
of artificially forced loops, which were found sufficient to activate gene expression
highly292. The 3D interactions between HPV16 and the host genome were commonly
associated with CTCF binding sites in the host. CTCF is a zinc-finger protein that
binds to an insulator region in genomic DNA and plays a fundamental role in tran-
scriptional regulation and controlling higher order chromatin structure; furthermore,
CTCF proteins dimerise when bound to different DNA sequences, mediating long-
range chromatin looping293. It has previously been shown that CTCF is recruited
to the CTCF binding sites of the HPV18 genome294. HPV integration may there-
fore result in the insertion of an ectopic CTCF-binding site into the human genome,
which is able to form interacting loops with pre-existing host CTCF binding sites in
a similar manner to that observed as a result of HTLV-1 integration295. In W12 clone
G2 all virus-host interactions occurred within a single chromatin interaction domain
(TAD) with CTCF binding sites marking the TAD boundaries (IMR90, Dixon et
al., 2012252) (Figure 5.11); these data are in agreement similar observations made at
the colorectal cancer risk loci 8q24.21256. It is likely that CTCF binds to the host
genome at these sites and acts as an insulator preventing more distant virus-host
interactions. Additionally, in W12 clone H HPV16 integrates into the host genome
just outside a TAD boundary (Figure 5.13). In this instance integration resulted in
a substantial deletion of the host genome. It is possible that the positioning of the
TAD and associated boundary elements prevented an even greater deletion.
Integration in clone G2 results in the formation of a new ‘viro-loop’ — HPV16
genome to ARL15 intron 1. The interacting loop between the integrated HPV16
genome in clone G2 and the host genome within the first intron on gene ARL15
was shown to be a ‘relevant interaction’, which is defined as an interaction that co-
localises at a significantly higher frequency that random control probes at a similar
distance256; verification of this virus-host interaction by fluorescent in situ hybridi-
sation (FISH) demonstrated that the HPV16-host long-range interaction brings the
two genomic regions into closer physical proximity.
Analysis of RNA-seq data indicates that HPV16 integration results in disruption
of host gene expression at least 2.5 Mb either side of the integration site; both in-
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creases and decreases to host gene expression as a result of HPV integration have
previously been reported but are limited to <1.8 Mb across the integration win-
dow87. Interestingly, although the vast majority of 3D interactions were restricted
to within a TAD, changes to gene expression, as a result of HPV16 integration, were
observed beyond TAD boundaries. This may be a result of dramatic increases in vi-
ral oncogene E6 and E7 expression, which, as previously mentioned, has far-reaching
consequences and affects many cellular processes including the modulation of host
gene expression296; E6/E7-mediated changes to a plethora of host transcription fac-
tors is also a likely reason for changes to host gene expression across a broad genomic
locus. More recently, it has been shown that gene activation can occur via genetic
alterations that disrupt insulated neighbourhoods (TADs) as a consequence of aber-
rant activation by enhancers that are normally located outside of the TAD297, 298.
Therefore, it is possible that changes to the genomic sequence as a result of HPV16
integration, including deletion and focal amplification, could disrupt pre-existing
TAD boundaries causing changes to host gene expression.
In cases where HPV16 integrated within the coding region of a host gene, the
expression of that gene was consistently upregulated when compared with a 6-clone
average; this indicates that the introduction of an additional virus promoter, and
its associated regulatory/enhancer region (LCR), results in a greater level of tran-
scription. Amplified gene expression may be caused by increased transcription factor-
mediated RNAPII recruitment to the extra target sequence i.e. the p97 promoter163.
It has previously been shown that HPV-host fusion transcripts containing sequences
of known cellular genes that have both the viral and cellular sequences in sense ori-
entation — as they are in W12 clone H — the viral sequence was spliced to a cellular
exon sequence299; therefore, it is hypothesised that further analysis of the RNA-seq
data at the exon level may indicate increased expression of specific exons downstream
of the virus promoter illustrating that the virus promoter is able to contribute to
host gene expression.
Data presented in this chapter also demonstrate how virus-host 3D interactions
can affect host gene expression; the interaction between integrated HPV16 and
ARL15 in clone G2 resulted in a significant increase in ARL15 expression (Figure
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5.11 D). As previously discussed, this interaction is likely driven by virus and host
CTCF dimerisation leading to changes in the nuclear architecture of the host in this
region; it is hypothesised that in this situation the formation of a virus-host inter-
acting region and the introduction of the virus promoter is sufficient to increase the
transcription efficiency of host gene ARL15 as a result of increasing the local concen-
tration of gene promoters298. These data indicate that influence of HPV integration
can be exerted over greater distances by forming larger virus-host interactions than
previously described285.
Directly correlating HPV16 integration in a particular W12 clone with changes
to host gene expression by comparing the expression of host genes at and around
the integration site compared with random regions of the genome is an inadequate
method of comparison due to natural fluctuations in gene expression due to copy
number variations (CNVs) as well as chromatin structure affecting TF accessibility
etc. In addition, analysis of the RNA-seq data illustrated that when comparing the
W12 clones (A5, B, D2, G2, F, H, R) changes to gene expression occurred across
the whole genome. To address this issue we analysed the variance of gene expression
across the W12 clones and compared this to the chromosome in which the virus
had integrated. This analysis indicated that although significant changes were found
across the whole region (100 genes either side of the integration site), they were
predominantly found at, or close to, the site of HPV integration. These findings are
in keeping with the observation made by Ojesina et al. that gene expression levels at
sites of HPV integration were significantly higher in tumours with HPV integration
compared with the expression levels of the same genes across other tumours without
integration at that site97. Interestingly, however, HPV16 integration into the host
genome in W12 clone A5 resulted in the down regulation of the majority of host
genes near the integration site (Figure 5.15). A gene of interest in this region is IL-8,
a chemotactic factor for neutrophils and T-lymphocytes. IL-8 has been shown to
be downregulated as a result of HPV16 E6 and E7 onocoprotein expression300. The
downregulation of IL-8 expression may contribute to the ability of infected cells to
avoid the host immune response67.
Additionally, the variance in gene expression correlated with the gene expression
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data indicating that in clone G2 the bin containing ARL15 (bin 3) — the protein-
coding gene to which integrated HPV interacts with in 3D — was significant when
compared to the other six W12 clones (Figure 5.16 B). Additionally, the analysis of
the 3D interactions between the virus and the host illustrated that virus-host loops
and resultant changes to host architecture occurred within a TAD (W12 D2 Figure
5.8 & 5.12, W12 G2 Figure 5.6 & 5.11); however, changes to host gene expression and
indeed the variance in gene expression extend beyond these architectural boundaries
perhaps as a consequence of broader epigenetic changes.
Finally, analysis of the RNA-seq data highlighted the presence of virus-host tran-
scripts in G2 (Figure 5.18). Whilst it is known that splicing occurs from splice donor
sites in the virus into slice acceptor sites in the host, these genomic positions oc-
cur within the amplified virus-host region previously described. As such, it is not
possible to determine which of the integrated virus genomes and/or from how many
genomes splicing occurs. Furthermore, virus-host fusion transcripts have also been
detected originating from the splice donor site 880 within the virus E1 ORF299; this
site is present in the integrated HPV genome in clone G2 and therefore represents
an additional site of potential virus-host fusion transcript generation.
Overall, results presented in this chapter provide evidence that modifications
to the host genome as a result of HPV integration that are present in advanced
SCCs also occur in pre-malignant integrant cells derived in the absence of selective
pressure and are therefore characteristic of all HPV integration events. Further work
is needed to establish whether long-range virus-host interactions contribute to the
growth advantage and selection of particular cells across the mixed population of a
polyclonal SIL.
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Cervical malignancy is the fourth most common cause of cancer-related deaths
in women worldwide1. Despite recent advances in the prevention methods for cervi-
cal cancer, including implementation of population-wide cervical cytology screening
tests and introduction of HPV vaccination, approximately 300,000 women still die
as a result of cervical cancer every year1. As a result, there remains considerable
interest in developing novel targeted therapeutics based on improved understanding
of the biology of advanced cervical cancers. It is known that infection with HPV is a
necessary cause of cervical cancer15. In addition, integration of HRHPV types into
the host genome and subsequent deregulated expression of HPV oncogenes E6 and
E7 disrupts cell cycle control resulting in genetic instability and cell transformation.
As such, integration is known to be the major risk factor associated with disease
progression27. However, relatively little is known about how particular cells contain-
ing integrated HPV gain a growth advantage and are selected over other cells with
HPV integrated elsewhere in the genome. This thesis sought to determine epigenetic
mechanisms by which the transcription of integrated HPV16 oncogenes as well as
host genes are deregulated during the early stages of carcinogenesis and to eluci-
date differences between cells that have high levels of oncogene expression compared
with those that express the virus genome at low levels; it is important to understand
these processes as they may indicate new targets for silencing transcriptionally active
HRHPV integrants.
The work described and discussed in Chapter 3 demonstrated that the level of
HPV16 oncogene expression per integrated virus template and the selection of in-
dividual cells during cervical carcinogenesis is determined through multiple layers
of epigenetic regulation of the integrated HRHPV genome. Using a panel of five
W12 clones with significantly different E6/E7 expression per template and HPV16
genome copy number less than four, it was shown that cells with higher levels of
virus expression per template were associated with increased levels of host post-
translational modification (PTM) hallmarks of transcriptionally active chromatin
and reduced levels of repressive marks. Additionally, it was shown that there was
a greater abundance of the active/elongating form of the RNA polymerase-II en-
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zyme (RNAPII-Ser2P) together with the components of the positive transcription
elongation factor-b (P-TEFb), CDK9 and cyclin T1, responsible for Ser2 phosphory-
lation. Epigenetic regulation of the genome is highly complex; multiple mechanisms
intertwine and impact on one another, which facilitates a robust and multifaceted
transcriptional response. For example, in addition to relaxing chromatin structure
permitting the binding of transcription factors (TFs) at gene promoters, histone
acetylation — namely H3K27ac — plays an additional role in the regulation of
RNAPII activation301. The combinatorial regulation of gene expression by PTMs
and RNAPII function is reflected in the W12 clone system, as cells with high lev-
els of HPV16 E6/E7 expression show significantly greater association of H3K27ac
and RNAPII-Ser2P with the long control region (LCR), promoter (p97) and viral
oncogenes of the integrated virus genome.
Epigenetic regulation of gene expression is a dynamic and reversible process; as
such, there is a growing emphasis on using epigenetic therapies to reprogram neoplas-
tic cells toward a normal state302. Epigenetic therapies currently in the clinic and at
clinical trial have been designed to inhibit enzymes responsible for the writing and/or
removal of specific marks that determine chromatin structure, namely DNA methyl-
transferases (DNMTs) and histone deacetylases (HDACs)302. My data demonstrate
that enzymes responsible for the acetylation of histone tails (HATs: p300 and TIP60)
as well as the transition of RNAPII from poised to actively elongating (CDK9) were
functionally significant in the in vitro W12 cell system. Cells with higher HPV16
expression per template showed greater sensitivity to depletion and/or inhibition
of HATs and CDK9, as well as reduced sensitivity to histone deacetylase inhibition;
these data indicate that depending on acetylation levels and the cellular environment,
the levels of transcription of the integrated HPV16 genome may be modulated. In-
deed, the development of CDK9 inhibitors is currently an active area of investigation;
a number of small molecule inhibitors of CDK9 have demonstrated potent anticancer
activity against a number of different cell lines including cancer cells derived from
the cervix164.
Work presented in this thesis focussed on the impact of PTMs and associated
writer enzymes and the role of RNAPII on the levels of transcription from the virus
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promoter; however, further work carried out on the W12 clones (F, A5, D2, H and
G2) revealed that other epigenetic mechanisms also contribute to the levels of inte-
grated HPV16 expression. To further assess the level of chromatin accessibility, the
positions of nucleosomes across the HPV16 long control region (LCR) and oncogenes
E6 and E7 were assessed; nucleosome occupancy and positioning is dynamic and has
a critical impact on gene expression and regulation303. Across the W12 clones the
positions of nucleosomes were similar; however, clones with high expression per tem-
plate showed greater amount of exogenously applied CpG methylation at the early
promoter (p97) and directly after the transcription start site. This indicated a lower
average occupancy of the nucleosomes in cells with high expression per template and
therefore greater chromatin accessibility in this region203.
Future work should include determining whether the epigenetic features of in-
tegrated HPV16 are acquired from the host genome at the site of integration or,
conversely, whether chromatin is modified at the host sites as a result of HPV16 inte-
gration. Recent investigations into the virus and host epigenetic landscape following
HPV16 integration in head and neck cancers (HNSCC) provides evidence suggesting
that the epigenetic status of the virus is determined by the local chromatin environ-
ment of the host; levels of DNA methylation associated with the HPV16 genome were
significantly altered as a result of integration and were reflective of the methylation
status of the flanking host genome304.
In addition to analysing epigenetic modifications made to the integrated virus
chromatin that control the level of transcription from the virus promoter, work in
this thesis aimed to evaluate the organisation of chromatin in three dimensions at
the HPV integration locus to further elucidate mechanisms of virus and host gene
regulation. The work presented in Chapter 4 describes how chromatin conformation
capture techniques — SCRiBL Hi-C — can be adapted to generate a novel method to
elucidate three-dimensional (3D) interactions between the integrated HPV16 genome
and the host. Additionally, a capture sequencing experiment was designed and per-
formed concurrently in order to accurately map the virus-host breakpoints in the
W12 clones analysed.
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Following next generation sequencing of W12 clone SCRiBL Hi-C and capture-seq
DNA libraries, multiple analyses were conducted; these included virus-host break-
point identification and characterisation of DNA sequence at HPV16 integration
sites, the presence of virus-host interactions, nuclear architecture of the host and the
effect of HPV16 integration on host gene expression — these data are presented and
discussed in Chapter 5. Evaluation of the HPV16 integration sites in the W12 clones
showed that the virus frequently integrates within the coding region of a host gene,
consistent with data that indicates HPV16 integration sites in SCCs occur within
host genes significantly more frequently than is expected284. Although HPV integra-
tion sites in SCCs have been found distributed widely across the human genome282,
studies have found that HPV commonly integrates into genomic ‘hotspots’ a number
of which are at, or in close proximity to, common fragile sites (CFSs); a finding that
has been replicated with oropharyngeal SCC tumour samples305. Additionally, data
presented in this thesis are consistent with evidence from SCCs that demonstrates
HPV16 preferentially integrated into regions of open and active chromatin288, 289
and in regions that exhibit microhomology between the virus and host DNA se-
quences291, 282, 87, 283. Combined, these factors suggest that HPV genome integration
is non-random96, 88. It has been hypothesised that binding of the episomal HPV
genome to active gene promoters may be one method in which the virus ensures
the viral genome is retained in transcriptionally active regions of the nucleus306. In
particular, it has been shown that the episomal HPV genome is tethered to host
chromatin at regions associated with known fragile sites307; tethering to these re-
gions, via interaction with the host BRD4 protein, greatly increases the chances of
integration at that site and is also a mechanism for which non-random areas of the
genome are targeted for retrotransposon and retrovirus integration308.
Analysis of the HPV integration sites across the five W12 clones showed that
HPV16 integrates into the host genome via two distinct mechanisms. The first, and
most frequent integration mechanism, resulted in looping of the virus genome and
amplification of a portion of the host genome adjacent to the integrated virus. In-
tegration via looping meant that in cells with virus copy number greater than one,
only one 5’ and 3’ virus-host breakpoint exist. Both the looping mechanism of in-
212
Concluding discussion and future work
tegration and the presence of redundant, identical breakpoints have previously been
observed in advanced HPV-positive cancer cell lines and provide evidence that HPV
directly promotes genomic instability176. Here my work demonstrates that a similar
method of integration occurs in all cells regardless of whether they are selected during
carcinogenesis. The second type of integration mechanism saw the HPV16 genome
integrated directly into a host gene, MAPK10, resulting in a large deletion of host
DNA; additionally, in clone H the virus and host sequences are both in the same
orientation raising the possibility of coding virus-host fusion transcripts. These find-
ings warrant further investigation; western blot analysis using a polyclonal antibody
for MAPK10 would detect if, as a result of truncation, mRNAs of different lengths
are successfully transcribed into proteins of different molecular weight. Additionally,
protein expression analysis of host genes into which HPV16 has integrated could be
used to determine whether the abundance of protein is reflective of the transcript
levels determined by RNA-seq. Furthermore, in-depth analysis of the RNA-seq data
at the gene exon level will provide a greater insight into the direct effect of HPV
integration on the expression of host genes into which the virus has integrated.
Next generation sequencing (NGS) is far superior to earlier techniques employed
to identify sites of HPV integration. In this investigation the virus-host breakpoints
in the W12 clones differed to those previously identified104; in particular, it was
found that clones F and A5 have identical sites of integration. In light of this, it is
important to view recent meta-analyses of HPV integration sites with uncertainty,
as it is likely that a reasonable number of integration sites included in the analysis
are incorrect having been previously identified using inadequate technologies284, 289.
In the future it would be prudent to perform a similar capture sequencing reaction
using similar methodology employed in this thesis to accurately identify virus-host
breakpoints across a large number of W12 integrant clones to fully understand and
exploit the unique model system.
Initial investigations into the potential role of host gene expression on cell se-
lection included analysis of RNA-seq data for each of the W12 clones. Analysis in
this thesis sought to determine the effect of HPV16 integration on gene expression
locally, therefore resultant changes to host gene expression 2.5 Mb either side of the
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integration site were determined. These data indicated that HPV16 integration re-
sults in significant disruption of host gene expression across the entire 5 Mb window.
In addition, in cases where HPV16 integrated within the coding region of a gene,
the expression of that gene was significantly upregulated. These data are consistent
with studies that have demonstrated host gene expression in SCCs is modulated as
a result of HPV16 integration87, 296, 96.
To determine whether the disruption of host genes contribute to early cell selec-
tion events, in vitro gene function experiments should be carried out comparing W12
clones with similar levels of HPV16 E6/E7 oncoproteins but significantly different
cell growth rates183. Employing the recently emerged CRISPR-Cas9 (clustered, reg-
ularly interspaced, short palindromic repeats (CRISPR)-CRISPR-associated protein
9) genome editing technologies would enable efficient and precise genetic manipula-
tion of genomes. Specifically, a CRISPR-Cas9 system could be designed and used to
knock out amplified or over expressed host genes at the site of HPV16 integration
or genes which interact with the virus in 3D, identified by SCRiBL Hi-C. Based
on data from this thesis, upregulated host gene ARL15 (ADP Ribosylation Factor
Like GTPase 15), which contacts the integrated virus in 3D in clone G2, repre-
sents a good candidate to perform functional experiments. Phenotypic effects of
host gene modulation should be quantified and could include proliferation rates, cell
cycle assays (both via FACS), clonogenicity, migration and invasion. Alternatively
the CRISPR/Cas9 system could be altered by redesigning the guide RNA (gRNA)
to target the HPV16 genome; gene expression analysis following resultant knock-
out of the HPV16 DNA fragment would determine whether removal of the virus
promoter/enhancer from the genomic region affects host gene expression. Recently,
similar methodology was used to demonstrate that removal of the HPV18 genome
reduced MYC gene expression by approximately 30%309.
Future study of the effect of HPV and host gene expression on cell selection could
also involve epigenome editing using nuclease-null or ‘dead’ Cas9 (dCas9) CRIPSR-
Cas9 technologies. dCas9 is generated by introducing point mutations in the nuclease
domains of Cas9 and its use permits targeting specific DNA loci without cleavage310.
dCas9 can subsequently be fused to an epigenetic effector; previous studies have
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shown that dCas9 tethered to a HAT results in transcriptional activation311 whilst
gene silencing has been caused as a result of dCas9 fused to the Krupel-associated
box (KRAB) repressor312. To induce gene specific silencing, promoter sites could be
artificially supressed by direct targeting of dCas9 fused to the catalytic domain of a
DNA methyltransferase (e.g. DNMT3A)313, 314. Again, both the HPV16 genome —
specifically the viral promoter — as well as the promoters of interacting host genes
identified by SCRiBL Hi-C, i.e. ARL15, could be targeted using this technology.
Following the discovery of a long-range interaction (508 kb) between integrated
HPV18 and the MYC gene locus and associated increases in MYC gene expression
in the advanced carcinoma HeLa cell line285, this thesis sought to determine whether
such long-range genomic interactions are common in SCC cells and, additionally,
whether virus-host interactions exist prior to cell selection in premalignant lesions.
Analysis of the SCRiBL Hi-C libraries revealed that W12 clones that contain more
than one copy of the virus genome formed both cis short- and long-range HPV16-host
interactions; the significant virus-host long-range (∼1Mb) interaction with ARL15 in
clone G2 was particularly informative, indicating not only that virus-host interac-
tions are a feature of HPV integration, but also that 3D interactions from the virus
can significantly modulate host gene expression. This long-range interaction may be
mediated by CTCF dimerisation and results in changes to the nuclear architecture of
the host in this region. The association between genome topology and transcriptional
activity has been widely reported, with the disruption of topologically-associating
domains (TADs) linked to ectopic and/or aberrant enhancer expression causing dis-
ease315. It would be interesting to determine whether knockout of either of the
CTCF binding sites facilitating the virus-host interaction — either the ectopic puta-
tive site within HPV16 genome or the individual CTCF site within ARL15 — using
CRISPR/Cas9 technology would result in decreased expression of ARL15 and/or
whether the virus genome forms different long-range interactions within the TAD,
as has been demonstrated315.
In the future, the same SCRiBL Hi-C analysis should be performed in the out-
growth clone W12Ser2p31, in which the HPV genome integrates into the 8q24.21
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genomic locus. It would be particularly interesting to see whether, as in HeLa cells,
integrated HPV16 forms a long-range interaction to the proto-oncogene MYC ; eval-
uating the 3D interactions of the outgrowth clone may indicate whether this plays a
role in the selection of individual integrant clone following long-term culture.
In depth analysis of the 3D structure of the nucleus and how chromatin organi-
sation affects gene regulation is a rapidly developing area of research, particularly in
elucidating structural changes and disruption that result in disease. Despite the re-
cent developments of 3C technologies in the last fifteen years — 3C236, 4C242, 5C244,
Hi-C252, 246, 251 and ChIA-PET316 — alternative methods are already being gener-
ated to improve existing methods used to evaluate nuclear architecture. 3C-based
approaches have technical limitations; methods are reliant on restriction enzyme di-
gest and subsequent ligation to capture interactions between DNA segments, as such,
biases in GC content, protein occupancy and restriction site density occur. One such
method redesigned the Capture-C protocol using DNA rather than RNA biotinylated
oligonucleotides; this has led to increased sensitivity, identifying both weak cis and
trans interactions, and superior efficiency — multiple independent 3C libraries from
different samples can be processed in a single reaction, minimizing experimental vari-
ation and allowing for precise comparison of chromosome conformations in different
cell types317. Even more recently, a different approach to deciphering nuclear ar-
chitecture is genome architecture mapping (GAM); GAM is the first genome-wide
method for capturing 3D proximities between any number of genomic loci without
ligation and measures 3D distances by combining ultrathin cryosectioning with laser
microdissection and DNA sequencing318. Moreover, to fully appreciate the dynamics
of nuclear organisation, it will be important to combine population-based models
with data on individual cells at high resolution; this will require a multidisciplinary
approach bringing together genomics, biophysics and imaging. The 4D Nucleome
Program (NIH) is one initiative that seeks to combine expertise in the aforemen-
tioned fields to understand: the principles underlying nuclear organization in space
and time; the role nuclear organization plays in gene expression and cellular function;
and how changes in nuclear organization affect normal development and differenti-
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ation as well as various diseases. In the future it would be beneficial to review and
possibly implement some of the emerging technologies being used to evaluate the
nuclear architecture of cells containing integrated HPV16 at even greater resolution.
The findings presented in this doctoral thesis further our understanding of the
impact of HPV integration during early cervical carcinogenesis. To date, the ma-
jority of studies have focussed on the biological properties of advanced SCCs —
the endpoint of the clonal selection process — and have not addressed the dynamic
changes that underpin progression from pre-malignancies to carcinomas. Results pre-
sented here illustrate that many of the virus and host alterations seen in advanced
SCCs brought about as a consequence of HPV integration are characteristic of all
integration events and are present in cells regardless of whether they are ultimately
selected during carcinogenesis. This thesis forms the foundation for future work that
may elucidate potential therapeutic targets for epigenetic therapies in cervical SCCs
containing integrated HRHPV.
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Key: 
NNNNNN: Nucleotide base change  
NNNNNN: Nucleotide deletion in ~1/7 copies of viral genome  
NNNNNN: Nucleotide deletion 
NNNNNN: Unread sequence 	
W12 E ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
Par 1 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
Par 2 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC 
W12 F ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 A5 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 D2 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 H ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 J3 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 R2 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 Q ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 H2 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 G2 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 S2 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 3 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
W12 E3 ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC	
SiHa ACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACACCCACC		
W12 E ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
Par 1 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
Par 2 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 F ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 A5 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 D2 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 H ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 J3 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 R2 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 Q ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 H2 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 G2 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 S2 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 3 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
W12 E3 ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT	
SiHa ACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTAT		
W12 E GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
Par 1 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
Par 2 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 F GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 A5 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 D2 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 H GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 J3 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 R2 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 Q GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 H2 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 G2 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 S2 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 3 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
W12 E3 GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT	
SiHa GTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATAT		
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W12 E TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
Par 1 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
Par 2 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 F TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 A5 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 D2 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 H TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 J3 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 R2 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 Q TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 H2 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 G2 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 S2 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 3 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
W12 E3 TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG	
SiHa TAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATG		
W12 E CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
Par 1 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
Par 2 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 F CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 A5 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 D2 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 H CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 J3 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 R2 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 Q CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 H2 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 G2 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 S2 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 3 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
W12 E3 CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG	
SiHa CTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG		
W12 E TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
Par 1 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
Par 2 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT 
W12 F TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 A5 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 D2 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 H TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 J3 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 R2 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 Q TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 H2 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 G2 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 S2 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 3 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
W12 E3 TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT	
SiHa TGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATAT							
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W12 E ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
Par 1 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
Par 2 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT 
W12 F ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 A5 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 D2 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 H ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 J3 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 R2 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 Q ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 H2 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 G2 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 S2 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 3 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
W12 E3 ACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT	
SiHa ACTATATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTT		
W12 E TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
Par 1 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
Par 2 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC 
W12 F TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 A5 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 D2 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 H TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 J3 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 R2 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 Q TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 H2 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 G2 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 S2 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 3 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
W12 E3 TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC	
SiHa TTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTAC		
W12 E GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
Par 1 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
Par 2 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA 
W12 F GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 A5 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 D2 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 H GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 J3 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 R2 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 Q GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 H2 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 G2 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 S2 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 3 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
W12 E3 GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA	
SiHa GTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCA								
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W12 E TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
Par 1 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
Par 2 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT 
W12 F TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 A5 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 D2 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 H TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 J3 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 R2 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 Q TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 H2 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 G2 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 S2 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 3 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
W12 E3 TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT	
SiHa TTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCAT		
W12 E ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
Par 1 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
Par 2 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT 
W12 F ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 A5 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 D2 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 H ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 J3 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 R2 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 Q ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 H2 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 G2 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 S2 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 3 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
W12 E3 ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT	
SiHa ATAAAATAAATCACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCT		
W12 E TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
Par 1 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
Par 2 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT 
W12 F TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 A5 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 D2 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 H TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 J3 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 R2 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 Q TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 H2 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 G2 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 S2 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 3 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
W12 E3 TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT	
SiHa TGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAAT								
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W12 E GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
Par 1 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
Par 2 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC 
W12 F GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 A5 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 D2 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 H GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 J3 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 R2 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 Q GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 H2 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 G2 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 S2 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 3 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
W12 E3 GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC	
SiHa GTCACCCTAGTTCATACATGAACTGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAAC		
W12 E TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
Par 1 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
Par 2 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT 
W12 F TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 A5 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 D2 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 H TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 J3 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 R2 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 Q TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 H2 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 G2 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 S2 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 3 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
W12 E3 TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT	
SiHa TGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAAT		
W12 E ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
Par 1 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
Par 2 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA 
W12 F ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 A5 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 D2 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 H ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 J3 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 R2 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 Q ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 H2 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 G2 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 S2 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 3 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
W12 E3 ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA	
SiHa ACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAA								
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W12 E CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
Par 1 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
Par 2 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC 
W12 F CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 A5 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 D2 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 H CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 J3 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 R2 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 Q CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 H2 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 G2 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 S2 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 3 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
W12 E3 CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC	
SiHa CCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCC		
W12 E ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
Par 1 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
Par 2 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT 
W12 F ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 A5 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 D2 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 H ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 J3 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 R2 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 Q ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 H2 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 G2 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 S2 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 3 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
W12 E3 ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT	
SiHa ACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGAT		
W12 E ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
Par 1 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
Par 2 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT 
W12 F ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 A5 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 D2 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 H ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 J3 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 R2 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 Q ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 H2 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 G2 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 S2 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 3 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
W12 E3 ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	
SiHa ATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT 	
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ORIGINAL ARTICLE
HPV16 oncogene expression levels during early cervical
carcinogenesis are determined by the balance of epigenetic
chromatin modiﬁcations at the integrated virus genome
IJ Groves, ELA Knight, QY Ang, CG Scarpini and N Coleman
In cervical squamous cell carcinomas, high-risk human papillomavirus (HRHPV) DNA is usually integrated into host chromosomes.
Multiple integration events are thought to be present within the cells of a polyclonal premalignant lesion and the features that
underpin clonal selection of one particular integrant remain poorly understood. We previously used the W12 model system to
generate a panel of cervical keratinocyte clones, derived from cells of a low-grade premalignant lesion naturally infected with the
major HRHPV type, HPV16. The cells were isolated regardless of their selective advantage and differed only by the site of HPV16
integration into the host genome. We used this resource to test the hypothesis that levels of HPV16 E6/E7 oncogene expression in
premalignant cells are regulated epigenetically. We performed a comprehensive analysis of the epigenetic landscape of the
integrated HPV16 DNA in selected clones, in which levels of virus oncogene expression per DNA template varied ~ 6.6-fold. Across
the cells examined, higher levels of virus expression per template were associated with more open chromatin at the HPV16 long
control region, together with greater loading of chromatin remodelling enzymes and lower nucleosome occupancy. There were
higher levels of histone post-translational modiﬁcation hallmarks of transcriptionally active chromatin and lower levels of repressive
hallmarks. There was greater abundance of the active/elongating form of the RNA polymerase-II enzyme (RNAPII-Ser2P), together
with CDK9, the component of positive transcription elongation factor b complex responsible for Ser2 phosphorylation. The changes
observed were functionally signiﬁcant, as cells with higher HPV16 expression per template showed greater sensitivity to depletion
and/or inhibition of histone acetyltransferases and CDK9 and less sensitivity to histone deacetylase inhibition. We conclude that
virus gene expression per template following HPV16 integration is determined through multiple layers of epigenetic regulation,
which are likely to contribute to selection of individual cells during cervical carcinogenesis.
Oncogene advance online publication, 15 February 2016; doi:10.1038/onc.2016.8
INTRODUCTION
Infection with high-risk human papillomavirus (HRHPV) is respon-
sible for over 600 000 new cancers per annum, including over
500 000 carcinomas of the cervix.1 The majority of cervical
malignancies are squamous cell carcinomas (SCCs), which arise
from a mixed population of HRHPV-infected cells by clonal
selection of cells with the greatest competitive growth
advantage.2,3 In ~ 85% of cervical SCCs the selected cells contain
HRHPV DNA that is integrated into host chromosomes. In the
remaining ~ 15% of cases the virus genome remains in the extra-
chromosomal (episomal) state, as is also seen in the normal virus
lifecycle.4–6
In the squamous epithelial lesions that result from productive
HRHPV infections, there are ~ 100 virus episome copies in each
basal layer cell.7,8 In the lower cell layers, the necessary expression
of the HRHPV early genes E6 and E7 occurs through transcriptional
initiation at the virus early promoter (p97 in the case of the major
HRHPV, HPV16), while cell maturation is associated with activation
of the virus late promoter (p670 for HPV16) and expression of late
virus genes. These events are linked to changes in transcription
factor binding and altered chromatin structure, based on histone
post-translational modiﬁcations (PTMs) at nucleosomes associated
with the HRHPV genome.3,9–13
Integration of HRHPV genomes is thought to occur in
premalignant squamous intraepithelial lesions (SILs). The prob-
ability of integration increases with time14 and multiple integra-
tion events are thought to be present across the cells of a
polyclonal SIL. However, relatively little is known about how
particular cells containing integrated HPV gain a growth
advantage over other cells with HPV integrated elsewhere in the
genome. Notably, the signiﬁcance of virus transcriptional dereg-
ulation in individual integrants during these early events in
cervical carcinogenesis is poorly understood. Most studies to date
have concerned the end point of the clonal selection process, by
focusing on the virus integrants seen in the SCC cells themselves,
and have not addressed the dynamic changes that underpin
progression from SILs to carcinomas. It is difﬁcult to study such
processes by cross-sectional analysis of clinical samples, as the key
events that precede clonal selection early in cervical carcinogen-
esis occur in the basal epithelial cells of low-grade SILs (LSILs),4,15
which would need to be isolated by tissue micro-dissection.
A more informative approach has been to study experimental
in vitro models, including W12.
The W12 system was developed from a polyclonal culture of
cervical squamous cells (keratinocytes) naturally infected with
HPV16, which were derived by explant culture of a cervical LSIL.7
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At early passages, these ‘parental’ W12 cells are phenotypically
and genetically stable. They allow maintenance of HPV16
episomes at ~ 100 copies per cell and recapitulate an LSIL in
three-dimensional organotypic culture. Following long-term cul-
ture of W12, however, the cells lose these properties and closely
mirror the virus and host events associated with cervical
carcinogenesis in vivo, with phenotypic progression of the
reformed epithelia to high-grade SIL and then SCC.4 These events
may be associated with deregulation of episome numbers and
transcriptional control (e.g. W12 series 4 and W12E cells).2,6 More
typically, however, there is a change in the virus physical state
from episomal to integrated, due to loss of trans-repressive
episomes and emergence of a clonal population containing the
HPV16 integration event that confers the greatest growth
advantage.16 In different W12 series, different integration sites
are seen in the selected cells.16
We previously used limiting dilution cloning of polyclonal
parental W12 cells at early passage, to sample the range of
integration events that exists prior to episome clearance and
integrant emergence.14 The cells were selected under non-
competitive conditions, allowing isolation of clones regardless of
whether they had a selective advantage in mixed cell populations.
By this method, we derived a series of clones from an identical
genetic background that differed only by the site of HPV16
integration into the host genome. The large majority of clones
showed no evidence of full-length HPV16 concatemerisation17
and were therefore so called type I integrants.2 Several clones
contained multiple copies of the E6/E7 oncogenes, consistent with
local DNA rearrangements following integration. At the early
passages examined (i.e. prior to clonal evolution events), all clones
recapitulated a premalignant SIL phenotype in organotypic tissue
culture, with no evidence of invasiveness.17
The W12 clones therefore represent a unique system to
examine the host and virus factors that determine selection of a
particular HPV16 integrant from the range that exists in a typical
polyclonal population of premalignant cervical keratinocytes.
Across 17 representative clones analysed, levels of HPV16 E6
and E7 transcripts per cell varied by ~ 6-fold and correlated
closely. Only seven of the clones analysed (41%) showed
signiﬁcantly greater expression of HPV16 E6 and E7 than the
episome-containing LSIL-like cells from which they were derived,
indicating that HPV integration per se does not necessarily lead to
increased levels of virus oncogenes per cell.17 Interestingly, levels
of E6/E7 transcript per DNA template across the clones varied by
~ 16-fold.17
In the present study, we used the W12 clones to investigate
how different HPV16 integration events in basal-type premalig-
nant cervical keratinocytes lead to different levels of virus
oncogene expression. In order to provide a tractable system for
our experiments, we chose cells without full-length HPV16
concatemerisation and with four or less copies of integrated virus
DNA per cell. Of the ﬁve such clones available, two (F and A5)
showed high levels of E6/E7 expression per template, two (D2 and
H) showed medium levels and one (G2) showed low levels, with
~ 6.6-fold variation in expression levels across the ﬁve clones
(Table 1). In our previous preliminary analysis of a restricted
sequence of the HPV16 genome in the ﬁve clones,17 we found
that levels of HPV16 expression per template were associated with
different distributions of a selected small number of histone
PTMs.17,18 We therefore hypothesised that variation in levels of
expression per DNA template following HPV16 integration were
due to epigenetic differences in the virus chromatin. We used the
W12 clones to undertake a detailed and extensive analysis of the
epigenetic landscape on the integrated HPV16 genome, focussing
on the relationships between virus oncogene expression per
template and chromatin accessibility, histone PTMs and activity of
RNA polymerase-II (RNAPII).
RESULTS
HPV16 oncogene expression per template associates with
accessibility of virus chromatin
No mutations were seen in any of the ﬁve W12 clones following
PCR ampliﬁcation and sequencing of the HPV16 long control
region (LCR) (data not shown). By formaldehyde-assisted isolation
of regulatory elements, enrichment of open chromatin (i.e. with
lower nucleosome occupancy) at the HPV16 LCR and early
promoter was greatest in cells with high levels of virus gene
expression per template (F and A5) and showed progressive
reductions through cells with medium expression per template
(D2 and H) to cells with low expression per template (G2)
(Figure 1a). The positions of nucleosomes, as indicated by
nucleosome occupancy and methylome sequencing, were similar
across all clones and usually spaced 150–200 bp apart. These
positions were indicated by low levels of exogenously applied
GpC methylation. However, clones with high expression per
template showed greater amounts of exogenously applied GpC
methylation at the early promoter and directly after the
transcription start site (Figure 1b), indicating lower average
occupancy of the nucleosomes and therefore greater chromatin
accessibility in this region. Cells with higher virus expression levels
per template also showed a greater abundance of the ATP-
dependent chromatin remodelling enzymes BRG1 and INI1 across
the virus genome (Figures 1c and d), in keeping with greater
openness/accessibility of the HPV16 chromatin in these cells. Both
enzymes were most abundant over the virus early region,
including the early and late promoters. There was a striking peak
Table 1. Details of the W12 clones studied
Clone Integration site Ploidy HPV16 gene copy number HPV16 E6/E7 expression
per template
Expression per
template category
E6 E7 Mean E6/E7 E2-5′ E2-3′
F 4q13.3 2N 1 1 1 1 1 248.6 (±31.8) HIGH
A5 8p11.21 2N 1 1 1 1 1 215.6 (±14.9)
D2 18q21.2 2N 3 4 4 0 3 118.5 (±12.0) MEDIUM
H 4q21.23 2N 1 1 1 0 1 100.1 (±12.4)
G2 21q22.1 2N 3 3 3 3 0 37.5 (±4.2) LOW
All virus gene copy numbers were adjusted for cell ploidy and rounded to the nearest whole number. Levels of HPV16 E6 and E7 transcripts per template were
referenced individually to low passage episome-containing W12 cells (W12 Series6 p11) and mean values (± s.e.m.) were determined from three biological
replicates. Clone G2 showed three different virus–host junction transcripts by RNA-sequencing and clone D2 showed four different virus–host junction
transcripts (data not shown). All clones tested (F, A5, D2 and G2) reformed an LSIL in organotypic tissue culture.
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Figure 1. Levels of HPV16 transcription per template associate with virus genome accessibility. (a) In each graph the y-axis shows fold enrichment of
open chromatin across the HPV16 genome, as determined by FAIRE using three biological replicates. Values were normalised to the efﬁciency of
enrichment, as determined by the ratio of GAPDH promoter to GAPDH open reading frame qPCR. The x-axis and underlying schematic show the
region of the HPV16 genome analysed. The panels show data for the clones in which transcription levels per template were high, medium (MED) or
low. (b) Virus genome occupancy by nucleosomes or other DNA-binding proteins, as determined by NOMe sequencing using four biological
replicates. Regions with a lower rate of occupancy are indicated by higher levels of exogenously applied GpC methylation. The degree of GpC
methylation is shown as a heat map (see key), with circles at individual nucleotide positions. (c, d) Association of chromatin remodelling enzymes
BRG1 and INI1 with the integrated HPV16 genome across the cell lines. The y-axis shows relative levels of enrichment of BRG1 (c) and INI1 (d),
derived from three biological replicates in each case and normalised to host control target regions (see Supplementary Table S1). The x-axis and
underlying schematic show the region of the HPV16 genome analysed. In all panels, data for each of the ﬁve clones are colour coded according to
the key at the foot of the ﬁgure. This code is maintained in all subsequent ﬁgures. In all panels, bars=mean± s.e.m. Abbreviation: FAIRE,
formaldehyde-assisted isolation of regulatory element; NOMe, nucleosome occupancy and methylation.
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of INI1 abundance at the early promoter and transcription start
site in clone F.
High HPV16 expression requires activating chromatin marks
We next quantiﬁed levels of histone PTMs on the integrated virus
chromatin. Higher virus expression per template was associated
with greater levels of histone 3 lysine 4 tri-methylation (H3K4me3),
a hallmark of transcriptional activity. We extended our previous
observations17 by showing that this mark was only present
downstream of the HPV16 early promoter and was absent from
the late region (Figure 2a). Key enzymatic writers of the mark,
SETD1A and MLL1, were also more abundant at the virus genome
in cells with higher expression per template, with consistent
enrichment at the LCR and early promoter (Figures 2b and c).
There was more variable enrichment over the late and early
regions, with higher levels of SETD1A in clones A5 and D2 and
MLL1 in A5. The cells with high expression per template also
showed enrichment of histone PTMs associated with gene
enhancer/promoter regions, with strong enrichment of
H3K4me1 across the entire virus genome, including the late
genes (Figure 2d), and greater abundance of H3K27ac, predomi-
nantly at the LCR and early genes (Figure 2e).
Conversely, lower levels of expression per template were
associated with higher levels of repressive histone PTMs, namely
di-methylation of histone 3 lysines 9 and 27 (H3K9me2 and
H3K27me2) (Supplementary Figures S1A and C). However, there
was very little enrichment of tri-methylated forms of these
histones (H3K9me3 and H3K27me3) at any of the integrated
HPV16 genomes (Supplementary Figures S1B and D). The cells
with lower expression also showed higher levels of endogenous
CpG DNA methylation across the HPV16 genomic region analysed
(nt 6731 to 1287) (Figure 3a). There was a prominent peak of DNA
methylation at the LCR in G2, the only clone showing low
expression per template (Figure 3b). Levels of methylation at L1
were variable, including between clones with similar levels of virus
gene expression per template (Figure 3b).
HPV16 transcription per template associates with histone
methylation modifying enzymes
Higher virus expression per template was associated with higher
levels of general histone 3 acetylation (H3ac) (Figure 4a), together
with greater abundance of the histone acetyltransferases (HATs)
p300 and TIP60, across the entire HPV16 genome (Figures 4b and
c). The abundance of these enzymes at the HPV16 genome showed
no relation to total levels in the cells, indicating speciﬁc loading
onto the virus chromatin (Supplementary Figure S2). High levels of
p300 across the HPV16 genome were associated with high overall
abundance of cJun (Supplementary Figure S3A), which can act as a
p300 recruiter protein.19 However, there was no close association
between levels of p300 and cJun at individual sites on the virus
genome. Levels of TIP60 were not associated with those of its
potential recruiter protein YY1 (Supplementary Figure S3B), but did
associate closely with levels of H3K4me1 (Figure 2d).
We tested the functional signiﬁcance of HAT recruitment in
determining levels of HPV16 transcript expression. We inhibited
p300 or TIP60 in the cells with the highest and lowest levels of
virus early gene expression per template (clones F and G2,
respectively) (Figures 4d–k). We did not examine post-
transcriptional effects on HPV16 oncoprotein levels in these
experiments. We observed signiﬁcantly greater reductions in
E6/E7 transcript levels in clone F vs G2 when p300 was depleted
using siRNA (Figure 4h) or speciﬁcally inhibited using C646
(Figure 4j) and when TIP60 was depleted using siRNAs (Figure 4i)
or speciﬁcally inhibited using MG149 (Figure 4k).
Mirroring these observations with HATs, cells with lower virus
transcript levels per template showed higher abundance of
histone deacetylase 1 (HDAC1) (Figure 5a). In the absence of
speciﬁc siRNAs targeting HDAC1, we used the class I/II HDAC-
speciﬁc small-molecule inhibitor Trichostatin-A. After 16 h of
treatment, this produced signiﬁcantly greater increases in HPV16
E6/E7 transcript levels in clone G2 than in clone F (Figure 5b).
Transcript levels per template associate with active RNAPII,
determined by P-TEFb (CDK9)
There were no differences across the clones in the overall amounts
of RNAPII associated with the HPV16 genome (Figure 6a).
However, cells with lower virus expression per template showed
higher amounts of the poised/paused or stalled form of RNAPII,
Ser5P, across the early genes (Figure 6b). Conversely, cells with
higher expression per template showed greater amounts of the
active/elongating form of RNAPII, Ser2P, across the virus LCR and
early genes (Figure 6c), together with higher levels of histone 3
lysine 36 tri-methylation (H3K36me3), a histone PTM associated
with transcriptional elongation (Figure 6d). There were also higher
levels of the positive transcription elongation factor b (P-TEFb)
complex kinase CDK9 (Figure 7a), which is responsible for
phosphorylation of the RNAPII C-terminal domain at Ser2.
Depletion of CDK9 (Figures 7b and c) produced signiﬁcantly
greater reductions in E6/E7 transcript levels in clone F (higher
expression per template) than in clone G2 (lower expression per
template) (Figure 7d) (F vs G2 Po0.001).
We next investigated the consequences of inhibiting CDK9
function in high expressing clone F cells. As the chromatin yield
from siRNA experiments was too low, we used the small-molecule
inhibitor Flavopiridol, which caused 87% reduction in E6/E7
transcript levels (Supplementary Figure S4A). Similar effects were
also seen using other small inhibitors with predominant speciﬁcity
for CDK9 (Supplementary Figure S4A). While Flavopiridol pro-
duced no change in overall levels of CDK9 recruitment at the
HPV16 genome (Figure 8a), there were reduced levels of total
RNAPII, particularly downstream of the virus early promoter
(Figure 8b). There was also less elongating RNAPII-Ser2P down-
stream of the transcription start site, with evidence of redistribu-
tion to the LCR/early promoter region (Figure 8c). In addition, the
LCR and early genes showed striking decreases in the histone PTM
mark of transcriptional activation, H3K4me3 (Figure 8d), mirrored
by increases in the mark of constitutive heterochromatin and
transcriptional repression, H3K9me2 (Figure 8e).
Similar observations to those made in clone F were seen in the
cervical SCC cell line SiHa. Indeed, the CDK9 inhibitors (including
Flavopiridol) produced greater reductions in E6/E7 expression in SiHa
than in clone F (95%) (Supplementary Figure S4A), while Flavopiridol
led to more pronounced shifts in epigenetic marks and reduced
RNAPII-Ser2P levels (Figures 8f–j). Transcript levels in SiHa reduced by
480% over the ﬁrst 8 h of Flavopiridol treatment (Supplementary
Figure S4B), consistent with profound transcriptional shut off of the
integrated HPV16 DNA. These changes were associated with
complete inhibition of cell growth (Supplementary Figure S4C).
DISCUSSION
The W12 cell clones represent a unique resource that has enabled
us to study the factors associated with the large differences in
virus oncogene expression per template observed following
natural HPV16 integration events in premalignant basal cervical
keratinocytes. We focussed on ﬁve clones from the same genetic
background, in which HPV16 was integrated at low copy number
without full-length virus concatemers. The cells were studied at a
very early stage after cloning, when levels of E6/E7 varied by
~ 6.6-fold but the cells had not shown the effects of HPV16
oncoprotein-driven genomic instability and still recapitulated an
LSIL phenotype in organotypic tissue culture. Our ﬁndings indicate
that levels of HPV16 expression following integration are
determined through multiple layers of epigenetic regulation.
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Figure 2. Associations with active histone PTMs and modifying enzymes. Levels of association of the H3K4me3 histone PTM (derived from four
biological replicates) (a) and the associated histone-modifying enzymes SETD1A (three replicates) (b) and MLL1 (four replicates) (c); as well as
the transcriptional enhancer marks H3K4me1 (three replicates) (d) and H3K27ac (two replicates) (e). In each graph, the y-axis shows the
relative levels of enrichment, normalised to host control target regions (see Supplementary Table S1). The x-axis and underlying schematic
show the region of the HPV16 genome analysed. In all panels, data are colour coded according to the key at the foot of the ﬁgure.
Bars=mean± s.e.m.
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Our initial data showed that high virus expression per template
was associated with open chromatin at the HPV16 LCR, together
with greater loading of chromatin remodelling enzymes and less
nucleosome occupancy across the HPV16 early promoter and the
oncogenes E6/E7. Together, these changes would be expected to
increase template accessibility for the cellular transcriptional
machinery, enabling transcriptional activation and RNAPII
elongation. The reasons for the relative abundance of BRG1 and
INI1 over the virus early region are not certain but may be related
to the ability of these enzymes to orchestrate long-range
interactions between promoter-enhancer regions.20,21
Levels of HPV16 expression per template were positively
associated with higher abundance of histone PTMs that marked
transcriptionally active chromatin, together with the cognate
Figure 3. Associations with CpG DNA methylation. (a) Cumulative levels of endogenous CpG DNA methylation across the integrated HPV16
genomes, derived from three biological replicates. The coloured bars in each stack correspond to individual CpG sites. The order of the bars in
each stack (from bottom to top) corresponds to the order of the CpG coordinates (from left to right) in the genome map at the base of the
panel. P-values (Student’s t-test): **Po0.01, ***Po0.001. (b) Percentage of endogenous DNA methylation at CpG dinucleotides across the
HPV16 genome (y-axis). The x-axis and underlying schematic show the region of the HPV16 genome analysed. Bars=mean+s.e.m.
Chromatin modiﬁcations determine HPV16 expression
IJ Groves et al
6
Oncogene (2016) 1 – 14 © 2016 Macmillan Publishers Limited
231
Figure 4. Associations with histone acetylation and HAT abundance/activity. (a–c) Levels of the H3ac histone PTM (derived from three
biological replicates) (a) and the associated HAT enzymes p300 (three replicates) (b) and TIP60 (three replicates) (c). In each graph, the y-axis
shows the relative levels of enrichment, normalised to host control target regions (see Supplementary Table S1). The x-axis and underlying
schematic show the region of the HPV16 genome analysed. In all panels, data are colour coded according to the key beneath panel c.
(d–k) Depletion/inhibition in clones F and G2 of HAT enzymes p300 (upper row) and TIP60 (lower row). The panels show levels of depletion of
target mRNAs (d, e), target protein (f, g) and HPV16 E6/E7 transcripts (h, i) in siRNA-treated vs NTC-treated cells, together with HPV16 E6/E7
transcript levels in cells treated with speciﬁc small-molecule inhibitors, vs cells treated with vehicle only (j, k). All data for p300 were derived
from four biological replicates and all data for TIP60 from six biological replicates. Each western blot used protein samples from all replicate
experiments combined. Bars=mean± s.e.m. P-values (Student’s t-test): *Po0.05, **Po0.01, ***Po0.001, NS=not signiﬁcant. Abbreviation:
NTC, non-targeting control.
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writer enzymes. The presence of the transcriptional activation
mark H3K4me3 was associated with consistent enrichment for the
H3K4 methylases SETD1A and MLL1 at the LCR, where the
enzymes would be recruited to the activating RNAPII complex.
This observation is paralleled by evidence that a speciﬁc isoform
of MLL5 (MLL5β) is recruited via a distal AP1 site at the HPV18 LCR
and is necessary for virus oncogene expression.22 The reasons for
the different distributions of H3K4me3 and H4K4me1 are unclear
and may be related to the relative distribution or balance of the
H3K4 methylases and their cofactors.23
Expression levels per template were negatively associated with
repressive heterochromatin marks and with overall levels of
endogenous CpG DNA methylation. In the type I HPV16 integrants
studied here, there was no clear relationship between virus
expression per template and L1 methylation. At present, there is
considerable interest in using HRHPV methylation as a clinical
diagnostic test, for example to triage cytology samples.24 Our data
indicate a need for further investigations of the associations
between HRHPV L1 methylation and virus parameters (e.g.
physical state, presence or absence of full-length concatemers,
levels of early gene expression per template), in order to
understand better the potentially complex relationship between
L1 methylation and cervical neoplastic progression.
Interestingly, the repressive heterochromatin marks H3K9me2
and H3K27me2 were present at much greater overall abundance
than the equivalent tri-methyl marks H3K9me3 and H3K27me3.
Previous work has shown a global reduction in H3K27me3 in
HRHPV-infected cells, caused by virus-driven upregulation of
H3K27 demethylases KDM6A and KDM6B, and inhibition of the
polycomb repressive complex 2, the writer of the H3K27me3
mark.25,26 The absence of these heterochromatic tri-methyl
marks is also consistent with chromatin immunoprecipitation
sequencing data from the HPV18-positive cervical adenocarci-
noma cell line HeLa27 and analyses of undifferentiated and
differentiated squamous epithelial cells containing HPV31 episo-
mal genomes.11 Indeed, for naturally occurring HRHPV integrants
(as opposed to those generated experimentally) signiﬁcant levels
of heterochromatic marks, including H4K20me3, have only been
reported in CaSki cervical SCC cells, in which there is an unusually
high number of integrated HPV16 genomes (~600 copies).28
Virus expression per template was associated with histone
acetylation at the integrated HPV16 genomes, consistent with our
previous ﬁndings in episome-associated cervical carcinogenesis6
and with observations using genetically modiﬁed HPV16
templates.29 Histone acetylation associated positively with levels
of both HATs examined, p300 and TIP60. High levels of p300 were
associated with greater overall abundance of cJun, a potential
component of the AP1 complex, which is a possible mechanism of
p300 recruitment. While it has previously been shown that p300
can activate HPV gene expression,19,30,31 our data demonstrate a
functional, dose-dependent relationship between levels of p300
and HPV16 gene expression, as cells with high virus expression per
template showed signiﬁcantly greater sensitivity to p300 deple-
tion or inhibition than those with low expression per template.
Similar observations were made when inhibiting TIP60. Interest-
ingly, there is evidence that TIP60 is a transcriptional repressor at
the HPV18 early enhancer/promoter and can be targeted for
degradation by the HPV18 E6 protein.31,32 Inhibition using MG149
also indicated an activating role for TIP60 in episome-containing
parental W12 cells (data not shown), despite the presence of E2
protein, which has been shown to organise TIP60-mediated
repression of the HPV18 LCR.33 Therefore, the function of TIP60 at
HPV16 genomes is not obviously dictated by template structure.
Figure 5. Associations with HDAC abundance/activity. (a) Levels of association of HDAC1 enzyme. The y-axis shows the relative levels of
enrichment, derived from two biological replicates and normalised to host control target regions (see Supplementary Table S1). The x-axis and
underlying schematic show the region of the HPV16 genome analysed. (b) Changes in HPV16 E6/E7 transcript levels following type I/type II
HDAC inhibition with TSA in clones F and G2, derived from three biological replicates. Bars=mean± s.e.m. P-values (Student’s t-test):
*Po0.05.
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The reasons for the disparate observations concerning TIP60
function are unclear. The mechanism of TIP60 recruitment may be
relevant, as we observed no overall association between levels of
TIP60 and YY1 in W12 cells, whereas YY1 was found at the
integrated HPV18 genome in HeLa cells, where TIP60 is
repressive.31 In the absence of YY1, TIP60 can be recruited to
chromatin via activated RNAPII-Ser2P itself34 and by various other
transcription factors including E2F1, MYC, MAX and MXI1, all of
which have been found at the HPV18 LCR.27 Indeed, increased
TIP60 recruitment to the hTERT promoter, likely through MYC
interaction, was seen in human foreskin keratinocytes expressing
HPV16 E6 protein.35 TIP60 has also been shown to interact directly
with chromatin through its chromodomain. This can occur via the
repressive mark H3K9me3 at DNA double-strand breaks36 but also
via the active marks H3K4me3 (enabling TIP60 to act as a histone
code reader/translator)37 and H3K4me1.38 The latter, when
combined with H3K27ac, is an indicator of active enhancers.39 In
the W12 cells with high virus expression per template, these marks
Figure 6. Associations with RNAPII and H3K36me3. Levels of association of total RNAPII (derived from three biological replicates) (a), RNAPII-
Ser5P (poised/paused) (three replicates) (b), RNAPII-Ser2P (active/elongating) (three replicates) (c) and H3K36me3 (two replicates) (d). In each
graph, the y-axis shows the relative levels of enrichment, normalised to host control target regions (see Supplementary Table S1). The x-axis
and underlying schematic show the region of the HPV16 genome analysed. In all panels, data are colour coded according to the key at the
foot of the ﬁgure. Bars=mean± s.e.m.
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were present, together with p300, at the integrated HPV16 LCR,
which therefore appears to be acting as a canonical enhancer of
transcription. Interestingly, such marks were also present over the
virus late gene region, which, when out of the context of the
episomal genome, may augment integrated HPV16 gene
expression.
The differences in HAT recruitment between the clones were
mirrored by differences in HDAC1 abundance at the HPV16
genome. HDAC1 levels were greater in cells with less virus gene
expression per template, which showed signiﬁcantly greater
increases in transcript levels following HDAC inhibition. However,
HDAC1 was detectable at the virus genome in all clones and all
showed increased gene expression levels following HDAC
inhibition with TSA over a relatively long duration of 16 h. These
observations are consistent with data describing the necessity for
HDAC presence at gene promoter regions, in order to allow
resetting of histone acetylation during the dynamic turnover of
these marks that accompanies RNAPII progression.34,40
While virus expression per template showed no association with
overall levels of RNAPII at the HPV16 genome, there was an
association with levels of the active/elongating form of the
enzyme (RNAPII-Ser2P), together with those of CDK9, the
component of P-TEFb responsible for phosphorylating Ser2 of
the RNAPII C-terminal domain. The CDK9 enzyme was functionally
signiﬁcant, as evidenced by a greater sensitivity to depletion in
cells with higher HPV16 gene expression per template. We also
observed striking changes in the distribution of RNAPII and
chromatin marks following treatment with Flavopiridol. While this
small molecule can inhibit multiple CDKs and affect cell cycle
progression, its major mode of action is considered to be
inhibition of CDK9.41,42 The importance of P-TEFb/CDK9 in
transcription of integrated HPV16 supports observations for other
viruses. For example, CDK9 is necessary to relieve RNAPII pausing
at the Epstein-Barr virus C promoter and drive transcription of
polycistronic virus mRNAs,43 while P-TEFb is required for Tat-
driven transcriptional elongation at the human immunodeﬁciency
virus (HIV) long terminal repeat.44
Together, our data are consistent with the model shown in
Figure 9. Integrated HPV16 templates showing higher levels of
oncogene expression are associated with more accessible DNA,
via the action of chromatin remodellers. This accessibility leads to
the recruitment of activating histone-modifying enzymes, either
directly or via transcription factors. In turn, these enzymes
methylate and acetylate histone tails, so that the recruitment
and activation of RNAPII can occur through activating complexes
such as P-TEFb. While the integrated templates with lower
expression levels are still able to activate RNAPII, there is a shift
in the balance of activating and repressing enzymes that affects
gene expression levels. In future work, it will be important to study
the mechanisms by which initial virus template accessibility is
determined, including whether HPV16 acquires the features of the
host chromatin at integration sites. The W12 system will allow
detailed dissection of the relative roles of virus factors, such as
those described here, and host genes in providing individual cells
with a selective advantage during the early stages of cervical
neoplastic progression.
MATERIALS AND METHODS
Cell culture
Previous publications have given detailed descriptions of the W12
system,6,16,45 including generation of the W12 cell clones.14,17 The ﬁve
clones selected for further investigation (Table 1) were episome-free and
did not express the HPV16 transcriptional regulator E2.17 All W12 cells were
Figure 7. Associations with CDK9 abundance/activity. (a) Levels of association of CDK9. The y-axis shows the relative levels of enrichment,
derived from three biological replicates and normalised to host control target regions (see Supplementary Table S1). The x-axis and underlying
schematic show the region of the HPV16 genome analysed. (b–d) Depletion of CDK9 using siRNAs, showing levels of target mRNA (b) and
protein (c), together with changes in HPV16 E6/E7 transcript levels (d), in siRNA-treated vs NTC-treated cells. All data were derived from two
biological replicates. The western blot used protein samples from both replicates combined. Bars=mean± s.e.m. P-values (Student’s t-test):
*Po0.05, **Po0.01, ***Po0.001, NS=not signiﬁcant. Abbreviation: NTC, non-targeting control.
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grown in monolayer culture, as described,46 in order to restrict cell
differentiation and maintain the phenotype of the basal epithelial cell
layer, the key site of HRHPV transcriptional deregulation in cervical
carcinogenesis.4,15 Cells were analysed at the lowest available passage (p)
after cloning (typically p3 to p8), in order to minimise any effects of
genomic instability caused by deregulated HPV16 oncogene expression.
We also used the HPV16-positive cervical SCC cell line SiHa,47 which
contains ~ 2 integrated virus copies and was grown as described.48
Figure 8. Effects of CDK9 inhibition. Effects of Flavopiridol in clone F (LSIL phenotype) and SiHa (SCC phenotype). Rows show levels of CDK9
(a, f), total RNAPII (b, g), RNAPII-Ser2P (active/elongating) (c, h), H3K4me3 (active) (d, i) and H3K9me2/3 (repressed) (e, j). In each graph, the
y-axis shows the relative levels of enrichment, derived from two biological replicates and normalised to host control target regions
(see Supplementary Table S1). The x-axis and underlying schematic show the region of the HPV16 genome analysed. Solid lines= control-
treated cells; dotted lines= Flavopiridol-treated cells. Bars=mean± s.e.m.
Chromatin modiﬁcations determine HPV16 expression
IJ Groves et al
11
© 2016 Macmillan Publishers Limited Oncogene (2016) 1 – 14
236
Treatment with small-molecule inhibitors
Cells were treated for 16 h with medium supplemented with small-
molecule inhibitors, using the highest doses that did not produce cell
death over the timecourse of the experiments. The small-molecule
inhibitors used were: p300 inhibitor, C646 (SML0002; Sigma-Aldrich,
Dorset, UK; 25 μM); TIP60 inhibitor, MG149 (Axon 1785; Axon Medchem,
Groningen, Netherlands; 150 μM); HDAC inhibitor, Trichostatin-A (T1952;
Sigma-Aldrich; 400 nM); or CDK9 inhibitors, Flavopiridol (F3055; Sigma-
Aldrich; 150 nM), Roscovitine (C3249; Sigma-Aldrich; 20 μM) or DRB (D1916;
Sigma-Aldrich; 50 μM). For analysis of cell growth, cells were seeded at
5 × 104 per well and treated with Flavopiridol after 24 h. Total live cell
counts were carried out every 24 h over 5 days, using Trypan blue staining.
In all experiments, negative control cells were treated with equivalent
volumes of DMSO vehicle (vol/vol).
Gene depletion
Each target gene was depleted using human Flexitube siRNAs (Qiagen,
Crawley, UK): CDK9 (CDK9_5 SI00605066; CDK9_6 SI00605073); p300
(EP300_7 SI02626267); TIP60 (KAT5_2 SI05120304); non-targeting control
(AllStars Negative Control siRNA, 1027280). All siRNAs were used at 10 nM,
with cells being transfected at 20–30% conﬂuence using Lipofectamine
RNAiMAX (Invitrogen, Paisley, UK) as described.49,50
Quantiﬁcation of host proteins and HPV16 transcripts
Quantitative western immunoblotting was carried out as described,6,17,51
using the primary antibodies listed in Supplementary Table S1. Protein
concentrations were compared with those of the β-tubulin loading control
(Abcam, Cambridge, UK; 6ng/ml), using ImageJ software. Levels of HPV16
E6 and E7 transcripts were measured using SYBRGreen quantitative reverse
transcription–PCR (qRT–PCR), as described.17 Primers and conditions are
given in Supplementary Table S2. Relative transcript levels were
determined using the Pfafﬂ equation,52 normalised to the mean of four
housekeeping genes53 and residual levels of the target protein, then
referenced to control samples.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as described,6,17 using
chromatin immunoprecipitation-validated primary antibodies and appro-
priate serum/IgG negative controls (Supplementary Table S1). In contrast
to our previous assessment of a relatively limited region of the HPV16
genome, we analysed 6094 nucleotides (nt) of HPV sequence, from the L2
gene, through the LCR, to the E1 gene (nt 3936 to 2158). This genomic
region was present in all ﬁve clones, with the exception of nt 3936 to 6039
in clone H and nt 3936 to 4419 in clone D2. Primers and conditions used
for qPCR are given in Supplementary Table S3. Efﬁciency of immunopre-
cipitation of each target was normalised using control region qPCR primers
(Supplementary Table S4).
Formaldehyde-assisted isolation of regulatory elements and
nucleosome occupancy and methylome sequencing
Formaldehyde-assisted isolation of regulatory element was carried out as
described.54 Quantiﬁcation of HPV16 DNA sequences was carried out by
qPCR and normalised to the efﬁciency of enrichment, as determined by
the ratio of GAPDH promoter (open)55 to GAPDH open reading frame
(closed).43 Primers and conditions for qPCR were those in Supplementary
Tables S3 and S4. The occupancy of nucleosomes or other DNA-binding
proteins between the HPV16 early promoter and E1 gene (nt 7902 to 1012)
was assessed by nucleosome occupancy and methylome sequencing
(Active Motif, La Hulpe, Belgium), which measures the distribution of
exogenous GpC DNA methylation.56 Samples were ampliﬁed in duplicate
using PCR primers designed to exclude either GpC or CpG dinucleotides, in
order to eliminate ampliﬁcation bias (Supplementary Table S5). PCR
products were Sanger sequenced, using 5′- and 3′-end primers to conﬁrm
reads from each end of the product. Each analysis was carried out in
duplicate and the degree of cytosine methylation for each nucleotide
position averaged across replicates. Percentage GpC methylation was
scored in 20% intervals, from which a heatmap was generated.
HPV16 DNA methylation
Five hundred nanograms of genomic DNA were bisulphite-converted
using the EpiTect Bisulﬁte Kit (59104; Qiagen), then desulphonated,
washed and eluted in 40 μl of buffer. PCR ampliﬁcation of HPV16
sequences was carried out using Immolase (Bioline, London, UK) and the
primers listed in Supplementary Table S6. LINE1 ampliﬁcation was also
carried out as a methylation-positive conversion control. Sequencing
primers were designed using PyroQ software (Pyromark MD, Qiagen) and
analysis performed on a Pyromark MD pyrosequencer, using standard
protocols and controls. For each cell line, assays were performed in
duplicate on a minimum of three independently prepared bisulphite-
converted DNA samples.
Figure 9. Working model of the multilayered epigenetic changes that enable high levels of virus gene expression per template following
HPV16 integration. Recruitment of chromatin remodelling enzymes (BRG1/INI1) to the HPV16 genome, possibly through host steroid hormone
nuclear receptors (NR), allows greater accessibility to the virus chromatin of transcription factors (e.g. cJun/AP1) and histone-modifying
enzymes, including MLL1 and SETD1A, which can write the H3K4me1/3 marks. Recruitment of HATs can occur though interactions with
transcription factors (e.g. p300) and histone PTMs, which may allow TIP60 recruitment through its chromodomain. Once acetylation of
histones has occurred, recruitment of CDK9 (the enzymatic component of P-TEFb) is able to activate RNAPII through phosphorylation of Ser2
at the C-terminal domain, leading to stimulation of transcription from the HPV16 early promoter.
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